Šw‰ï”­•\i2003”NˆÈ~j

1.    ŠÖŒû•x”üŽq, XŒû°, •Ÿ“‡Žu•à, ˆäê—S—¢Žq, ”©ŽR Ži, ’Ø“c^”¿, •½–{Žu‰——¢, ‰ª“c‘ìÆ, –L‰ª®Ž÷, “c’†G˜a, ˆ°“c—²Ži, ¼‘º “ž, 씨“ÄŽjD“ú–{–òŠw‰ï‘æ144”N‰ïC2024, 3, 28-31, ‰¡•liƒ|ƒXƒ^[j

2.    ‹{–{•ü‰ÀAŒj–Ø‘ŽqA–Ø‘º Œ’A씨“ÄŽjDƒpƒNƒŠƒ^ƒLƒZƒ‹“Š—^‚ª‚ñŠ³ŽÒ‚É‚¨‚¢‚ÄŒŒ‰t‹ÃŒÅ”\’ቺ‹y‚ÑR‹ÃŒÅ–ò‚Ì•¹—p‚ª‰»Šw—Ö@—U”­«––½_ŒoáŠQ‚É‹y‚Ú‚·‰e‹¿D“ú–{–òŠw‰ï‘æ144”N‰ïC2024, 3, 28-31, ‰¡•liŒû“ªj

3.    ŽR–{‘쎑AŠâªŽDA‹{–{•ü‰ÀA’Ø“c^”¿AŠÖŒû•x”üŽqA匴Š²•vAª–{ ˜iA’O–ìFˆêA씨“ÄŽjDƒAƒ“ƒWƒIƒeƒ“ƒVƒ“•ÏŠ·y‘f‘jŠQ–ò‚ÆAT1Žó—e‘ÌhR–ò‚É‚æ‚é—L’É«“œ”A•a «_ŒoáŠQ‚Ì—}§F•ÛŒ¯–ò‹Ç‚̃ŒƒZƒvƒgƒf[ƒ^‰ðÍ‚É‚æ‚錟ØD“ú–{–òŠw‰ï‘æ144”N‰ïC2024, 3, 28-31, ‰¡•liŒû“ªj

4.    ‘q‹´ãÄ‘¾˜YA¼–샒jAÎì‰À“ÞA씨“ÄŽjA‚‹´Ž”VA匴Š²•vA‘å’¹ “ODÝ‘îŽ{ÝŠ³ŽÒ‚É‚¨‚¯‚éáy‚Ý‚ÌŒ»ó‚ƃXƒLƒ“ƒPƒA‚ÌŽÀ‘Ô’²¸D“ú–{–òŠw‰ï‘æ144”N‰ïC2024, 3, 28-31, ‰¡•liƒ|ƒXƒ^[j

5.    Kawabata, A. Distinct modulation of Cav3.2 function by sulfide and polysulfide. 6th International Calcium Channel Conference. 2024, 2, 25 – 3, 1, Boracay Island, Phillipine (Invited speaker)

6.    씨“ÄŽjDZinc‚Æsulfide‚É‚æ‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠˆ«’²ß‚Æ’É‚ÝEáy‚ÝD’É‚ÝŒ¤‹†‰ï2023. 2024”N1ŒŽ11-12“úA‰ªèiŒû“ªjD

7.    씨“ÄŽjD•ÂŒo‚É‚æ‚éƒGƒXƒgƒƒQƒ“Œ¸­‚Ɖ»Šw—Ö@—U”­«––½_ŒoáŠQD‘æ97‰ñ“ú–{–ò—Šw‰ï”N‰ïAƒVƒ“ƒ|ƒWƒEƒ€u«ƒzƒ‹ƒ‚ƒ“‚Æ’É‚ÝEáy‚ÝviƒI[ƒKƒiƒCƒU[F–ØŒûE씨jD2023, 12, 14-16, _ŒËiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

8.    ŠÖŒû•x”üŽqAXŒû°A•Ÿ“‡Žu•àAˆäê—S—¢ŽqA’Ø“c^”¿A•½–{Žu‰——¢A‰ª“c‘ì–çA–L‰ª®Ž÷A“c’†G˜aAˆ°“c—²ŽiA¼‘º“žA씨“ÄŽjDH2SŽY¶y‘fcystathionine-ƒÀ-synthase‚ð‘jŠQ‚·‚éƒJƒ‹ƒrƒhƒp‚ƃxƒ“ƒZƒ‰ƒWƒh‚̓{ƒ‹ƒeƒ]ƒ~ƒuŠ´Žó«‚¨‚æ‚Ñ’ïR«‘½”­«œ‘Žî×–E‚̶‘¶‚ð—}§‚·‚éD‘æ97‰ñ“ú–{–ò—Šw‰ï”N‰ïD2023, 12, 14-16, _ŒËiŒû“ªj

9.    ²‹vŠÔŠC’nA’†–ì—yAŠâªŽDA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjDƒŒƒvƒ`ƒ“Žó—e‘̈â“`ŽqŒ‡‘¹‚¨‚æ‚Ñ‚Ž‰–bHÛŽæ‚É‚æ‚é2Œ^“œ”A•aƒ‚ƒfƒ‹ƒ}ƒEƒX‚Ì—L’É«––½_ŒoáŠQ‚Ö‚ÌHMGB1‚ƃAƒiƒtƒBƒ‰ƒgƒLƒVƒ“C5a‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ97‰ñ“ú–{–ò—Šw‰ï”N‰ïD2023, 12, 14-16, _ŒËiŒû“ªj

10. ”©ŽRŽiA’Ø“c^”¿Aˆäê—S—¢ŽqAŠ}”g‰ÃlAŠÖŒû•x”üŽqA‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjDV‹Kpimozide—U“±‘ÌKTtp38‚ÍTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹ˆË‘¶«‚Ì‘Ì«’É‚¨‚æ‚Ñ“à‘Ÿ’É‚ð—}§‚·‚éD‘æ97‰ñ“ú–{–ò—Šw‰ï”N‰ïD2023, 12, 14-16, _ŒËiŒû“ªj

11. ’Ø“c^”¿A²X–؉ÔØAShin EunkyungA‰ª‘º—I‘¾A“°–{从ÑAŠÖŒû•x”üŽqA‰ª“c‘ìÆA–L‰ª®Ž÷A—F–ì–õŽqA¼–x³—mA씨“ÄŽjD‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚ÌŒ‹’°‰ß•q‚ÉŠÖ—^‚·‚éHMGB1‚Ì—R—ˆ×–E‚Ì“¯’è‚ÆRAGEhR–òazeliragon‚¨‚æ‚ÑŠÖ߉ŠE’°‰ŠŽ¡—Öòsulfasalazine‚ð—p‚¢‚½—\–h“I‰î“üD‘æ97‰ñ“ú–{–ò—Šw‰ï”N‰ïD2023, 12, 14-16, _ŒËiƒ|ƒXƒ^[j

12. ŠÖçç“lAŠÝ–{Ê–ìA“°–{从ÑAš¢”öŒ«ŒåA“c“‡˜aŽ÷A¼‰i_–¾A¼–{ˆŸŽÑØA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjDOxaliplatin—U‹N––½_ŒoáŠQ‚Ö‚ÌŒŒ¬”—R—ˆHMGB1‚¨‚æ‚Ñ•â‘ÌC5a/CaRŒn‚ÌŠÖ—^D‘æ73‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘å‰ïD2023, 10, 14, _ŒËiŒû“ªj

13. ²‹vŠÔŠC’nA’†–ì—yA‘å“Œ–ƒÆAŠâªŽDA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjDˆâ“`«‚¨‚æ‚Ñ‚Ž‰–bHÛŽæ‚É‚æ‚é2Œ^“œ”A•aƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚é—L’É«––½_ŒoáŠQ‚ɑ΂·‚éthrombomodulin alfa ‚Ì—}§Œø‰ÊFHMGB1‚Æ•â‘ÌC5a‚Ì•sŠˆ«‰»‚ªŠÖ—^‚·‚é‰Â”\«‚ɂ‚¢‚ÄD‘æ73‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘å‰ïD2023, 10, 14, _ŒËiƒ|ƒXƒ^[j

14. ‘å“Œ–ƒÆA’†–ì—yA²‹vŠÔŠC’nAŠâªŽDA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjD‚Ž‰–bHÛŽæ‚É‚æ‚é2Œ^“œ”A•aƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚é—L’É«––½_ŒoáŠQ‚Ì”­Œ»‚É‚ÍHMGB1Aƒ}ƒNƒƒtƒ@[ƒW‚¨‚æ‚ÑŒŒ¬”‚ªŠÖ—^‚·‚éD‘æ73‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘å‰ïD2023, 10, 14, _ŒËiƒ|ƒXƒ^[j

15. •y“cŽDAª–{˜iA‹{–{•ü‰ÀA—Ñ—F“TA“c’†‰ëKA‘Å’J˜a‹LA¬ò—SˆêA•½“c“ÖŽmA’Ø“c^”¿AŠÖŒû•x”üŽqA’O–ìFˆêA씨“ÄŽjDƒŒƒjƒ“EƒAƒ“ƒMƒIƒeƒ“ƒVƒ“Œn‘jŠQ–ò‚Í“œ”A•a«––½_ŒoáŠQ‚Ì”­Ç‚ð—}§‚·‚éF3•a‰@‚Å‚ÌŒã‚ëŒü‚«ƒRƒz[ƒgŒ¤‹†‚ÆŠî‘bŒ¤‹†‚Å‚ÌŒŸØD‘æ33‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïD2023, 11, 3-5, å‘äiŒû“ªjD

16. 씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Æ—°‰»•¨Fáu’ÉE‘~áyŽ¡—ÕW“I•ªŽq‚Æ‚µ‚Ẳ”\«DƒVƒ“ƒ|ƒWƒEƒ€‚Ruáu’ÉŒ¤‹†‚ÌV“WŠJ`Šî‘bŒ¤‹†‚©‚ç—Õ°‰ž—p‚Ü‚Å`vA‘æ42‰ñ’Á’É–òEƒIƒsƒIƒCƒhƒyƒvƒ`ƒhƒVƒ“ƒ|ƒWƒEƒ€2023D2023, 9, 2-3, “Œ‹žiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

17. ŠÖçç“lAŠÝ–{Ê–ìA“°–{从ÑAš¢”öŒ«ŒåA“c“‡˜aŽ÷A¼‰i_–¾A¼–{ˆŸŽÑØA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjDOxaliplatin—U”­«––½_ŒoáŠQ‚Ì”­Ç‹@˜‰ðÍFŒŒ¬”—R—ˆHMGB1‚Æ•â‘ÌC5a/C5aRŒn‚ÌŠÖ—^‚ɂ‚¢‚ÄD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2023D2023, 8, 24-25, “¿“‡iƒ|ƒXƒ^[j

18. ‹àŒõ“‰ÀA’Ø“c^”¿AŠÖçç“lA¼–{ˆŸŽÑØA—F–ì–õŽqA¼–x³—mA씨“ÄŽjD”’‹à»Ücisplatin‚¨‚æ‚у^ƒLƒTƒ“Œn»Üpaclitaxel‚É‚æ‚éƒ}ƒEƒX‚̉»Šw—Ö@—U”­«––½_ŒoáŠQ‚Ö‚ÌŒŒ¬”—R—ˆHMGB1‚ÌŠÖ—^¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2023D2023, 8, 24-25, “¿“‡iƒ|ƒXƒ^[j

19. ”©ŽRŽiA’Ø“c^”¿Aˆäê—S—¢ŽqAŠ}”g‰ÃlAŠÖŒû•x”üŽqA‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2023D2023, 8, 24-25, “¿“‡iƒ|ƒXƒ^[j

20. 씨“ÄŽjD’É‚Ý‚ÆŒŒ‰t‹ÃŒÅŒnDƒVƒ“ƒ|ƒWƒEƒ€u’É‚Ý‚Ì‘½–Ê«F“«áu’É‚ÉŠÖ—^‚·‚鑽—l‚ȶ‘̃VƒXƒeƒ€‚ɂ‚¢‚ÄvA¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2023D2023, 8, 24-25, “¿“‡iƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

21. Kawabata, A. Role of HMGB1 and thrombin/thrombomodulin in somatic and visceral pain processing. Symposium gHMGB1 and proteinases in inflammation and pain: possible druggable targetsh organized by M. Cunningham and A. Kawabata, 19th World Congress of Basic and Clinical Pharmacology. 2023, 7, 2-7, Glasgow, UK (Symposium speaker).

22. ¼‘ºÊ‰ÔA’Ø“c^”¿AŽRãp•à–²A—F–ì–õŽqA¼–x³—mA씨“ÄŽjD‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¢‚Äthrombomodulin alfa‚Íthrombin ˆË‘¶«HMGB1•sŠˆ«‰»ì—p‚ɉÁ‚¦‚ÄTAFIŠˆ«‰»ì—p‚ð‰î‚µ‚½•â‘ÌC5a•sŠˆ«‰»‚É‚æ‚茋’°’É‚ð—}§‚·‚éD‘æ143‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2023, 6, 24, –¼ŒÃ‰®iŒû“ªjD

23. ’Ø“c^”¿A²X–؉ÔØAShin EunkyungA‰ª‘º—I‘¾A“°–{从ÑAŠÖŒû•x”üŽqA‰ª“c ‘ìÆA–L‰ª ®Ž÷A씨“ÄŽjDButyrate—U‹NŒ‹’°‰ß•q‚ւ̃}ƒNƒƒtƒ@[ƒW‚¨‚æ‚Ñ’°ƒOƒŠƒA×–E—R—ˆHMGB1‚ÌŠÖ—^‚ÆRAGEhR–òazeliragon‚¨‚æ‚уŠƒEƒ}ƒ`E‰ŠÇ«’°Ž¾Š³Ž¡—Öòsulfasalazine‚ÌŒø‰ÊD‘æ143‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2023, 6, 24, –¼ŒÃ‰®iŒû“ªjD

24. ŠâªŽDAŠÝ–{Ê–ìAŠÖçç“lA‹{–{•ü‰ÀA“¡ˆä—Ç•½A“c’†‰ëKA‘Å’J˜a‹LA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ““Š—^Œã‚É”F‚ß‚ç‚ê‚鉻Šw—Ö@—U”­«––½_ŒoáŠQ‚ɑ΂·‚éRŒŒ¬”–ò‚Ì—\–hŒø‰ÊFŠî‘bŒ¤‹†’mŒ©‚ƃŠƒAƒ‹ƒ[ƒ‹ƒhƒf[ƒ^‰ðÍ‚É‚æ‚éƒqƒg‚Å‚ÌŒŸØD‘æ143‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2023, 6, 24, –¼ŒÃ‰®iŒû“ªjD

25. ‹{–{•ü‰ÀAŒj–Ø‘ŽqA–Ø‘ºŒ’A씨“ÄŽjBƒpƒNƒŠƒ^ƒLƒZƒ‹“Š—^‚ª‚ñŠ³ŽÒ‚É‚¨‚¯‚鉻Šw—Ö@—U”­«––½_ŒoáŠQ‚É‹y‚Ú‚·ŒŒ‰t‹ÃŒÅŠˆ«’ቺ‚ÆŒoŒûR‹ÃŒÅ–ò“Š—^‚̉e‹¿D‘æ143‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2023, 6, 24, –¼ŒÃ‰®iŒû“ªjD

26. Š}”g‰ÃlAŽR–{‘쎑A‹{–{•ü‰ÀA¼–샒jA匴Š²•vAŠâé³GA씨“ÄŽjDƒŒƒZƒvƒgƒf[ƒ^‚ð—p‚¢‚½potentially inappropriate medications (PIMs)‚ÌŽÀ‘Ô’²¸F‚—î‚Ì“œ”A•aŠ³ŽÒ‚É‚¨‚¢‚Ä“Á‚É’ˆÓ‚ð—v‚·‚éPIMs‚Æ«·‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28, ŽD–yiŒû“ªjD

27. ŠÖŒû•x”üŽq, ‘“cŠ°Žu, Š}”g‰Ãl, ¬’r”JX, “싽—DŠó, “‡“cNO, ™–{‰Ê•à, ²“¡Žs, ’†‘º‹XŽi, ŽRŒû_–¾, “c糌³ŽO, ŠÛ–{^•ã, ’Ø“c^”¿, 씨“ÄŽjDƒTƒ‹ƒtƒ@ƒCƒh‚É‚æ‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹ˆË‘¶«áu’É‘‹­‚Æ—L‹@ƒQƒ‹ƒ}ƒjƒEƒ€Ge-132‚É‚æ‚é—°‰©•ß‘¨‚ð‰î‚µ‚½áu’É—}§D“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28, ŽD–yiƒ|ƒXƒ^[jD

28. ŠÝ–{Ê–ìA“°–{从ÑAŠÖçç“lA¼‰i_–¾A¼–{ˆŸŽÑØA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjDRŒŒ¬”–ò‚̓IƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQiOIPNj‚ð—}§‚·‚éFOIPN”­Ç‚É‚¨‚¯‚錌¬”—R—ˆHMGB1‚Ì–ðŠ„D“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28, ŽD–yiŒû“ªjD

29. •y“cŽDAª–{˜iA‹{–{•ü‰ÀA—Ñ—F“TA“c’†‰ëKA‘Å’J˜a‹LA‘º’†’B–çA¬ò—SˆêA•½“c“ÖŽmA’Ø“c^”¿AŠÖŒû•x”üŽqA’O–ìFˆêA씨“ÄŽjD‚ŒŒˆ³‚ð‡•¹‚·‚é“œ”A•aŠ³ŽÒ‚É‚¨‚¯‚é––½_ŒoáŠQ‚Ì”­Ç‚ɑ΂·‚éƒAƒ“ƒMƒIƒeƒ“ƒVƒ“•ÏŠ·y‘f‘jŠQ–ò‚Ü‚½‚ÍŽó—e‘ÌhR–ò‚Ì—}§Œø‰ÊF3•a‰@‚Å‚Ì—Õ°’mŒ©‚ÆŠî‘bŒ¤‹†‚É‚æ‚錟ØD“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28, ŽD–yiŒû“ªjD

30. ’†–ì—yA²‹vŠÔŠC’nA•y“cŽDA’Ø“c^”¿A—F–ì–õŽqA¼–x³—mA씨“ÄŽjD2Œ^“œ”A•aƒ}ƒEƒX‚É‚¨‚¢‚Äthrombomodulin alfa‚ÍHMGB1‚Æ•â‘ÌC5a‚ð•sŠˆ«‰»‚·‚邱‚Æ‚Å—L’É«––½_ŒoáŠQ‚ð—}§‚·‚éD“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28, ŽD–yiŒû“ªjD

31. –Ø–ìŽuDA‘q‹´ãÄ‘¾˜NAåb“c–¾–çAŽO“ˆŠG”üä»A¼ŽRˆÉ‘ãA“ì–ì仓ßA¼ì—T”VA’Ø“c^”¿AŠÖŒû•x”üŽqA‰ª“c‘ìÆA–L‰ª®Ž÷A씨 “ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚éTŒ^Ca2+ƒ`ƒƒƒlƒ‹ˆË‘¶«‘~áy‚ɑ΂·‚éV‹Kƒsƒ‚ƒWƒh—U“±‘ÌKTtp‰»‡•¨‚Ì—}§Œø‰ÊD“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28, ŽD–yiƒ|ƒXƒ^[jD

32. —Ñ —F“T , •y“cŽDC‹{–{•ü‰À, •½“c“ÖŽm, ‘º’†’B–çA¬ò—SˆêA씨“ÄŽjD”ñ“]ˆÚ«‘O—§‘BŠà‚Ì‹Ž¨’ïR«Šl“¾‚ƶŠˆKŠµ•a‚ÌŠÖ˜A«D“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28, ŽD–yiŒû“ªjD

33. 씨“ÄŽjDHMGB1‚ð•W“I‚Æ‚·‚鉻Šw—Ö@—U”­«––½_ŒoáŠQ‚Ì—\–hDƒVƒ“ƒ|ƒWƒEƒ€u––½_ŒovA’É‚ÝŒ¤‹†‰ïD2023, 1, 19-20, ‰ªèiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[jD

34. 씨“ÄŽjD‰»Šw—Ö@—U”­«––½_ŒoáŠQ‚ÆHMGB1‚ɂ‚¢‚ÄD‘æ38‰ñ‘n–òE–ò—ƒtƒH[ƒ‰ƒ€‰ªŽRD2022, 12, 24, ‰ªŽRizoomji‹³ˆçu‰‰jD

35. 씨“ÄŽjAŠÝ–{Ê–ìA“°–{从ÑA¼‰i_–¾A¼–{ˆŸŽÑØA’Ø“c^”¿AŠÖŒû•x”üŽqA‰¤“oä»A¼–x³—mDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U”­«––½_ŒoáŠQ(OIPN)‚ɑ΂·‚éRŒŒ¬”–ò‚Ì—\–hŒø‰ÊFOPIN‚Ö‚ÌŒŒ¬”—R—ˆHMGB1‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ44‰ñ“ú–{áu’ÉŠw‰ïD2022, 12, 2-3, Šò•ŒiŒû“ªjD

36. ŠÖŒû•x”üŽq, ‘“cŠ°Žu, Š}”g‰Ãl, ¬’r”JX, “싽—DŠó, “‡“cNO, ™–{‰Ê•à, ²“¡Žs, ’†‘º‹XŽi, ŽRŒû_–¾, “c糌³ŽO, ŠÛ–{^•ã, ’Ø“c^”¿, 씨“ÄŽjDSulfides‚É‚æ‚éCav3.2ƒ`ƒƒƒlƒ‹Šˆ«E’É‚ÝŠ´Žó«˜´i‚Ærepagermanium‚É‚æ‚ésulfide•ß‘¨‚¨‚æ‚ÑCav3.2ˆË‘¶«áu’É—}§D‘æ44‰ñ“ú–{áu’ÉŠw‰ïD2022, 12, 2-3, Šò•ŒiŒû“ªjD

37. 씨“ÄŽjD‘n–ò‚Æ–ò•¨—Ö@“K³‰»‚ÉŒü‚¯‚½—Õ°–òŠw‚Æ–ò—Šw‚Ì“‡“IŒ¤‹†ƒAƒvƒ[ƒ`DƒVƒ“ƒ|ƒWƒEƒ€u–òŠw‚Ì‚È‚©‚Ì–ò—ŠwFˆã–òŒ¤‹†‚Ì‘½—l‚ȃAƒvƒ[ƒ`vD‘æ96‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 11, 30 – 12, 2, ‰¡•liƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

38. ŠÝ–{Ê–ìA“°–{从ÑA¼‰i_–¾A¼–{ˆŸŽÑØA’Ø“c^”¿AŠÖŒû•x”üŽqA‰¤“oä»A¼–x³—mA씨“ÄŽji”­•\ŽÒjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQiOIPNj‚Ö‚ÌŒŒ¬”—R—ˆHMGB1‚ÌŠÖ—^FRŒŒ¬”–ò‚ÌOIPN—\–hŒø‰Ê‚ɂ‚¢‚ÄD‘æ96‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 11, 30 – 12, 2, ‰¡•liŒû“ªj

39. ŠÖŒû•x”üŽqAˆÀ’B‹`ŽjA“‡“cNOA’†‘º‹XŽiA씨“ÄŽjDH2S‚¨‚æ‚ÑATP•â‘¨ì—p‚ð—L‚·‚érepagermanium (Ge-132) ‚̓}ƒEƒX‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”­«––½_ŒoáŠQ‚ð—}§‚·‚éD‘æ96‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 11, 30 – 12, 2, ‰¡•liƒ|ƒXƒ^[j

40. “c“‡˜aŽ÷Aš¢”öŒ«ŒåA’Ø“c^”¿A‰¤“oä»A¼–x³—mA“ì’B˜YAˆÉ“¡²•qA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚é•â‘̃AƒiƒtƒBƒ‰ƒgƒLƒVƒ“C5a—U‹NƒAƒƒfƒBƒjƒA‚Ì”­Œ»ƒƒJƒjƒYƒ€‚ɂ‚¢‚ÄD‘æ96‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 11, 30 – 12, 2, ‰¡•liƒ|ƒXƒ^[j

41. Š}”g‰Ãl, ‚“‡NG , –Ø–ì‹M”Ž, Îìç_, ’·“ì•S, –L‰ª®Ž÷, ŠÖŒû•x”üŽq, ’Ø“c^”¿, 죓Ďj, ‘å‹v•Û‚‚âŽq, ‹g“c@”É, ‰ª“c‘ìÆ, 씨“ÄŽjD’èŒ^R¸_•a–òpimozide‚Ì\‘¢“WŠJ‚É‚æ‚èŠJ”­‚µ‚½V‹KTŒ^Ca‚Q{ƒ`ƒƒƒlƒ‹‘jŠQ–òKTtp38Fƒ`ƒƒƒlƒ‹‘I‘ð«A“d‹C¶—Šw“I“Á’¥A’Á’ÉŠˆ«‚Ì•]‰¿D‘æ96‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 11, 30 – 12, 2, ‰¡•liŒû“ªjD

42. š¢”öŒ«ŒåA’r“c—TÆA’Ø“c^”¿A‰¤“oä»A¼–x³—mA“ì’B˜YAˆÉ“¡²•qA씨“ÄŽjDŠˆ«‰»protein C‚Íproteinases-activated receptor 1 ‚ð‰î‚µ‚Ä_ŒoáŠQ«áu’É‚ð—}§‚·‚éD‘æ96‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 11, 30 – 12, 2, ‰¡•liŒû“ªjD

43. Š}”g‰Ãl, ¼‘º—³‹M, ŠÖŒû•x”üŽq, ‚“‡NG, –Ø–ì‹M”Ž, ’Ø“c^”¿, Îìç_, ’·“ì•S, –L‰ª®Ž÷, ‰ª“c‘ìÆ, ‘å‹v•Û‚‚âŽq, ‹g“c”É, 씨“ÄŽjDTŒ^Ca2+ƒ`ƒƒƒlƒ‹ (Cav3)  ‘jŠQŠˆ«‚ð—L‚·‚éV‹Kpimozide—U“±‘ÌKTtp38‚Ì–ò—Šw“I“Á«‚̉ðÍ‘æ142‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2022, 11, 12, “Œ‘åãiŒû“ªjD

44. ¼–{ˆŸŽÑØA’Ø“c^”¿AŠÑŒËˆ»”TA•½–{Žu‰——¢A—F–ì–õŽqA¼–x³—mA씨“ÄŽjD—‘‘ƒ“EoŒã‚ɃAƒƒ}ƒ^[ƒ[‘jŠQ–ò‚ð“Š—^‚µ‚½ƒ}ƒEƒX‚Å‚Í’´’á—p—ʃpƒNƒŠƒ^ƒLƒZƒ‹‚É‚æ‚艻Šw—Ö@—U”­«––½_ŒoáŠQ‚ª”­Ç‚·‚éD‘æ142‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2022, 11, 12, “Œ‘åãiŒû“ªjD

45. ¼‘ºÊ‰ÔAŽRãp•à–²A’Ø“c^”¿A씨“ÄŽjDButyrate—U‹NŒ‹’°‰ß•q‚Ö‚Ì•â‘ÌC5a‚ÌŠÖ—^D‘æ72‰ñ@“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2022, 10, 8, –‡•ûiƒ|ƒXƒ^[jD

46. ¼‘º—³‹MAŠ}”g ‰ÃlA‚“‡NGA–Ø–ì‹M”ŽAÎìç_A’·“ì•SA‰ª“c‘ìÆAŠÖŒû•x”üŽqA‹g“c”ÉA‘å‹v•Û‚‚âŽqA–L‰ª®Ž÷A씨 “ÄŽjD’èŒ^R¸_•a–òPimozide‚Ì\‘¢“WŠJŒ¤‹†‚É‚æ‚èŠJ”­‚µ‚½V‹Káu’ÉŽ¡—Öò‚Ì–ò—Šw“I«Ž¿D‘æ72‰ñ@“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2022, 10, 8, –‡•ûiŒû“ªjD

47. •y“cŽDA‹{–{•ü‰ÀA“c’†‰ëKA‘Å’J˜a‹LA¬ò—SˆêA‘º’†’B–çAª–{˜iA’O–ìFˆêA’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDƒAƒ“ƒMƒIƒeƒ“ƒVƒ“•ÏŠ·y‘f‘jŠQ–ò‚ƃAƒ“ƒMƒIƒeƒ“ƒVƒ“IIŽó—e‘ÌhR–ò‚Í“œ”A•a«––½_ŒoáŠQ‚Ì”­Ç‚ð—}§‚·‚éF—Õ°EŠî‘b—Z‡Œ¤‹†‚É‚æ‚éƒGƒrƒfƒ“ƒXD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2022D2022, 8, 25-26, ɪiƒ|ƒXƒ^[j

48. š¢”öŒ«ŒåA’r“c—TÆA’Ø“c^”¿A‰¤“oä»A¼–x³—mA“ì’B˜YAˆÉ“¡²•qA씨“ÄŽjDŠˆ«‰»ƒvƒƒeƒCƒ“C‚Í_ŒoáŠQ«áu’É‚ð—}§‚·‚éFProteinase-activated receptor-1iPAR1j‚ÌŠÖ—^‚ɂ‚¢‚ÄD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2022D2022, 8, 25-26, ɪiƒ|ƒXƒ^[j

49. ˆäê—S—¢ŽqA–{šêò˜ÐA’Ø“c^”¿A죓ĎjA‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjD–F‘°L-ƒAƒ~ƒmŽ_’E’YŽ_y‘f‚ð‘jŠQ‚µ‚È‚¢D-carbidopa‚ÍH2SŽY¶y‘fcystathionine-ƒÀ-synthase‚ð‘jŠQ‚·‚邱‚Æ‚ÅTNBS—U‹NŒ‹’°’É‚ð—}§‚·‚éD‘æ141‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2022, 7, 1, ‚¼ZoomiŒû“ªj

50. ŠÝ–{Ê–ìA“°–{从ÑA¼‰i_–¾A¼–{ˆŸŽÑØA’Ø“c^”¿AŠÖŒû•x”üŽqA‰¤“oä»A¼–x³—mA씨“ÄŽjDOxaliplatin—U‹N––½_ŒoáŠQ‚É‚ÍŒŒ¬”—R—ˆHMGB1‚ªŠÖ—^‚·‚éD‘æ141‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2022, 7, 1, ‚¼ZoomiŒû“ªj

51. –ؗt—DˆßA’J’ÃŒ’‘¾A’r“c—TÆAŠÖŒû•x”üŽqA’Ø“c^”¿AWang DengliA¼–x³—mA씨@“ÄŽjDR‚ª‚ñÜvincristine‚¨‚æ‚Ñbortezomib‚É‚æ‚è—U‹N‚³‚ê‚é––½_ŒoáŠQ‚ÉŠÖ—^‚·‚éƒ}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£ƒƒJƒjƒYƒ€‚Ì‘ŠˆáD“ú–{–òŠw‰ï‘æ142”N‰ïD2022, 3, 26-28, –¼ŒÃ‰®ZoomiŒû“ªj

52. ²X–؉ÔØAShin EunkyungA–ì’†Œ‹A’Ø“c^”¿AWang Dengli A¼–x³—mA씨“ÄŽjDButyrate—U‹NŒ‹’°‰ß•q‚É‚¨‚¯‚éƒ}ƒNƒƒtƒ@[ƒW‚¨‚æ‚Ñ’°ŠÇƒOƒŠƒA—R—ˆHMGB1‚Ì–ðŠ„D“ú–{–òŠw‰ï‘æ142”N‰ïD2022, 3, 26-28, –¼ŒÃ‰®ZoomiŒû“ªj

53. Š}”g‰ÃlAŽR–{‘쎑A‹{–{•ü‰ÀA¼–샒jA匴Š²•vAŠâé³GA씨“ÄŽjDƒŒƒZƒvƒgƒf[ƒ^‚ð—p‚¢‚½potentially inappropriate medications (PIMs)‚ÌŽÀ‘Ô’²¸F”F’mÇŠ³ŽÒ‚É‚¨‚¢‚Ä“Á‚É’ˆÓ‚ð—v‚·‚éPIMsˆ•û‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï‘æ142”N‰ïD2022, 3, 26-28, –¼ŒÃ‰®ZoomiŒû“ªj

54. ŠÖŒû•x”üŽqCXŒû°C•Ÿ“‡Žu•àCˆäê—S—¢ŽqC’Ø“c^”¿C•½–{Žu‰——¢C‰ª“c‘ìÆC–L‰ª®Ž÷C“c’†G˜aCˆ°“c—²ŽiC¼‘º“žC씨“ÄŽjD“àˆö«H2SŽY¶‘jŠQ‚É‚æ‚鑽”­«œ‘Žî×–E‚̶‘¶—}§: ƒJƒ‹ƒrƒhƒp‚ƃxƒ“ƒZƒ‰ƒWƒh‚Ìcystathionine-ƒÀ-synthase‘jŠQŠˆ«‚ƃ{ƒ‹ƒeƒ]ƒ~ƒu‘Ï«‘½”­«œ‘ŽîŽ¡—Âւ̉ž—p‚ɂ‚¢‚ÄD‘æ95‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 3, 7-9, •Ÿ‰ªiƒ|ƒXƒ^[j

55. ŽÅ–ì“Þ”¿AˆÀ’B‹`ŽjA˜e’Jq•½Aó–ìŠG仉ÖAŠÖŒû•x”üŽqA‰ª“c‘ìÆA¼ì—T”VA–L‰ª®Ž÷A씨“ÄŽjDRAGEhR–òazeliragon‚̓qƒg‘O—§‘B‚ª‚ñ—R—ˆLNCaP×–E‚̶‘¶E‘B‚ð—}§‚·‚éF‰e‹¿‚ð‚¤‚¯‚é×–EƒVƒOƒiƒ‹‚̉ðÍD‘æ95‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 3, 7-9, •Ÿ‰ªiƒ|ƒXƒ^[j

56. š¢”öŒ«ŒåA’Ø“c^”¿A“c“‡˜aŽ÷AŠÖŒû•x”üŽqA¼–x³—mA“ì@’B˜YAˆÉ“¡²•qA씨“ÄŽjDThrombomodulin/thrombinŒn‚ÅŽY¶‚³‚ê‚éTAFIa/carboxypeptidase B‚Í•â‘̬•ªC5a‚ð•sŠˆ«‰»‚·‚邱‚Æ‚Åoxaliplatin—U”­«––½_ŒoáŠQ‚ð—}§‚·‚éD‘æ95‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 3, 7-9, •Ÿ‰ªiŒû“ªj

57. Š}”g‰ÃlA“싽—DŠóA‘“cŠ°ŽuAŠÖŒû•x”üŽqA‘å‹v•Û‚‚âŽqA‹g“c@”ÉA씨“ÄŽjDƒ|ƒŠƒTƒ‹ƒtƒ@ƒCƒh‚̓Tƒ‹ƒtƒ@ƒCƒh‚ÌCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‹@”\˜´iì—p‚ðÄŒ»‚Å‚«‚È‚¢FˆŸ‰”e˜a«‚Ì‘Šˆá‚ªŠÖ—^‚·‚é‰Â”\«‚ɂ‚¢‚ÄD‘æ95‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 3, 7-9, •Ÿ‰ªiŒû“ªj

58. “°–{从ÑA“c‘º‚ЂȂÌAŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDRƒŠƒEƒ}ƒ`–òsulfasalazine‚ÍToll-like receptor 4ŽhŒƒ‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£‚ð—}§‚·‚邱‚ƂʼnŠÇ«áu’É‚ðŒyŒ¸‚·‚éD‘æ95‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 3, 7-9, •Ÿ‰ªiŒû“ªF‰pŒêj

59. •y“cŽDA’†–ì—yA’Ø“c^”¿A“c’†‰ëKA‘Å’J˜a‹LA‘º’†’B–çA씨“ÄŽjD“œ”A•a«––½_ŒoáŠQ‚ÍthrombinˆË‘¶“I‚Éthrombomodulin alfa‚É‚æ‚Á‚Ä—}§‚³‚êR‹ÃŒÅ–ò‚É‚æ‚Á‚Ä‘ˆ«‚·‚éFŠî‘bE—Õ°—Z‡Œ¤‹†‚É‚æ‚éV’mŒ©D‘æ95‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 3, 7-9, •Ÿ‰ªiŒû“ªF‰pŒêj

60. ŠÖŒû•x”üŽqA‘“cŠ°ŽuAŠ}”g‰ÃlA¬’r”JXA“싽—DŠóA“‡“cNOA¼–{‰Ê•àA²“¡ŽsA’†‘º‹XŽiAŽRŒû_–¾A“c糌³ŽOAŠÛ–{^•ãA’Ø“c^”¿A씨“ÄŽjDƒTƒ‹ƒtƒ@ƒCƒh‚É‚æ‚éCav3.2ˆË‘¶«áu’É‚Æ—L‹@ƒQƒ‹ƒ}ƒjƒEƒ€‚ÌŒø‰ÊD’É‚ÝŒ¤‹†‰ïi2021”N“xjA2022, 1, 31, ‰ªèiƒŠƒ‚[ƒgjiŒû“ªj

61. š¢”öŒ«ŒåA’Ø“c^”¿A“c“‡˜aŽ÷AŠÖŒû•x”üŽqA¼–x³—mA“ì@’B˜YAˆÉ“¡²•qA씨“ÄŽjDThrombomodulin alfa‚Ìoxaliplatin—U”­«––½_ŒoáŠQ—}§ì—p”­Œ»‚É‚¨‚¯‚éHMGB1•sŠˆ«‰»‚Æprotein C‹y‚ÑTAFIŠˆ«‰»‚Ì‘Š‘ΓId—v«‚Ɖº—¬ƒVƒOƒiƒ‹•ªŽq‚̉ðÍD‘æ140‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 11, 13, “Þ—ÇiŒû“ªj

62. Š}”g‰ÃlA“싽—DŠóA‘“cŠ°ŽuAŠÖŒû•x”ü1A‘å‹v•Û‚‚âŽqA‹g“c@”ÉA씨“ÄŽjDCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì‹@”\‚É‚¨‚æ‚Ú‚·ƒTƒ‹ƒtƒ@ƒCƒh‚ƃ|ƒŠƒTƒ‹ƒtƒ@ƒCƒh‚̈قȂéŒø‰ÊFˆŸ‰”‚̉ʂ½‚·–ðŠ„‚É‚Â‚¢‚ÄD‘æ140‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 11, 13, “Þ—ÇiŒû“ªj

63. “°–{从ÑA“c‘º‚ЂȂÌAŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDRƒŠƒEƒ}ƒ`–òsulfasalazine‚̓}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£‚ð—}§‚·‚邱‚Æ‚Ålipopolysaccharide—U‹NƒAƒƒfƒBƒjƒA‚ð—}§‚·‚éD‘æ140‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 11, 13, “Þ—ÇiŒû“ªj

64. “싽—DŠóA‘“cŠ°ŽuAŠ}”g‰ÃlAŠÖŒû•x”üŽqA‘å‹v•Û‚‚âŽqA‹g“c@”ÉA씨“ÄŽjDƒTƒ‹ƒtƒ@ƒCƒh‚É‚æ‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‹@”\‘‹­ƒƒJƒjƒYƒ€‚̉ðÍFƒ|ƒŠƒTƒ‹ƒtƒ@ƒCƒh‚Ƃ̈Ⴂ‚ƈŸ‰”‚ÌŠÖ—^D‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

65. “c“‡˜aŽ÷Aš¢”öŒ«ŒåA’Ø“c^”¿A¼–x³—mA씨“ÄŽj@ƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQ‚Ö‚Ì•â‘ÌC5a‚ÌŠÖ—^D‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

66. ’†–ì—yA•y“cŽDA’Ø“c^”¿A씨“ÄŽj@ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚Í2Œ^“œ”A•adb/dbƒ}ƒEƒX‚É‚¨‚¯‚é—L’É«––½_ŒoáŠQ‚ðƒgƒƒ“ƒrƒ“ˆË‘¶«‚É—}§‚·‚éFƒXƒgƒŒƒvƒgƒ]ƒVƒ“—U”­1Œ^“œ”A•aƒ‚ƒfƒ‹‚Ƃ̈Ⴂ‚ɂ‚¢‚ÄD‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

67. –ؗt—DˆßA’r“c—TÆAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽj.@ƒvƒƒeƒAƒ\[ƒ€‘jŠQ–ò‚̓}ƒNƒƒtƒ@[ƒW‚©‚çƒJƒXƒp[ƒ[ˆË‘¶«‚ÉHMGB1‚ð—V—£‚³‚¹‚éF‘½”­«œ‘ŽîŽ¡—Öòƒ{ƒ‹ƒeƒ]ƒ~ƒu—U”­«––½_ŒoáŠQ‚Ö‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

68. XŒû°AŠÖŒû•x”üŽqA•Ÿ“‡Žu•àA–{šêò˜ÐAˆäê—S—¢ŽqA’Ø“c^”¿A•½–{Žu‰——¢A“c’†G˜aAˆ°“c—²ŽiA¼‘º“žA씨“ÄŽjD–F‘°LƒAƒ~ƒmŽ_’E’YŽ_y‘f‘jŠQ–òƒJƒ‹ƒrƒhƒp‚ƃxƒ“ƒZƒ‰ƒWƒh‚Í‘½”­«œ‘Žî×–E‚̶‘¶E‘B‚ð—}§‚·‚éFH2SŽY¶‘jŠQì—p‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

69. ˆäê—S—¢ŽqA–{šêò˜ÐA’Ø“c^”¿A죓ĎjAŠâé³GA씨“ÄŽjD–F‘°LƒAƒ~ƒmŽ_’E’YŽ_y‘f‘jŠQ–òƒJƒ‹ƒrƒhƒp‚ÍH2SŽY¶y‘fcystathionine-ƒÀ-synthase‚ð‘jŠQ‚·‚邱‚Æ‚Å“à‘Ÿ’É‚ð—}§‚·‚éD‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD@

70. ’Ø“c^”¿A씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQ‚Ì”­ÇƒƒJƒjƒYƒ€‚̉ðÍ\HMGB1‚¨‚æ‚Ñ“àˆö«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“/ƒgƒƒ“ƒrƒ“‚Ì–ðŠ„\D‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgji§—ãÜŽóÜu‰‰jD

71. Š}”g‰ÃlA–Ø–ì‹M”ŽAÎìç_A‚“‡NGA’·“ì•SA‰ª“c‘ìÆAŠÖŒû•x”üŽqA‹g“c ”ÉA‘å‹v•Û‚‚âŽqA–L‰ª®Ž÷A씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQŠˆ«‚ð—L‚·‚é’èŒ^R¸_•a–òpimozide‚Ì\‘¢“WŠJŒ¤‹†‚É‚æ‚éV‹K“«áu’ÉŽ¡—Öò‚Ì‘n»D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2021D2021, 8, 26, ŽD–yiƒnƒCƒtƒŒƒbƒNƒXjiƒ|ƒXƒ^[j

72. ŠÑŒËˆ»”TA’Ø“c^”¿A•½–{Žu‰——¢A¼‰i_–¾A‹{–{•ü‰ÀA¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒGƒXƒgƒƒQƒ“‚̓}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£‚ÆHMGB1Š´Žó«‚ð’ቺ‚³‚¹‚邱‚ƂŃpƒNƒŠƒ^ƒLƒZƒ‹—U”­«––½_ŒoáŠQ‚ð—}§“I‚ɧŒä‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2021D2021, 8, 26, ŽD–yiƒnƒCƒtƒŒƒbƒNƒXjiƒ|ƒXƒ^[j

73. ²X–؉ÔØAShin EunkyungA–ì’†Œ‹AŠ’J—œŠGA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDButyrate—U‹N‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹‚É‚¨‚¯‚錋’°‰ß•q‚ւ̃}ƒNƒƒtƒ@[ƒW‚¨‚æ‚Ñ’°ŠÇƒOƒŠƒA×–E—R—ˆHMGB1‚ÌŠÖ—^D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2021D2021, 8, 26, ŽD–yiƒnƒCƒtƒŒƒbƒNƒXjiƒ|ƒXƒ^[j

74. š¢”öŒ«ŒåA“c“‡˜aŽ÷A’Ø“c^”¿A¼–x³—mA씨“ÄŽjDThrombomodulin alfa‚É‚æ‚éoxaliplatin—U‹N––½_ŒoáŠQ”­Ç—}§ì—p‚ÉŠÖ—^‚·‚郃JƒjƒYƒ€‚̉ðÍFHMGB1•sŠˆ«‰»ì—p‚Æprotein C‹y‚ÑTAFIŠˆ«‰»ì—p‚ÌŠñ—^‚ɂ‚¢‚ÄD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2021D2021, 8, 26, ŽD–yiƒnƒCƒtƒŒƒbƒNƒXjiƒ|ƒXƒ^[j

75. ’Ø“c^”¿A씨“ÄŽjD“à‘Ÿ’É‚Ì”­Ç‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑHMGB1‚Ì–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2021D2021, 8, 26, ŽD–yiƒnƒCƒtƒŒƒbƒNƒXjiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

76.–Ø–ì‹M”ŽAŠ}”g‰ÃAÎìç_A‚“‡NGA’·“ì•SA‰ª“c‘ìÆAŠÖŒû•x”üŽqA‹g“c”ÉA‘å‹v•Û‚‚âŽqA–L‰ª®Ž÷A씨“ÄŽjDR¸_•a–òpimozide‚Ì\‘¢“WŠJ‚É‚æ‚éV‹K‘I‘ð“ITŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–ò‚Ì‘n»FV‚½‚ȓ«áu’ÉŽ¡—Öò‚ÌŠJ”­‚ÉŒü‚¯‚ÄD‘æ139‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 6, 26, –¼ŒÃ‰®iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[j

77. ‘q‹´ãÄ‘¾˜YA¼ŽRˆÉ‘ãA“ì–ì仓ßA–Ø–ì‹M”ŽA‚“‡NGAŠ}”g‰ÃA–Ø–ìŽuDA¼ì—T”VAÎìç_A‰ª“c‘ìÆAŠÖŒû•x”üŽqA’Ø“c^”¿A–L‰ª®Ž÷A씨 “ÄŽjDH2S‹Ÿ—^‘ÌNa2S‚̃}ƒEƒX–j”ç“à“Š—^‚É‚æ‚è—U‹N‚³‚ê‚éCav3.2ˆË‘¶«‘~áy‚¨‚æ‚Ñáu’ɂɑ΂·‚é’èŒ^R¸_•a–òpimozide‚ÆD2Žó—e‘ÌŽÕ’fŠˆ«‚ðŒ¸Žã‚³‚¹‚½V‹Kpimozide—U“±‘ÌKTtp-5‚ÌìD‘æ139‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 6, 26, –¼ŒÃ‰®iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[j

78. ŠÖŒû•x”üŽqA•Ÿ“‡Žu•àAXŒû°A•½–{Žu‰——¢A“c’†G˜aAˆ°“c—²ŽiA¼‘º“žA씨“ÄŽjDH2SŽY¶y‘fcystathionine-ƒÀ-synthase‚Ì‘jŠQ–ò‚̓{ƒ‹ƒeƒ]ƒ~ƒu‘Ï«‚ðŠl“¾‚µ‚½‘½”­«œ‘Žî×–E‚̶‘¶E‘B‚ð—}§‚·‚éD‘æ139‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 6, 26, –¼ŒÃ‰®iƒŠƒ‚[ƒgjiŒû“ªj

79. ŠÑŒËˆ»”TA’Ø“c^”¿A•½–{Žu‰——¢A¼‰i_–¾A‹{–{•ü‰ÀA¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒGƒXƒgƒƒQƒ“‚̓}ƒNƒƒtƒ@[ƒW‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U‹NHMGB1—V—£‚ƃ}ƒEƒX‚É‚¨‚¯‚éHMGB1—U‹NƒAƒƒfƒBƒjƒA‚ð—}§‚·‚éFƒGƒXƒgƒƒQƒ“’ቺ‚É‚æ‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”­«––½_ŒoáŠQdlj»‚Æ‚ÌŠÖŒW‚ɂ‚¢‚ÄD‘æ139‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 6, 26, –¼ŒÃ‰®iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[j

80. 씨“ÄŽjD“à‘Ÿ’É‚É‚¨‚¯‚éƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚Ì–ðŠ„‚ÆŽ¡—ÕW“I•ªŽq‚Æ‚µ‚Ẳ”\«DƒVƒ“ƒ|ƒWƒEƒ€u“à‘Ÿ’ÉE“à‘ŸŠ´Šo‚Ì‹@”\Œ`‘ÔŠw“IŠî”Õ‚Æ‚»‚̈Ù킪‚à‚½‚ç‚·•a‘ÔvA‘æ126‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï‚Æ‘æ98‰ñ“ú–{¶—Šw‰ï‘å‰ï‚̇“¯‘å‰ïD2021, 3, 28-30, –¼ŒÃ‰®iƒŠƒ‚[ƒgjiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[jD

81. ‰Æ“c³ŽqA‹{–{•ü‰ÀA׌©ŒõˆêA‚“c[—²A’|ãŠwA씨“ÄŽjD–òŠw•”¶‚É‚¨‚¯‚éˆê”Ê–¼‚Ƥ•i–¼‚É‚æ‚éˆã–ò•i”FŽ¯‚É‹y‚Ú‚·•a‰@ŽÀ–±ŽÀK‚̉e‹¿D“ú–{–òŠw‰ï@‘æ141”N‰ïA2021, 3, 26-29, L“‡iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

82. “c’†”ŽlA‘åˆäŒMAœA£‰ë˜NA¬ì‹œA‰““¡„AŽRì•x—YA씨“ÄŽjDV‹KTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQÜ‚Ì‘n»Œ¤‹†D“ú–{–òŠw‰ï@‘æ141”N‰ïA2021, 3, 26-29, L“‡iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

83. •½–{Žu‰——¢AŸÇ–씣A‹g”N³GAúå]³ŽkA‹{–{•ü‰ÀA’|ãŠwA씨@“ÄŽjD—«ŠàŠ³ŽÒ‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”­«––½_ŒoáŠQ‚Ì”­ÇEdlj»‚ÉŠñ—^‚·‚éˆöŽq‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï@‘æ141”N‰ïA2021, 3, 26-29, L“‡iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

84. ŠÑŒËˆ»”TA•½–{Žu‰——¢A’Ø“c^”¿A¼‰i_–¾A‹{–{•ü‰ÀA¬ò—SˆêA¼–x³—mA씨“ÄŽjD—‘‘ƒ“Eoƒ}ƒEƒX‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”­«––½_ŒoáŠQ‚¨‚æ‚ÑHMGB1—U‹NƒAƒƒfƒBƒjƒA‚Ì‘ˆ«D‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ïD2021, 3, 8-10, ŽD–yiƒŠƒ‚[ƒgjiŒû“ªjD

85. ŽRãp•à–²A¼ˆä˜aŽ÷A’Ø“c^”¿A¼–x³—mA씨“ÄŽjDƒgƒƒ“ƒrƒ“‘jŠQ–ò‚ÍHMGB1‚ªŠÖ—^‚·‚錋’°’É‚ÆäNã÷’ɂ𑈫‚³‚¹‚éF“à‘ ’ɧŒä‚É‚¨‚¯‚é“àˆö«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“^ƒgƒƒ“ƒrƒ“Œn‚Ì–ðŠ„D‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ïD2021, 3, 8-10, ŽD–yiƒŠƒ‚[ƒgjiŒû“ªjD

86. ŠÖŒû•x”üŽq, ’†•‚ä‚¢, ’Ø“c^”¿A¼–x³—mA씨“ÄŽjD¿œ_Œo‘¹ƒ}ƒEƒX‚©‚ç“Eo‚µ‚½Œãª_Œoß_Œo×–E‚Ì“Ë‹NL’·‘£i‚ɂ̓}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚ªŠÖ—^‚·‚éD‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ïD2021, 3, 8-10, ŽD–yiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

87. ¬’r”JXA™–{‰Ê•àA‘“cŠ°ŽuA“‡“cNOA²“¡ŽsA’†‘º‹XŽiAŽRŒû_–¾A“c糌³ŽOAŠÛ–{^•ãAŠ}”g‰ÃlAŠÖŒû•x”üŽqA‘å‹v•Û‚‚âŽqA‹g“c”ÉA씨“ÄŽjDRepagermanium…‰ð•¨‚Ísulfide‚ð•ß‘¨‚·‚邱‚Æ‚ÅH2S‚É‚æ‚éCav3.2ƒ`ƒƒƒlƒ‹Šˆ«ã¸‚Æ“à‘Ÿ’É‚¨‚æ‚Ñ‘Ì«’É‚ð—}§‚·‚éD‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ïD2021, 3, 8-10, ŽD–yiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

88. ‘q‹´ãÄ‘¾˜YA¼ŽRˆÉ‘ãA“ì–ì仓ßA¼ì—T”VAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDƒ}ƒEƒX‚¨‚¢‚Ä—°‰»•¨‚Ì–j”ç“à“Š—^‚É‚æ‚è—U‹N‚³‚ê‚éáy‚Ý‚Æ’É‚ÝFCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹ˆâ“`ŽqŒ‡Ž¸‚̉e‹¿D‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ïD2021, 3, 8-10, ŽD–yiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

89. “°–{从ÑAŠ˜Œû—ÍA‰Æ‘º–ƒˆßŽqAŠÖŒû•x”üŽqA씨“ÄŽjD_Œo—R—ˆATP‚Ípaclitaxel‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£‚ð‘£i‚·‚éF‰»Šw—Ö@—U”­«––½_ŒoáŠQ‚É‚¨‚¯‚é_Œo|–Ɖu˜AŠÖ”}‰î•¨Ž¿‚Æ‚µ‚Ä‚ÌATP‚Ì–ðŠ„D‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ïD2021, 3, 8-10, ŽD–yiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

90. ŠÖŒû•x”üŽqA¬’r”JXA“‡“cNOA™–{‰Ê•àA‘“cŠ°ŽuA²“¡ŽsA’†‘º‹XŽiAŽRŒû_–¾A“c糌³ŽOAŠÛ–{^•ãAŠ}”g‰ÃlA’Ø“c^”¿A씨“ÄŽjD—L‹@ƒQƒ‹ƒ}ƒjƒEƒ€‰»‡•¨repagermanium‚ÌH2S/Cav3.2‚ð‰î‚µ‚½‘Ì«’É‚¨‚æ‚Ñ“à‘Ÿ’ɂɑ΂·‚é—}§Œø‰ÊDƒVƒ“ƒ|ƒWƒEƒ€uV‚µ‚¢áu’ÉŽ¡—Öò‚ÌŠJ”­‚ð–ÚŽw‚µ‚½–ò—ŠwŒ¤‹†vA‘æ138‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2020, 11, 14, “Œ‘åãiƒŠƒ‚[ƒgjiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[jD

91. “c’†”ŽlA¬ì‹œA’†‘º‰p¶A’Ø“c^”¿A¬¼—²’jA¡ˆä—˜ˆÀAŽRì•x—YAŠÖŒû•x”üŽqA씨“ÄŽjDV‹KCav3.2‘jŠQÜNCP-1117‚Ì–ò—ƒvƒƒtƒ@ƒCƒ‹D‘æ138‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2020, 11, 14, “Œ‘åãiƒŠƒ‚[ƒgjiŒû“ªjD

92. “Œ–{g—Ú”üAã–ìŽR‹ËŽqA¼ì—T”VAŠÖŒû•y”üŽqA’Ø“c^”¿A‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjD’†•ªŽqƒwƒpƒŠƒjƒ‹ƒtƒFƒjƒ‹ƒAƒ‰ƒjƒ“‚ÍRAGE‚ªŠÖ—^‚·‚é’É‚Ý‚ð—}§‚·‚éD‘æ138‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2020, 11, 14, “Œ‘åãiƒŠƒ‚[ƒgjiŒû“ªjD

93. •y“cŽDA“c’†‰ëKA‘Å’J˜a‹LA‘º’†’B–çA씨“ÄŽjD“œ”A•aŠ³ŽÒ‚É‚¨‚¢‚ÄR‹ÃŒÅ–ò‚Í––½_ŒoáŠQ‚Ì”­Ç‚ð‘£i‚·‚éFŒã‚ëŒü‚«ƒRƒz[ƒg—Õ°Œ¤‹†‚É‚æ‚éŠî‘bŒ¤‹†’mŒ©‚ÌŒŸØD‘æ138‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2020, 11, 14, “Œ‘åãiƒŠƒ‚[ƒgjiŒû“ªjD

94. —Ñ —F“TA‹{–{•ü‰ÀA•½“c“ÖŽmA’·ˆä‹IÍA씨“ÄŽjD‘O—§‘BŠà‚Ì‹Ž¨’ïR«Šl“¾‚ƶŠˆKŠµ•a‚ÌŠÖ˜A«D‘æ138‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2020, 11, 14, “Œ‘åãiƒŠƒ‚[ƒgjiŒû“ªjD

95. ’Ø“c ^”¿A•Ÿ“c —º‘¾˜YA—Ñ —C—ºA‹{è ‹M–çAã“cTAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQ‚É‚¨‚¯‚éHMGB1‚Ì–ðŠ„‚Æƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“/ƒgƒƒ“ƒrƒ“Œn‚É‚æ‚é—}§“I§ŒäD‘æ70‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘å‰ïD2020, 10, 10, ‘’ÃiƒŠƒ‚[ƒgjiŒû“ªjD

96. •y“cŽDA“c’†‰ë”VA‘Å’J˜a‹LA‘º’†’B–çA‰ªè˜aˆêA씨“ÄŽjD“œ”A•a«––½_ŒoáŠQ‚Ì”­Œ»‚É‹y‚Ú‚·R‹ÃŒÅ–ò‚̉e‹¿‚ÉŠÖ‚·‚éŒã‚ëŒü‚«ƒRƒz[ƒgŒ¤‹†D‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïD2020, 9, 20, –¼ŒÃ‰®iƒŠƒ‚[ƒgjD

97. ‹{–{•ü‰ÀA•xŽm’J¹“TA”¨’†dŽA¬ò—SˆêA씨“ÄŽjD•ÂŒoŒã‚Ì“û‚ª‚ñŠ³ŽÒ‚̓pƒNƒŠƒ^ƒLƒZƒ‹—U”­«––½_ŒoáŠQ‚Ì”­ÇEdlj»ƒŠƒXƒN‚ª‚‚¢D‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïD2020, 9, 20, –¼ŒÃ‰®iƒŠƒ‚[ƒgjD

98. —Ñ —F“TA‹{–{•ü‰ÀA•½“c“ÖŽmA’·ˆä‹IÍA씨“ÄŽjD‘O—§‘BŠà‚Ì‹Ž¨’ïR«Šl“¾‚Æ—Õ°ˆöŽq‚ÌŠÖ˜A«‚É‚¨‚¯‚é’T¸Œ¤‹†D‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïD2020, 9, 20, –¼ŒÃ‰®iƒŠƒ‚[ƒgjD

99. Kawabata, A., Nishikawa, H. Higashimoto, K., Uenoyama, K., Sekiguchi, F., Tsubota1, M., Okada, T., Toyooka, N. Middle molecular weight heparinylphenylalanine selectively blocks RAGE and reduces HMGB1-dependent neuropathic and visceral pain in mice. 12th FENS Forum of Neuroscience. 2020, 7, 11-15, Glasgow, UK. (poster; ƒŠƒ‚[ƒg)

100.       Sekiguchi, F., Yamashita, R., Yasui, H., Kawabata, A. Schwann cells from neonatal rat sciatic nerves secrete high mobility group box 1 (HMGB1), a pro-inflammatory and pro-nociceptive mediator, in response to paclitaxel. 12th FENS Forum of Neuroscience. 2020, 7, 11-15, Glasgow, UK. (poster; ƒŠƒ‚[ƒg)

101.       Kawabata, A. Neuroimmune crosstalk in neuropathic and visceral pain: HMGB1 and ATP as key mediators. In Symposium gNeuroimmune crosstalk and painh, organized by Kawabata, A. and Zamponi, G., ‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ïD2020, 3, 14-16, ‰¡•liƒŠƒ‚[ƒgjDiSymposium Organizer & Speakerj

102.       ‰Æ“c³ŽqA‹{–{•ü‰ÀA׌©ŒõˆêA‚“c[—²A’|ãŠwA씨“ÄŽjD–òŠw•”¶‚É‚¨‚¯‚éˆê”Ê–¼‚Ƥ•i–¼‚É‚æ‚éˆã–ò•i”FŽ¯‚É‹y‚Ú‚·•a‰@ŽÀ–±ŽÀK‚̉e‹¿D“ú–{–òŠw‰ï‘æ141”N‰ïD2021, 3, 26-29, L“‡iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

103.       “c’†”ŽlA‘åˆäŒMAœA£‰ë˜NA¬ì‹œA‰““¡„AŽRì•x—YA씨“ÄŽjDV‹KTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQÜ‚Ì‘n»Œ¤‹†D“ú–{–òŠw‰ï‘æ141”N‰ïD2021, 3, 26-29, L“‡iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

104.       •½–{Žu‰——¢AŸÇ–씣A‹g”N³GA–ö]³ŽkA‹{–{•ü‰ÀA’|ãŠwA씨“ÄŽjD—«ŠàŠ³ŽÒ‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”­«––½_ŒoáŠQ‚Ì”­ÇEdlj»‚ÉŠñ—^‚·‚éˆöŽq‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï‘æ141”N‰ïD2021, 3, 26-29, L“‡iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD

105.       씨“ÄŽjDŠî‘b‚Æ—Õ°‚Ì‘o•ûŒü«ƒAƒvƒ[ƒ`‚É‚æ‚é–ò—ŠwŒ¤‹†F‚ª‚ñŠ³ŽÒ‚É‚¨‚¯‚鉻Šw—Ö@‚̃ŠƒXƒNˆöŽq‰ðÍ‚©‚猩‚¦‚Ä‚«‚½‚à‚ÌD”N‰ïŠé‰æƒVƒ“ƒ|ƒWƒEƒ€u–ò—ŠwŒ¤‹†‚É‚¨‚¯‚é—Õ°ƒrƒbƒOƒf[ƒ^‚ÌŠˆ—pF‰¼àŒŸØ‚©‚çƒhƒ‰ƒbƒOƒŠƒ|ƒWƒVƒ‡ƒjƒ“ƒO‚Ü‚ÅvAorganized byÎàVA’†ìD‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ïD2020, 3, 14-16, ‰¡•liƒŠƒ‚[ƒgjDiƒVƒ“ƒ|ƒWƒEƒ€EƒXƒs[ƒJ[j

106.       ŠÖŒû•x”üŽqA•Ÿ“‡Žu•àA•½–{Žu‰——¢A“c’†G˜aAˆ°“c—²ŽiA¼‘º@“žA씨“ÄŽjD—°‰»…‘fŽY¶y‘f‘jŠQ–ò‚̓vƒƒeƒAƒ\[ƒ€‘jŠQ–òƒ{ƒ‹ƒeƒ]ƒ~ƒu‘Ï«‚ðŠl“¾‚µ‚½ƒqƒg‘½”­«œ‘ŽîKMS-11×–E‚̶‘¶‚ð—}§‚·‚éD‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ïD2020, 3, 14-16, ‰¡•liƒŠƒ‚[ƒgjDiƒ|ƒXƒ^[j

107.       ¬’r”JXA™–{‰Ê•àA‘“cŠ°ŽuA“‡“cNOA²“¡ŽsA’†‘º‹XŽiAŽRŒû_–¾A“c糌³ŽOAŠÛ–{^•ãAŠ}”g‰ÃlAŠÖŒû•x”üŽqA‘å‹v•Û‚‚âŽqA‹g“c@”ÉA씨“ÄŽjDRepagermanium‚ÍH2S‚Æ’¼Ú”½‰ž‚·‚邱‚Æ‚ÅH2S‚É‚æ‚è—U‹N‚³‚ê‚éCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹Šˆ«‚¨‚æ‚Ñ’É‚ÝŠ´Žó«‚Ì‘‘å‚ð—}§‚·‚éD‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ïD2020, 3, 14-16, ‰¡•lDi‰pŒêŒû“ª”­•\j

108.       ŠÑŒËˆ»”TA•½–{Žu‰——¢A’Ø“c^”¿A‹{–{•ü‰ÀA¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒGƒXƒgƒƒQƒ“Œ‡–R‚É‚æ‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”­«––½_ŒoáŠQ‚Ì‘ˆ«FHMGB1‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ïD2020, 3, 14-16, ‰¡•lDiƒ|ƒXƒ^[j

109.       “Œ–{‹v—Ú”üAã–ìŽR‹ËŽqA¼ì—T”VAŠÖŒû•x”üŽqA’Ø“c^”¿A–L‰ª®Ž÷A씨“ÄŽjDRAGE‘jŠQŠˆ«‚ð—L‚·‚é’†•ªŽqƒwƒpƒŠƒjƒ‹ƒtƒFƒjƒ‹ƒAƒ‰ƒjƒ“‚̓}ƒEƒX‚É‚¨‚¯‚éoxaliplatin—U”­«––½_ŒoáŠQ‚¨‚æ‚Ñbutyrate—U‹NŒ‹’°’É‚ð—}§‚·‚éD‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ïiƒŠƒ‚[ƒgjD2020, 3, 14-16, ‰¡•lDiƒ|ƒXƒ^[j

110.       Kawabata, A. Role of ATP/HMGB1/RAGE and H2S/Cav3.2 axes in cystitis-related bladder pain. gPain and Survival Strategyh, National Institute of Physiological Sciences International Workshop on Frontiers in Defensive Survival Circuit Researchi’É‚ÝŒ¤‹†‰ï2019j2020, 1, 7-8, Okazaki.iOralj

111.       Kamaguchi, R., Domoto, R., Sekiguchi, F., Tsubota, M., Nishibori, M., Kawabata, A. Hepatic injury aggravates oxaliplatin-induced peripheral neuropathy in mice: possible involvement of HMGB1 derived from the liver. gPain and Survival Strategyh, National Institute of Physiological Sciences International Workshop on Frontiers in Defensive Survival Circuit Researchi’É‚ÝŒ¤‹†‰ï2019j2020, 1, 7-8, Okazaki. iPosterj

112.    ‹{–{•ü‰ÀA•½–{Žu‰——¢AŠÑŒËˆ»”TA•xŽm’J¹“TA”¨’†dŽA’Ø“c^”¿A¬ò—SˆêA씨“ÄŽjDƒpƒNƒŠƒ^ƒLƒZƒ‹—U”­«––½_ŒoáŠQ‚̃ŠƒXƒNˆöŽq‰ðÍF‚ª‚ñ‚ÌŽí—Þ‚É‚æ‚éˆá‚¢‚ƉÁ—î‚̉e‹¿‚ɂ‚¢‚ÄD‘æ136‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï, 2018, 11, 23, –‡•ûDiŒû“ªj

113.    •½–{Žu‰——¢AŠÑŒËˆ»”TA‹{–{•ü‰ÀA’Ø“c^”¿A¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒpƒNƒŠƒ^ƒLƒZƒ‹—U”­«––½_ŒoáŠQ‚̃ŠƒXƒNˆöŽq‰ðÍF—‘‘ƒ“Eoƒ}ƒEƒX‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”­«––½_ŒoáŠQ‚Ì‘ˆ«FHMGB1‚ÌŠÖ—^‚ɂ‚¢‚ÄD@‘æ136‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï, 2018, 11, 23, –‡•ûDiŒû“ªj

114.    ¬’r”JXA™–{‰Ê•àA‘“cŠ°ŽuA“‡“cNOA²“¡ŽsA’†‘º‹XŽiAŽRŒû_–¾A“c糌³ŽOAŠÛ–{^•ãAŠ}”g‰ÃlAŠÖŒû•x”üŽqA씨“ÄŽjD—L‹@ƒQƒ‹ƒ}ƒjƒEƒ€‰»‡•¨repagermanium‚ÍH2S‚É‚æ‚è—U‹N‚³‚ê‚éCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹Šˆ«ã¸‚ƃ}ƒEƒX‚É‚¨‚¯‚éƒAƒƒfƒBƒjƒA‚ð’¼Ú“I‚É‘jŠQ‚·‚éD‘æ136‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï, 2018, 11, 23, –‡•ûDiŒû“ªj

115.       Kawabata, A. Role of HMGB1 and PRRs in pain processing. In Symposium gEmerging roles of DAMPs/alarmins and PRRs in neurological disordersh, organized by Kawabata, A., The 6th Asian College of Neuropsychopharmacology (AsCNP) Congress, 2019, 10, 11-13, Fukuoka. (Symposium speaker) 

116.       Sekiguchi, F., Yamashita, R., Yasui, H., Kawabata, A. Paclitaxel, an anti-cancer drug, causes extracellular release of HMGB1, a pro-inflammatory and pro-nociceptive mediator, in Schwann cells derived from neonatal rat sciatic nerves. The 6th Asian College of Neuropsychopharmacology (AsCNP) Congress, 2019, 10, 11-13, Fukuoka. (Poster)

117.       Tsubota, M., Fukuda, R., Hayashi, Y., Miyazaki, T., Ueda, S., Nishibori, M., Kawabata, A. Endogenous thrombin plays a preventive role against oxaliplatin-induced peripheral neuropathy: involvement of thrombomodulin-dependent inactivation of HMGB1 by thrombin. The 6th Asian College of Neuropsychopharmacology (AsCNP) Congress, 2019, 10, 11-13, Fukuoka. (Poster)

118.       Ikeda, Y., Miyazak, T., Tsubota, M., Tomita, S., Sekiguchi, F., Nishibori, M., Kawabata, A. Involvement of HMGB1 in bortezomib-induced peripheral neuropathy in mice. The 6th Asian College of Neuropsychopharmacology (AsCNP) Congress, 2019, 10, 11-13, Fukuoka. (Poster)

119.       Koike, N., Yasui, H., Sekiguchi, F., Tanabe, G., Kawabata, A. Role of T-type calcium channels in methamphetamine-induced hyperlocomotion and neuronal excitation in mice. The 6th Asian College of Neuropsychopharmacology (AsCNP) Congress, 2019, 10, 11-13, Fukuoka. (Poster)

120.       “Œ–{g—Ú”üAã–ìŽR‹ËŽqA¼ì—T”VAŠÖŒû•x”üŽqA’Ø“c^”¿A‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjD’†•ªŽqƒwƒpƒŠƒjƒ‹ƒtƒFƒjƒ‹ƒAƒ‰ƒjƒ“‚ÌRAGE‘jŠQŠˆ«‚ƃ}ƒEƒX‚É‚¨‚¯‚éoxaliplatin—U”­«––½_ŒoáŠQ‚¨‚æ‚Ñbutyrate—U‹NŒ‹’°’ɂɑ΂·‚é—}§ì—pD‘æ69‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ï, 2019, 10, 12, _ŒËDiƒ|ƒXƒ^[j

121.       Š˜Œû@—ÍA“°–{从ÑA¼‘ºä»AŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDŠÌáŠQ‚É‚æ‚éƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U”­«––½_ŒoáŠQ‚Ì‘ˆ«F •aŒ´ˆöŽqHMGB1‚ð—V—£‚·‚éŠÌ“à×–E‚Ì’TõD‘æ69‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ï, 2019, 10, 12, _ŒËDiƒ|ƒXƒ^[j

122.       ŽRãp•à–²A¼ˆä˜aŽ÷A’Ø“c^”¿A씨“ÄŽjD¶‘Ì“à‚É‚¨‚¢‚ăgƒƒ“ƒrƒ“Eƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“Œn‚Í“à‘Ÿ’É‚ð—}§“I‚ɧŒä‚µ‚Ä‚¢‚éD‘æ69‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ï, 2019, 10, 12, _ŒËDiƒ|ƒXƒ^[j

123.       •Ÿ“‡Žu•àA•½–{Žu‰——¢AŠÖŒû•x”üŽqA“c’†G˜aAˆ°“c—²ŽiA¼‘º@“žA씨“ÄŽjDƒqƒg‘½”­«œ‘Žî—R—ˆKMS-11×–E‚̃{ƒ‹ƒeƒ]ƒ~ƒu‘Ï«Šl“¾‚É‚¨‚¯‚é“àˆö«—°‰»…‘f‚Ì–ðŠ„D‘æ69‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ï, 2019, 10, 12, _ŒËDiƒ|ƒXƒ^[j

124.       Kawabata, A., Tsubota, M., Uebo, K., Miki, K., Sekiguchi, F., Ishigami, A. Dietary ascorbic acid restriction in GNL/SMP30-knockout mice unveils the role of ascorbic acid in regulation of Cav3.2-dependent pain. 11th Congress of the European Pain Federation EFIC (2019 Pain in Europe XI), 2019, 9, 4-7, Valencia, Spain. (Poster)

125.       Sekiguchi, F., Kasanami, Y., Onishi, R., Tsubota, M., Miyazaki, T., Hiramoto, S., Okazaki, K., Nguyen, H.D., Okada, T., Toyooka, N., Yoshida, S., Ohkubo, T., Kawabata, A. 6-Prenylnaringenin and its derivative, KTt45, are mixed T-type Ca2+ channel inhibitors/CB2 receptor agonists: antinociceptive activity in neuropathic and visceral pain models. 11th Congress of the European Pain Federation EFIC (2019 Pain in Europe XI), 2019, 9, 4-7, Valencia, Spain. (Poster)

126.       Matsui, K., Fukushi, S., Koike, N., Yamagata, A., Tsubota, M., Mukai, Y., Oita, A., Takada, M., Kawabata, A. Critical role of Cav3.2 T-type calcium channels in H2S-dependent somatic and visceral pain signaling in mice. 11th Congress of the European Pain Federation EFIC (2019 Pain in Europe XI), 2019, 9, 4-7, Valencia, Spain. (Poster)

127.       Domoto, R., Fukuda, R., Sekiguchi, F., Tsubota, M., Nishibori, M., Kawabata, A. Hepatic injury aggravates oxaliplatin-induced peripheral neuropathy in mice: possible involvement of HMGB1. 11th Congress of the European Pain Federation EFIC (2019 Pain in Europe XI), 2019, 9, 4-7, Valencia, Spain. (Poster)

128.       Hiramoto, S., Tsubota, M., Yamaguchi, K., Okazaki, K., Tanaka, J., Sekiguchi, F., Ishikura, H., Nishibori, M., Kawabata, A. Crosstalk between the HMGB1/RAGE and CSE/H2S/Cav3.2 pathways involved in cystitis-related bladder pain in mice. 11th Congress of the European Pain Federation EFIC (2019 Pain in Europe XI), 2019, 9, 4-7, Valencia, Spain. (Poster)

129.       ’Ø“c^”¿A•Ÿ“c—º‘¾˜YA—Ñ —C—ºA‹{è‹M–çAã“c TAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQ‚É‚¨‚¯‚éHMGB1Œn‚ƃgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“/ƒgƒƒ“ƒrƒ“Œn‚Ì‘Š”½“I–ðŠ„DŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2019@@2019, 8, 31, “Œ‹žDiŒû“ªj

130.       ¬’r”JXA™–{‰Ê•àA“‡“cNOA²“¡ŽsA’†‘ºéŽiAŽRŒû_–¾A“c糌³ŽOAŠÖŒû•x”üŽqA씨“ÄŽjD—L‹@ƒQƒ‹ƒ}ƒjƒEƒ€‰»‡•¨repagermanium…‰ð•¨‚Í‹C‘̃ƒfƒBƒG[ƒ^[H2S‚ð•ß‘¨‚·‚邱‚ƂŃAƒƒfƒBƒjƒA‚ð—}§‚·‚éDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2019@@2019, 8, 31, “Œ‹žDiŒû“ªj

131.       씨“ÄŽjD‰»Šw—Ö@—U”­«––½_ŒoáŠQ‚̃ŠƒXƒNˆöŽq‰ðÍ‚ÆHMGB1‚ð•W“I‚Æ‚·‚é—\–hí—ªFŠî‘bŒ¤‹†‚Æ—Õ°Œ¤‹†‚Ì—Z‡‚É‚æ‚éV’mŒ©‚ƃCƒmƒx[ƒVƒ‡ƒ“DƒVƒ“ƒ|ƒWƒEƒ€uŠî‘b‚Æ—Õ°‚Ì—Z‡‚©‚ç‚Ìáu’ÉŒ¤‹†viƒI[ƒKƒiƒCƒU[F씨“ÄŽjA’O–ìFˆêjA¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2019A2019, 8, 29-30, “Œ‹žDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

132.       ¬’r”JXAˆÀˆä—mŽ÷AŠÖŒû•x”üŽqA“c糌³ŽOA씨“ÄŽjDŠoÁ܃ƒ^ƒ“ƒtƒFƒ^ƒ~ƒ“‚É‚æ‚è—U‹N‚³‚ê‚éƒ}ƒEƒX‚Ìs“®—Ê‘‰Á‚Æ”]“àcFos”­Œ»‚É‚¨‚¯‚éTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2019@2019, 8, 29-30, “Œ‹žDiƒ|ƒXƒ^[j

133.       ™–{‰Ê•àA¬’r”JXA“‡“cNOA²“¡ŽsA’†‘º‹XŽiAŽRŒû_–¾A“c糌³ŽOAŠÖŒû•x”üŽqA씨“ÄŽjDRepagermanium…‰ð•¨3-(trihydroxygermyl)propanoic acid (THGP)‚ÍH2S‚É’¼Úì—p‚µŠOˆö«‚¨‚æ‚Ñ“àˆö«H2S‚É‚æ‚éƒAƒƒfƒBƒjƒA‚ð—}§‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2019@2019, 8, 29-30, “Œ‹žDiƒ|ƒXƒ^[j

134.       ŠÑŒËˆ»”TA•½–{Žu‰——¢A‹{–{•ü‰ÀA’Ø“c^”¿A¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒGƒXƒgƒƒQƒ“‚̓pƒNƒŠƒ^ƒLƒZƒ‹—U”­«––½_ŒoáŠQ‚ɑ΂µ‚Ä—}§“I‚Éì—p‚·‚éFƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚Æ‚ÌŠÖŒW‚ɂ‚¢‚ÄD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2019@2019, 8, 29-30, “Œ‹žDiƒ|ƒXƒ^[j

135.       Kawabata, A. Role of peripheral HMGB1 and thrombomodulin/thrombin in neuropathic pain. In Symposium gImpact of new advances in the DAMPs/alarmins and neuroinflammation researches on diverse neuronal diseasesh organized by Kawabata, A. and Okazawa, H., ‘æ42‰ñ“ú–{_Œo‰ÈŠw‰ï@2019, 7, 25-28, VŠƒDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

136.       ‹{–{•ü‰ÀA•xŽm’J¹“TA“°–{从ÑA”¨’†dŽA•ŸŽRhŠîAŠÖŒû•x”üŽqA¬ò—Sˆê@씨“ÄŽjDŠÌáŠQ‚̓{ƒ‹ƒeƒ]ƒ~ƒu—U”­«––½_ŒoáŠQ‚Ì”­ÇƒŠƒXƒN‚ð‘‘傳‚¹‚éD‘æ135‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2019, 6, 21, Šò•Œ.iŒû“ª”­•\j

137.       “°–{从ÑA‹{–{•ü‰ÀAŠÖŒû•x”üŽqA’Ø“c^”¿A¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚ÄŠÌáŠQ‚É‚æ‚è•úo‚³‚ê‚éHMGB1‚̓{ƒ‹ƒeƒ]ƒ~ƒu—U”­«––½_ŒoáŠQ‚𑈫‚³‚¹‚éD‘æ135‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2019, 6, 21, Šò•Œ.iŒû“ª”­•\j

138.       ’r“c—TÆA‹{è‹M–çA’Ø“c^”¿A•y“cŽDAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚ébortezomib—U”­«––½_ŒoáŠQ‚Ì”­Ç‚¨‚æ‚шێ‚É‚¨‚¯‚éHMGB1‚Ì–ðŠ„‚Æ‚»‚Ì‹NŒ¹D‘æ135‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2019, 6, 21, Šò•Œ.iŒû“ª”­•\j

139.       Kawabata, A. Distinct effects of T-type Ca2+ channel blockers and genetic deletion of Cav3.2 on somatic and visceral hypersensitivity. International Calcium Channel Meeting 2019, 2019, 3, 31-4, 5, Penang, Malaysia. (Invited speaker)

140.       씨“ÄŽjDHMGB1‚ð•W“I‚Æ‚·‚鉻Šw—Ö@—U”­«––½_ŒoáŠQ‚Ì”­Ç—\–hDƒVƒ“ƒ|ƒWƒEƒ€u‰»Šw—Ö@—U”­«––½_ŒoáŠQ‚Ì”­Ç‹@˜‚Æ‘ÎôFÅV‚ÌŒ¤‹†“®ŒüvA‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16, ‘åãDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

141.       ŠÖŒû•x”üŽqA씨“ÄŽjD‘O—§‘B‚ª‚ñ×–E‚É‚¨‚¯‚é’á“dˆÊŠˆ«‰»Cav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„DƒVƒ“ƒ|ƒWƒEƒ€uƒCƒIƒ“ƒ`ƒƒƒlƒ‹Eƒgƒ‰ƒ“ƒXƒ|[ƒ^[‚ð•W“I‚Æ‚µ‚½‚ª‚ñ‘n–òŒ¤‹†‚ÌV“WŠJvA‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16, ‘åãDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

142.       ’Ø“c^”¿A씨“ÄŽjD—°‰»…‘f‚É‚æ‚éCav3.2‚ð‰î‚·‚éáu’ɃVƒOƒiƒ‹‚Ì’²ßDƒVƒ“ƒ|ƒWƒEƒ€u—°‰»…‘f‚ð‚Í‚¶‚ß‚Æ‚µ‚½¶—Šˆ«ƒCƒIƒEŒ¤‹†‚ÌV“WŠJvA‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16, ‘åãDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

143.       “°–{从ÑA‹{–{•ü‰ÀA¼‘ºä»A•Ÿ“c—º‘¾˜YAŠÖŒû•x”üŽqA’Ø“c^”¿A¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒqƒg‚¨‚æ‚у}ƒEƒX‚É‚¨‚¢‚ÄŠÌáŠQ‚̓IƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U”­«––½_ŒoáŠQ‚Ì‘ˆ«ˆöŽq‚Å‚ ‚éFHMGB1‚ªŠÖ—^‚·‚é‰Â”\«‚ɂ‚¢‚ÄD‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16, ‘åãDiŒû“ª”­•\j

144.       •½–{Žu‰——¢A’¹ŽR—SŠóAžÄ–ØÊAŽRŒûŒOA’Ø“c^”¿A“c’†ˆêAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚ÄäNã÷‰Š‚É”º‚¤áu’ɃVƒOƒiƒ‹”­¶‚ÉŠÖ—^‚·‚éHMGB1/RAGEŒn‚ÆCSE/H2S/Cav3.2Œn‚̃NƒƒXƒg[ƒNFATP‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒWŠˆ«‰»‚Ì–ðŠ„D‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16, ‘åãDiƒ|ƒXƒ^[”­•\jD

145.       Š}”g‰ÃlA‘å¼—à‰ÀA–Ø–ì‹M”ŽAŠÖŒû•x”üŽqA’Ø“c^”¿A‹{è‹M–çA•½–{Žu‰——¢A‰ªèˆÇŽqANguyen Huy DuA‰ª“c‘ìÆA–L‰ª®Ž÷A‹g“c@”ÉA‘å‹v•Û‚‚âŽqA씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹AƒJƒ“ƒiƒrƒmƒCƒhŽó—e‘Ì‚¨‚æ‚ѓ«áu’É‚É‹y‚Ú‚·ƒzƒbƒv¬•ª6-prenylnaringenin‚Æ‚»‚Ì—U“±‘ÌKTt45‚ÌŒø‰ÊD‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16, ‘åãDiƒ|ƒXƒ^[”­•\jD

146.       ŽRŒûˆêŽ÷A“°–{从ÑAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDPaclitaxel‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£‚É‚¨‚¯‚écystathionine ƒÁ-lyase/H2SŒn‚Ì–ðŠ„‚Æ––½_ŒoáŠQ‚Ö‚ÌŠÖ—^D‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16, ‘åãDiƒ|ƒXƒ^[”­•\jD

147.       ¬’r”JXAˆÀˆä—mŽ÷AŠÖŒû•x”üŽqA“c糌³ŽOA씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚̓}ƒEƒX‚É‚¨‚¢‚ăƒ^ƒ“ƒtƒFƒ^ƒ~ƒ“‚É‚æ‚è—U‹N‚³‚ê‚és“®—Ê‘‰Á‚¨‚æ‚Ñ”]“à“Á’è•”ˆÊ‚É‚¨‚¯‚écFos”­Œ»‚ÉŠÖ—^‚·‚éD‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16, ‘åãDiƒ|ƒXƒ^[”­•\jD

148.       ’r“c—TÆA‹{è‹M–çA’Ø“c^”¿A•y“cŽDAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚ébortezomib—U”­«––½_ŒoáŠQ‚ÉŠÖ—^‚·‚éHMGB1‚Ì‹NŒ¹‚Æ•W“I•ªŽqF”­ÇŠú‚ƈێŠú‚É‚¨‚¯‚éˆá‚¢‚ɂ‚¢‚ÄD‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16, ‘åãDiƒ|ƒXƒ^[”­•\jD

149.       씨“ÄŽjD‰»Šw—Ö@—U”­«––½_ŒoáŠQ‚ÌŒ´ˆö•¨Ž¿‚Æ‚µ‚Ä‚ÌHMGB1‚Ì–ðŠ„F—Õ°ƒf[ƒ^‰ðÍ‚ÆŠî‘bŒ¤‹†‚ð‹ìŽg‚µ‚½ƒAƒvƒ[ƒ`D’É‚ÝŒ¤‹†‰ï2018D2018, 12, 13-14, ‰ªèDiŒû‰‰j

150.       “°–{从ÑAŽRŒûˆêŽ÷AŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW‚É‚¨‚¢‚ăpƒNƒŠƒ^ƒLƒZƒ‹‚É‚æ‚è—U”­‚³‚ê‚é“àˆö«H2S‚Ɉˑ¶‚µ‚½HMGB1—V—£F‰»Šw—Ö@—U”­«––½_ŒoáŠQ‚Ö‚ÌŠÖ—^D’É‚ÝŒ¤‹†‰ï2018D2018, 12, 13-14, ‰ªèDiƒ|ƒXƒ^[j

151.       씨“ÄŽjDCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹@|@‚Ç‚±‚ʼn½‚ð‚µ‚Ä‚¢‚é‚Ì‚©H@‘æ134‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[D‘æ134‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 11, 23, _ŒËDiµ‘Òu‰‰j

152.       ‹{–{•ü‰ÀA•ŸŽRhŠîA”¨’†dŽA•xŽm’J¹“TA“°–{从ÑAŠÖŒû•x”üŽqA¬ò—Sˆê@씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U”­––½_ŒoáŠQ‚̃ŠƒXƒNˆöŽqFŠÌ‹@”\áŠQ‚Æ‚ÌŠÖŒW‚ɂ‚¢‚ÄD‘æ134‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 11, 23, _ŒËDiŒû“ª”­•\j

153.       “°–{从ÑA¼‘ºä»AŠÖŒû•x”üŽqA’Ø“c^”¿A‹{–{•ü‰ÀA¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚ăIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U”­«––½_ŒoáŠQ‚ÍŠÌáŠQ‚É‚æ‚Á‚Ä‘ˆ«‚·‚éD‘æ134‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 11, 23, _ŒËDiŒû“ª”­•\j

154.       —Ñ@—C—ºA’Ø“c^”¿A•Ÿ“c—º‘¾˜YA‹{è‹M–çA¼–x³—mA씨“ÄŽjDƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“^ƒgƒƒ“ƒrƒ“Œn‚ÍHMGB1‚ð•sŠˆ«‰»‚·‚邱‚ƂŃIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U”­«––½_ŒoáŠQ‚Ì”­Ç‚ð—}§“I‚ɧŒä‚µ‚Ä‚¢‚éD‘æ134‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 11, 23, _ŒËDiŒû“ª”­•\j

155.       ¬’r”JXAˆÀˆä—mŽ÷AŠÖŒû•x”üŽqA“c糌³ŽOA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚ÄŠoÁ܃ƒ^ƒ“ƒtƒFƒ^ƒ~ƒ“‚É‚æ‚è—U‹N‚³‚ê‚és“®—Ê‘‰Á‚Æ”]“àcFos”­Œ»‚É‹y‚Ú‚·TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–ò‚ÌŒø‰ÊD‘æ134‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 11, 23, _ŒËDiŒû“ª”­•\j

156.       ’Ø“c^”¿A씨“ÄŽjD“à‘Ÿ’É”­Œ»‚É‚¨‚¯‚é—°‰»…‘f‚¨‚æ‚щߗ°‰»•¨‚Ì–ðŠ„D‘æ91‰ñ“ú–{¶‰»Šw‰ï‘å‰ï@ƒVƒ“ƒ|ƒWƒEƒ€uŠˆ«—°‰©Ží‚ÌV“WŠJ|—°‰»…‘f‚©‚ç‰ß—°‰»•¨‚Ü‚Å|vD9, 24-26, ‹ž“sDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

157.       Kawabata, A., Nishikawa, H., Uenoyama, K., Sekiguchi, F., Tsubota, M., Okada, T., Toyooka, N. Middle Molecular Weight Heparinylphenylalanine Prevents the Development of Chemotherapy-Induced Peripheral Neuropathy in Mice. 17th World Congress on Pain. 2018, 9, 12-16, Boston. (Poster)

158.       Matsui, K., Nakano, M., Tomochika, K., Tsubota, M., Kawabata, A. Pharmacological blockade and genetic deletion of Cav3.2 T-type Ca2+ channels abolish butyrate-induced colonic hypersensitivity in mice. 17th World Congress on Pain. 2018, 9, 12-16, Boston. (Poster)

159.       Wakitani, K., Sekiguchi, F., Tsubota, M., Nakamura, S., Nakanishi, I., Kawabata, A. Azelastine attenuates RAGE-dependent allodynia in mice: a discovery by a drug reprofiling/repositioning approach. 17th World Congress on Pain. 2018, 9, 12-16, Boston. (Poster)

160.       씨“ÄŽjDDAMPs‚Æ’É‚ÝD‘æ40‰ñ“ú–{¶•¨Šw“I¸_ˆãŠw‰ïE‘æ61‰ñ“ú–{_Œo‰»Šw‘å‰ï‡“¯”N‰ï@ƒVƒ“ƒ|ƒWƒEƒ€u_ŒoŽ¾Š³‚Ì‘•‚ƧŒä‚É‚¨‚¯‚éDAMPs‚Ì–ðŠ„vD2018, 9, 6-8, _ŒËDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

161.       “°–{从ÑAŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDPaclitaxel‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1•úo‚̓jƒ…[ƒƒ“—R—ˆATP‚É‚æ‚Á‚Ä‘£i‚³‚ê‚éF‰»Šw—Ö@—U‹N––½_ŒoáŠQ‚É‚¨‚¯‚é_ŒoŒn|–ƉuŒnƒNƒƒXƒg[ƒN‚Ì–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2018D2018, 8, 23-24, •Ÿ‰ªBiƒ|ƒXƒ^[j

162.       •½–{Žu‰——¢A’¹ŽR—SŠóAžÄ–Ø ÊA’Ø“c^”¿AŽRŒû@ŒOA“c’†ˆêAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDCyclophosphamide—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¢‚ÄATP/HMGB1/RAGEŒn‚ÍCSE/H2S/Cav3.2Œn‚Ìã—¬ƒVƒOƒiƒ‹‚Æ‚µ‚ÄäNã÷’É‚Ì”­Ç‚ÉŠÖ—^‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2018D2018, 8, 23-24, •Ÿ‰ªBiƒ|ƒXƒ^[j

163.       —Ñ@—C—ºA’Ø“c^”¿A•Ÿ“c—º‘¾˜YA‹{è‹M–çA¼–x³—mA씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQ‚ɑ΂·‚éƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚Ì—\–hŒø‰Ê‚É‹y‚Ú‚·R‹ÃŒÅ–ò‚̉e‹¿D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2018D2018, 8, 23-24, •Ÿ‰ªBiƒ|ƒXƒ^[jD

164.       Kawabata, A., Tomita, S., Miyazaki, T., Deguchi, T., Sekiguchi, F., Tsubota, M., Nguyen, H.D., Okada, T., Yoshida, S., Toyooka, N. Cav3.2 T-type calcium channels as therapeutic targets for bortezomib-induced peripheral neuropathy in mice. 11th FENS Forum of Neuroscience. 2018, 7, 7-11, Berlin. (Poster)

165.       Sekiguchi, F., Noda, S., Kasanami, Y., Onishi, R., Ono, S., Murata, K., Matsuda, H., Nguyen, H.D., Toyooka, N., Harada, N., Kawabata, A. Agonistic activity of 6-prenylnaringenin, a novel T-type Ca2+ channel inhibitor, toward cannabinoid CB1 receptors in neural progenitor-like NG108-15 cells and CB1-transfected HEK293 cells. 11th FENS Forum of Neuroscience. 2018, 7, 7-11, Berlin. (Poster)

166.       Domoto, R., Yamasoba, D., Sekiguchi, F., Tsubota, M., Nishibori, M., Kawabata, A. Molecular mechanisms for the HMGB1-dependent mechanical allodynia following intraplantar administration of lipopolysaccharide in mice. 11th FENS Forum of Neuroscience. 2018, 7, 7-11, Berlin. (Poster)

167.       Hiramoto, S., Tsubota, M., Yamaguchi, K., Toriyama, Y., Tanaka, J., Sekiguchi, F., Ishikura, H., Nishibori, M., Kawabata, A. ATP and HMGB1 mediate H2S-dependent bladder pain in mice with cyclophosphamide-induced cystitis. 11th FENS Forum of Neuroscience. 2018, 7, 7-11, Berlin. (Poster)

168.       Nakatake, Y., Sekiguchi, F., Tsubota, M., Tsujita, R., Honda, G., Kawabata, A. Effect of extracellular HMGB1 on neuritogenesis in mouse dorsal root ganglion neurons and its inhibition by thrombomodulin alfa. 11th FENS Forum of Neuroscience. 2018, 7, 7-11, Berlin. (Poster)

169.       Sekiguchi, F., Yagura, A., Kawabata, A. High mobility group box 1 suppresses smooth muscle tension in rat aorta via Toll-like receptor 4-dependent upregulation of iNOS. 18th World Congress of Basic and Clinical Pharmacology / ‘æ91‰ñ“ú–{–ò—Šw‰ï”N‰ïD2018, 7, 1-6, ‹ž“sDiPosterj

170.       Nishikawa, H., Uenoyama, K., Sekiguchi, F., Tsubota, M., Kawabata, A. Middle molecular weight heparinylphenylalanine is an analgesic with reduced risk of hemorrhage. 18th World Congress of Basic and Clinical Pharmacology / ‘æ91‰ñ“ú–{–ò—Šw‰ï”N‰ïD2018, 7, 1-6, ‹ž“sDiPosterj

171.       Domoto, R, Yamasoba, D., Yamanishi, H., Sekiguchi, F., Tsubota, M., Nishibori, M., Kawabata, A. Macrophage-derived HMGB1 is a key molecule in paclitaxel-induced peripheral neuropathy in mice: involvement of ROS generation and NF-ƒÈB activation. 18th World Congress of Basic and Clinical Pharmacology / ‘æ91‰ñ“ú–{–ò—Šw‰ï”N‰ïD2018, 7, 1-6, ‹ž“sDiOralj

172.       Hayashi, Y., Tsubota, M., Tsujita, R., Honda, G., Kawabata, A. Molecular mechanisms for the recombinant soluble thrombomodulin-induced suppression of HMGB1-dependent allodynia in mice: Roles of the N-terminal domains of thrombomodulin. 18th World Congress of Basic and Clinical Pharmacology / ‘æ91‰ñ“ú–{–ò—Šw‰ï”N‰ïD2018, 7, 1-6, ‹ž“sDiPosterj

173.    Tsubota, M., Matsui, K., Nakano, M. Tomochika, K., Sekiguchi, F., Kawabata, A. Role of Cav3.2 T-type calcium channels in the butyrate-induced colonic hypersensitivity in the mouse, a model for irritable bowel syndrome. 10th International Symposium on Cell/Tissue Injury and Cytoprotection/Organoprotection. 2018, 6, 28-30, ‹ž“sD

174.       씨“ÄŽjD“à‘Ÿ’É‚É‚¨‚¯‚éƒ}ƒNƒƒtƒ@[ƒW—R—ˆ HMGB1‚Ì–ðŠ„‚ÆŽ¡—ÕW“I•ªŽq‚Æ‚µ‚Ẳ”\«D‘æ40‰ñ“ú–{áu’ÉŠw‰ï@ƒVƒ“ƒ|ƒWƒEƒ€u“à‘Ÿ’É‚Ì•ªŽqƒƒJƒjƒYƒ€\“Á‚É_ŒoŒn‚ƖƉuŒn‚̃NƒƒXƒg[ƒN‚ɂ‚¢‚ÄvD2018, 6, 15-16, ’·èDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

175.       ¼ì—T”VAã–ìŽR‹ËŽqAŠÖŒû•x”üŽqA’Ø“c^”¿A‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjD’†•ªŽqƒwƒpƒŠƒjƒ‹ƒtƒFƒjƒ‹ƒAƒ‰ƒjƒ“‚͉»Šw—Ö@—U‹N––½_ŒoáŠQ‚ð—}§‚·‚éD‘æ40‰ñ“ú–{áu’ÉŠw‰ïD2018, 6, 15-16, ’·èDiƒ|ƒXƒ^[j

176.       ì’[—MŠóA—ш¤—¹A’Ø“c^”¿A’†•‚ä‚¢A’Ò“c—²ˆêAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjD‹}«‚¨‚æ‚Ñ–«pŒã’É‚É‚¨‚¯‚éHMGB1‚Ì–ðŠ„D‘æ40‰ñ“ú–{áu’ÉŠw‰ïD2018, 6, 15-16, ’·èDiŒû“ª”­•\j

177.       ˜e’Jq•½, ŠÖŒû•x”üŽq, ’Ø“c^”¿, ’†‘º^–ç, ’‡¼Œ÷, 씨“ÄŽjDRAGE‚ð•W“I‚Æ‚µ‚½‰»Šw—Ö@—U‹N––½_ŒoáŠQŽ¡—Öò‚Ì’TõF In silicoƒhƒ‰ƒbƒOEƒŠƒvƒƒtƒ@ƒCƒŠƒ“ƒO/ƒŠƒ|ƒWƒVƒ‡ƒjƒ“ƒO‚©‚ç‚̃Aƒvƒ[ƒ`D‘æ40‰ñ“ú–{áu’ÉŠw‰ïD2018, 6, 15-16, ’·èDiƒ|ƒXƒ^[j

178.       ¼ì—T”VAã–ìŽR‹ËŽqAŠÖŒû•x”üŽqA’Ø“c^”¿A‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjD‚ª‚ñ‰»Šw—Ö@—U‹N––½_ŒoáŠQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚é’†•ªŽqƒwƒpƒŠƒjƒ‹ƒtƒFƒjƒ‹ƒAƒ‰ƒjƒ“‚ÌRƒAƒƒfƒBƒjƒAì—pD‘æ133‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 6, 1, L“‡DiŒû“ª”­•\j

179.       ’Ø“c^”¿A¼ˆä˜aŽ÷A’†–ì^ŠóA—F‹ßŒAŠÖŒû•x”üŽqA씨“ÄŽjDTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQŠˆ«‚ð—L‚·‚éƒzƒbƒv¬•ª6-prenylnaringenin‚ÍŒ‹’°’É‚ð—}§‚·‚éD‘æ133‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 6, 1, L“‡DiŒû“ª”­•\jD

180.       ˜e’Jq•½, ŠÖŒû•x”üŽq, ’Ø“c^”¿, ’†‘º^–ç, ’‡¼Œ÷, 씨“ÄŽjDAzelastine‚ÍRAGE‚ªŠÖ—^‚·‚鉻Šw—Ö@—U‹N––½_ŒoáŠQ‚Ì”­Ç‚ð—}§‚·‚é | ƒhƒ‰ƒbƒOEƒŠƒvƒƒtƒ@ƒCƒŠƒ“ƒO^ƒŠƒ|ƒWƒVƒ‡ƒjƒ“ƒOŒ¤‹†‚©‚ç‚Ì’mŒ©D‘æ133‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 6, 1, L“‡DiŒû“ª”­•\j

181.       씨“ÄŽjD–«áu’É‚É‚¨‚¯‚éCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„‚ÆŽ¡—ÕW“I•ªŽq‚Æ‚µ‚Ẳ”\«D‘æ61‰ñ“ú–{“œ”A•aŠw‰ï”NŽŸŠwpW‰ï@ƒVƒ“ƒ|ƒWƒEƒ€u_ŒoáŠQ‚Ì•a‘Ô‚ÆŽ¡—à | ’É‚Ý‚ð‰ÈŠw‚·‚évD2018, 5, 24-26, “Œ‹žDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

182.       ’Ò“c—²ˆêA’Ø“c^”¿A—Ñ—C—ºA²”Œ°A–{“c„ˆêA씨“ÄŽjD’É‚ÝŒ¤‹†‰ï2017i’É‚Ý‚ð’†S‚Æ‚·‚é—LŠQ󋵓K‰ž‚Ì_Œoí—ªƒoƒCƒIƒƒW[jD2017, 12, 14-15, ‰ªèDiŒû“ª”­•\j

183.       씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ð•W“I‚Æ‚·‚é“«áu’É‚ÌŽ¡—ÃDƒ[ƒNƒVƒ‡ƒbƒvuƒJƒ‹ƒVƒEƒ€ƒVƒOƒiƒ‹“®‘Ô§Œä‚Ì•ªŽqŠî”Õ‚ÆŽ¾Š³Ž¡—Ãí—ªD2017”N“x¶–½‰ÈŠwŒnŠw‰ï‡“¯”NŽŸ‘å‰ïiConBio2017jD2017, 12, 6-9, _ŒËDiƒ[ƒNƒVƒ‡ƒbƒvƒXƒs[ƒJ[j.

184.       ”öè—FA¼‰ª‡‹IA’Ø“c^”¿A•y“cŽDAŠÖŒû•x”üŽqA“ì•ŽuA씨“ÄŽjDCyclophosphamide—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚éH2S/Cav3.2Œn‚ð‰î‚·‚éäNã÷’É‚Ì”­Œ»FNF-ƒÈBŒn‚Ì–ðŠ„‚ÆˆŸ‰”‚É‚æ‚駌äD‘æ132‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï  2017, 11, 24,@–L’†DiŒû“ª”­•\j

185.       ŠÖŒû•x”üŽqA–ì“cŽÑ—F—A“´Œû‘å˜aAŽR‰ª@÷AŠ}”g‰ÃlA‘å–ì@ä¿ANguyen Huy DuA–L‰ª®Ž÷A‘º“c˜a–çA¼“cGHA‹g“c@”ÉAŒ´“c¬MAˆÉ“¡—R—¢A‘å‹v•Û‚‚âŽqA씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–ò6-prenylnaringenin‚Æ‚»‚Ì—U“±‘̂̓Jƒ“ƒiƒrƒmƒCƒhCB1Žó—e‘Ì‚ð‰î‚µ‚Ä_Œo‘O‹ìNG108-15×–E‚Ì_Œo—l“Ë‹NL’·‚ð—U‹N‚·‚éD‘æ132‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï  2017, 11, 24,@–L’†DiŒû“ª”­•\j

186.       ’Ø“c^”¿A씨“ÄŽjDButyrate—U‹N‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚Ì’mŠo_Œo‰ß•q‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„D‘æ45‰ñ“ú–{’×ᇊw‰ïD2017, 11, 20-21, ‹ž“sDiŒû“ª”­•\j

187.       Kawabata, A., Tomita, S., Deguchi, T., Sekiguchi, F., Tsubota, M., Yoshida, S. The critical role of Cav3.2 T-type calcium channels in the peripheral neuropathy induced by bortezomib, a proteasome-inhibiting chemotherapy agent, in mice. Neuroscience 2017. 2017, 11, 11-15, Washington DC. (Poster)

188.       Sekiguchi, F., Tomita, S., Shikimi, S., Tsubota, M., Kawabata, A. Involvement of Cav3.2 T-type calcium channels in zinc deficiency-induced mechanical allodynia in mice. Neuroscience 2017. 2017, 11, 11-15, Washington DC. (Poster)

189.       Matsui, K., Terada, Y., Tsubota, M., Kawabata, A. Tacrolimus, a calcineurin inhibitor, promotes capsaicin-induced colonic pain in mice. Neuroscience 2017. 2017, 11, 11-15, Washington DC. (Poster)

190.       Domoto, R., Nakashima, K., Tsubota, M., Sekiguchi, F., Kawabata, A. Macrophages and NF-ƒÈB signaling mediate peripheral HMGB1-induced mechanical allodynia in mice. Neuroscience 2017. 2017, 11, 11-15, Washington DC. (Poster)

191.       Nakatake, Y., Sekiguchi, F., Tsubota, M., Tsujita, R., Honda, G., Kawabata, A. HMGB1-induced neurite outgrowth in mouse dorsal root ganglion neurons and its inhibition by thrombomodulin. Neuroscience 2017. 2017, 11, 11-15, Washington DC. (Poster)

192.       Hayashi, Y., Tsubota, M., Tsujita, R., Honda, G., Kawabata, A. Thrombin-dependent inhibition of HMGB1-induced mechanical allodynia by thrombomodulin in mice. Neuroscience 2017. 2017, 11, 11-15, Washington DC. (Poster)

193.       Kawabata, Y., Tsubota, M., Tsujita, R, Nishibori, M., Kawabata, A. Involvement of HMGB1 in postoperative pain. Neuroscience 2017. 2017, 11, 11-15, Washington DC. (Poster)

194.       Nguyen, H.D., Okada, T., Kitamura, S., Yamaoka, S., Horaguchi, Y., Kasanami, Y., Sekiguchi, F., Tsubota, M., Yoshida, S., Kawabata, A., Toyooka, N. ‘æ35‰ñƒƒfƒBƒVƒiƒ‹ƒPƒ~ƒXƒgƒŠ[ƒVƒ“ƒ|ƒWƒEƒ€D2017, 10, 25-27, –¼ŒÃ‰®iƒ|ƒXƒ^[”­•\j

195.       ”öè—FA¼‰ª‡‹IA’Ø“c^”¿A•y“cŽDAŠÖŒû•x”üŽqA“ì•ŽuA씨“ÄŽjDCyclophosphamide—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚鈟‰”Œ‡–R‚É‚æ‚éäNã÷’É‘‹­ƒƒJƒjƒYƒ€@\Cav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì‹@”\‘‹­‚Æ”­Œ»‘‰Á‚ÌŠÖ—^\D‘æ67‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘å‰ïD2017, 10, 14, _ŒËiŒû“ª”­•\j

196.       –î‘qˆ»”TAŠÖŒû•x”üŽqA씨“ÄŽjDŠj“àƒ^ƒ“ƒpƒNhigh mobility group box 1‚̓‰ƒbƒg‹¹•”‘å“®–¬‚É‚¨‚¢‚ÄiNOS”­Œ»—U“±‚ð‘£i‚·‚邱‚ƂŃtƒFƒjƒŒƒtƒŠƒ“Žûk‚ð—}§‚·‚éD‘æ67‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘å‰ïD2017, 10, 14, _ŒËiƒ|ƒXƒ^[”­•\j

197.       ŠÖŒû•x”üŽqA•y“cŽDAoŒû’q‘ãA’Ø“c^”¿A‹g“c”ÉA씨“ÄŽjDƒvƒƒeƒAƒ\[ƒ€‘jŠQì—p‚ð—L‚·‚鑽”­«œ‘ŽîŽ¡—Öòbortezomib‚É‚æ‚Á‚Ä—U‹N‚³‚ê‚éƒ}ƒEƒX‚Ì_ŒoáŠQ«áu’ɂɂ͈ꎟ’mŠo_Œo‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì”­Œ»—Ê‘‰Á‚ªŠÖ—^‚·‚éD‘æ39‰ñ“ú–{¶•¨Šw“I¸_ˆãŠw‰ïE‘æ47‰ñ“ú–{_Œo¸_–ò—Šw‰ï@‡“¯”N‰ïD2017, 9, 28, ŽD–yDiƒ|ƒXƒ^[”­•\j

198.       ’Ø“c^”¿AŠ’J—œŠGA–ì’†Œ‹AΈä—DŽqAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽj. Butyrate—U‹N‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錋’°’ɂւ̃}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚ÌŠÖ—^ioralj. ŽŸ¢‘ãƒVƒ“ƒ|ƒWƒEƒ€2017. 2017, 8, 26, ‹ž“siŒû“ª”­•\j

199.       “°–{@从ÑA’†“‡‰Ä“ÞAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚ÄHMGB1‘«’ê“à“Š—^‚É‚æ‚è—U‹N‚³‚ê‚é‹@ŠB“IƒAƒƒfƒBƒjƒA‚É‚ÍNF-ƒÈBƒVƒOƒiƒ‹‚ƃ}ƒNƒƒtƒ@[ƒW‚ªŠÖ—^‚·‚éDŽŸ¢‘ãƒVƒ“ƒ|ƒWƒEƒ€2017. 2017, 8, 26, ‹ž“siŒû“ª”­•\j

200.       ‹{è‹M–çA’Ø“c^”¿A•y“cŽDAoŒû’q‘ãAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjDBortezomib—U‹N_ŒoáŠQ«áu’ɂւ̃}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚ÌŠÖ—^DŽŸ¢‘ãƒVƒ“ƒ|ƒWƒEƒ€2017. 2017, 8, 26, ‹ž“siŒû“ª”­•\j

201.       —Ñ —C—ºA²”Œ°A’Ø“c^”¿A’Ò“c—²ˆêA–{“c„ˆêA씨“ÄŽjDƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚̓gƒƒ“ƒrƒ“ˆË‘¶“I‚ÉHMGB1‚ð•ª‰ð‚µ‰ŠÇ«áu’É‚ð—}§‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2017.@2017, 8, 24-25, ‹ž“sDiƒ|ƒXƒ^[j

202.       ’†•‚ä‚¢AŠÖŒû•x”üŽqA’Ø“c^”¿A’Ò“c—²ˆêA–{“c„ˆêA씨“ÄŽjDƒ}ƒEƒXŒãª_Œoß×–E‚É‚¨‚¢‚Äthrombomodulin alfa‚ÍŠÒŒ³Œ^HMGB1‚É‚æ‚è—U‹N‚³‚ê‚é_Œo“Ë‹NL’·‚ðƒgƒƒ“ƒrƒ“ˆË‘¶“I‚¨‚æ‚Ñ”ñˆË‘¶“I‚É—}§‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2017.@2017, 8, 24-25, ‹ž“sDiƒ|ƒXƒ^[j

203.       ’†“‡‰Ä“ÞA“°–{从ÑAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDƒŒƒhƒbƒNƒXó‘Ԃ̈قȂéHMGB1‚É‚æ‚é‹@ŠB“IƒAƒƒfƒBƒjƒA‚Ì”­Œ»ƒƒJƒjƒYƒ€‚̉ðÍFToll-like receptor 5ANMDAŽó—e‘Ì‚¨‚æ‚ÑNF-ƒÈB‚ÌŠÖ—^‚ƃ}ƒNƒƒtƒ@[ƒW‚Ì–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2017.@2017, 8, 24-25, ‹ž“sDiƒ|ƒXƒ^[j

204.       ì’[—MŠóA’Ø“c^”¿A’Ò“c—²ˆêA¼–x³—mA씨“ÄŽjDpŒã’É‚É‚¨‚¯‚éHMGB1ƒVƒOƒiƒ‹‚Ì–ðŠ„‚ÆŽ¡—ÕW“I•ªŽq‚Æ‚µ‚Ẳ”\«D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2017.@2017, 8, 24-25, ‹ž“sDiƒ|ƒXƒ^[j

205.       ¼ˆä˜aŽ÷A’†–ì^ŠóA—F‹ßŒA’Ø“c^”¿A씨“ÄŽjDButyrate—U‹N‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錋’°‚Ì’mŠo_Œo‰ß•q‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2017.@2017, 8, 24-25, ‹ž“sDiƒ|ƒXƒ^[j

206.       Kawabata, A. HMGB1 and pain. Symposium gMolecular Mechanisms of pain – implications for pain therapeuticsh ‘æ40‰ñ“ú–{_Œo‰ÈŠw‘å‰ïD2017, 7, 20-23, ç—tDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

207.       ŠÖŒû•x”üŽqA–ì“cŽÑ—F—A‘å–ì@ä¿A“´Œû‘å˜aAŠ}”g‰ÃlANguyen Huy Du A–L‰ª®Ž÷A‘º“c˜a–çA¼“cGHAŒ´“c¬MAˆÉ“¡—R—¢A씨“ÄŽjD6-prenylnaringenin‚Í_Œo‘O‹ì—lNG108-15×–E‚É‚¨‚¢‚ÄTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQŠˆ«‚ƃJƒ“ƒiƒrƒmƒCƒhCB1Žó—e‘̃AƒSƒjƒXƒgŠˆ«‚ðŽ¦‚·D‘æ40‰ñ“ú–{_Œo‰ÈŠw‘å‰ïD2017, 7, 20-23, ç—tDiƒ|ƒXƒ^[j

208.       ’Ø“c ^”¿A•Ÿ“c —º‘¾˜YA‹{è ‹M–çA씨 “ÄŽjDCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ð•W“I‚Æ‚·‚éƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQ‚ÌŽ¡—ÃD‘æ40‰ñ“ú–{_Œo‰ÈŠw‘å‰ïD2017, 7, 20-23, ç—tDiƒ|ƒXƒ^[j

209.       ‹{è‹M–çA’Ø“c^”¿A•y“cŽDAoŒû’q‘ãAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW—R—ˆhigh mobility group box1‚Íbortezomib—U‹N_ŒoáŠQ«áu’É‚ÉŠÖ—^‚·‚éD‘æ131‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2017, 6, 30, –¼ŒÃ‰®DiŒû“ª”­•\j

210.       ’†“‡‰Ä“ÞA“°–{从ÑAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjD––½‘gD’†‚̃`ƒI[ƒ‹Œ^‚¨‚æ‚уWƒXƒ‹ƒtƒBƒhŒ^high mobility group box 1‚É‚æ‚è—U‹N‚³‚ê‚é’ÉŠo‘‹­‚ւ̃}ƒNƒƒtƒ@[ƒW‚ÌŠÖ—^D‘æ131‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2017, 6, 30, –¼ŒÃ‰®DiŒû“ª”­•\j

211.       ’†•‚ä‚¢AŠÖŒû•x”üŽqA’Ø“c^”¿A’Ò“c—²ˆêA–{“c„ˆêA씨“ÄŽjDƒ}ƒEƒXÒ‘Œãª_Œoß×–E‚É‚¨‚¯‚éHMGB1—U‹N_Œo“Ë‹NL’·‚Æ‚»‚ê‚ɑ΂·‚éˆâ“`Žq‘g‚ÝŠ·‚¦ƒqƒg‰Â—n«thrombomodulin‚ÌŒø‰ÊD‘æ131‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2017, 6, 30, –¼ŒÃ‰®DiŒû“ª”­•\j

212.       ’Ø“c^”¿A•Ÿ“c—º‘¾˜YAŠÖŒû•x”üŽqA‹{è‹M–çA“°–{从ÑAˆÀˆä—mŽ÷AŽR‰ºä»‰ÁAã“cTA¼“c•ŽiAΑqG‹±A¼–x³—mA씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N_ŒoáŠQ«áu’É‚Ì”­ÇƒƒJƒjƒYƒ€‚̉ðÍFCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÆHMGB1‚ÌŠÖ—^D‘æ39‰ñ“ú–{áu’ÉŠw‰ïD2017, 6, 16, _ŒËDiŒû“ª”­•\j

213.       •½–{ Žu‰——¢AŽRŒûŒOA’Ø“c^”¿A“c’†ˆêAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NŠÔŽ¿«äNã÷‰Š—lƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚éäNã÷’É‚ÍATP/HMGB1/H2SƒVƒOƒiƒ‹‚ð‰î‚µ‚Ä”­Œ»‚·‚éD‘æ39‰ñ“ú–{áu’ÉŠw‰ïD2017, 6, 16, _ŒËDiŒû“ª”­•\j

214.       ŠÖŒû•x”üŽqA•y“cŽDAoŒû’q‘ãA’Ø“c^”¿A‹g“c”ÉA씨“ÄŽjDƒvƒƒeƒAƒ\[ƒ€‘jŠQ–òbortezomib—U‹N_ŒoáŠQ«áu’ɂɂ͈ꎟ’mŠo_Œo‚É‚¨‚¯‚éCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚̃^ƒ“ƒpƒN—Ê‘‰Á‚ªŠÖ—^‚·‚éD‘æ39‰ñ“ú–{áu’ÉŠw‰ïD2017, 6, 16, _ŒËDiƒ|ƒXƒ^[”­•\j

215.       ’Ò“c—²ˆêA—Ñ—C—ºA’Ø“c^”¿A–{“c„ˆêA씨“ÄŽjDƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚̓gƒƒ“ƒrƒ“ˆË‘¶«‚ÉHMGB1—U‹N’ÉŠo‰ß•q‚ð—}§‚·‚éD‘æ39‰ñ“ú–{áu’ÉŠw‰ïD2017, 6, 16, _ŒËDiƒ|ƒXƒ^[”­•\j

216.       ’Ø“c^”¿A•Ÿ“c—º‘¾˜YAŠÖŒû•x”üŽqA‹{è‹M–çA“°–{从ÑAˆÀˆä—mŽ÷A¼“c•ŽiAΑqG‹±A¼–x³—mA씨“ÄŽjDOxaliplatin—U‹N_ŒoáŠQ«áu’É‚É‚¨‚¯‚éHMGB1‚Æ‚»‚Ì•W“I•ªŽq‚Ì–ðŠ„Fƒ}ƒNƒƒtƒ@[ƒW”ñˆË‘¶“I‹@˜‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3, 15-17, ’·èDiŒû“ª”­•\j

217.       •y“cŽDAoŒû’q‘ãAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDR‚ª‚ñ–òƒ{ƒ‹ƒeƒ]ƒ~ƒu‚É‚æ‚è—U‹N‚³‚ê‚é_ŒoáŠQ«áu’É‚É‚ÍCav3.2 TŒ^ƒJƒ‹ƒVƒ€ƒ`ƒƒƒlƒ‹‚Ì”­Œ»‘‰Á‚ªŠÖ—^‚·‚éD‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3, 15-17, ’·èDiŒû“ª”­•\j

218.       ì’[—MŠóA’Ø“c^”¿A’Ò“c—²ˆêA¼–x³—mA씨“ÄŽjDHMGB1‚ÍpŒã’É‚ÉŠÖ—^‚·‚éD‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3, 15-17, ’·èDiŒû“ª”­•\j

219.       —Ñ—C—ºA’Ø“c^”¿A’Ò“c—²ˆêA–{“c„ˆêA씨“ÄŽjDƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚ÌHMGB1—U‹N’ÉŠo‰ß•q‚ɑ΂·‚é—}§Œø‰Ê‚̓gƒƒ“ƒrƒ“‚Ɉˑ¶‚·‚éD‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3, 15-17, ’·èDiŒû“ª”­•\j

220.       ¼ˆä˜aŽ÷A’†–ì^ŠóAΈä—DŽqAŽ›“c˜Ð‰ÁA’Ø“c^”¿A씨“ÄŽjDŒ‹’°’É”­ÇƒƒJƒjƒYƒ€‚̉ðÍFNŠQŽó—eƒjƒ…[ƒƒ“”­Œ»•ªŽqTRPV1APAR2‚¨‚æ‚ÑCav3.2‚Ì–ðŠ„D‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3, 15-17, ’·èDiƒ|ƒXƒ^[j

221.       ‹{–{•ü‰À, ’Ø“c^”¿, ’‹”n²‹I, 씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚éƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷‰ŠEäNã÷’É‚Í”½•œŠ¦—âƒXƒgƒŒƒX‚É‚æ‚èŒyŒ¸‚³‚ê‚éFƒXƒgƒŒƒX‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒW‹@”\’ቺ‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3, 15-17, ’·èDiƒ|ƒXƒ^[j

222.       “°–{从ÑAŽR‘Z‘å’qAŽR¼LŽ÷AŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDƒpƒNƒŠƒ^ƒLƒZƒ‹‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£‚Ì•ªŽqƒƒJƒjƒYƒ€F‰»Šw—Ö@—U‹N––½_ŒoáŠQ‚Ì”­Ç‚É‚¨‚¯‚é–ðŠ„D‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3, 15-17, ’·èDiƒ|ƒXƒ^[j

223.       ŠÖŒû•x”üŽqA–ì“cŽÑ—F—A‘å–ì@ä¿A‘º“c˜a–çA¼“cGHANguyen, H.D.A–L‰ª®Ž÷A씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–ò6-prenylnaringenin‚̓Jƒ“ƒiƒrƒmƒCƒhCB1Žó—e‘Ì‚ð‰î‚µ‚Ä_Œo‘O‹ì—lNG108-15×–E‚Ì_Œo“Ë‹NL’£‚ð‘£i‚·‚éD‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3, 15-17, ’·èDiƒ|ƒXƒ^[j

224.       ’Ø“c^”¿A•Ÿ“c—º‘¾˜YAŠÖŒû•x”üŽqA‹{è‹M–çA“°–{从ÑAˆÀˆä—mŽ÷AŽR‰ºä»‰ÁA¼“c•ŽiAΑqG‹±A¼–x³—mA씨“ÄŽjDR‚ª‚ñ–òƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N_ŒoáŠQ«áu’É‚Ö‚ÌCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÆHMGB1‚ÌŠÖ—^‚ɂ‚¢‚ÄD’É‚ÝŒ¤‹†‰ï2016u’É‚Ý‚Ì—‰ð‚ð–ÚŽw‚µ‚½æ’[“IƒAƒvƒ[ƒ`vD2017, 1, 30-31, ‰ªèDiŒû“ª”­•\j

225.       “°–{从ÑAŽR‘Z‘å’qAŽR¼LŽ÷AŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDPaclitaxel—U‹N’ÉŠo‰ß•q‚ւ̃}ƒNƒƒtƒ@[ƒW—R—ˆhigh mobility group box 1‚ÌŠÖ—^’É‚ÝŒ¤‹†‰ï2016u’É‚Ý‚Ì—‰ð‚ð–ÚŽw‚µ‚½æ’[“IƒAƒvƒ[ƒ`vD2017, 1, 30-31, ‰ªèDiŒû“ª”­•\j

226.       ‹{è‹M–çA’Ø“c^”¿A•y“cŽDAoŒû’q‘ãAŠÖŒû•x”üŽqAŽR‘Z‘å’qA¼–x³—mA씨“ÄŽjDBortezomib—U‹N_ŒoáŠQ«áu’É‚Ö‚ÌŠj“àƒ^ƒ“ƒpƒNhigh mobility group box1‚ÌŠÖ—^D‘æ130‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2016, 11, 19, ‹ž“sDiƒ|ƒXƒ^[j

227.       ã“c•‘A[ŠC˜aŽ÷Aó–ìŠG仉ÖAŠÖŒû•x”üŽqA‹g“c”ÉA씨“ÄŽjDƒqƒg‘O—§‘BŠà×–E‚É‚¨‚¯‚éinterleukin-6—U‹N_Œo“à•ª”å—l•ª‰»‚É”º‚¤Cav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì”­Œ»‘‰Á‚ÉŠÖ—^‚·‚é×–EƒVƒOƒiƒ‹‚̉ðÍD‘æ130‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2016, 11, 19, ‹ž“sDiŒû“ª”­•\j

228.       •½–{Žu‰——¢AŽRŒûŒOA’Ø“c^”¿A“c’†ˆêAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷’É‚Ì”­Œ»ƒƒJƒjƒYƒ€‚̉ðÍFƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚É‚æ‚éRAGEŠˆ«‰»‚ð‰î‚·‚éH2SŽY¶y‘f‚Ì”­Œ»—U“±‚ÌŠÖ—^D‘æ130‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2016, 11, 19, ‹ž“sDiŒû“ª”­•\j

229.       —Ñ—C—ºA’Ø“c^”¿A’Ò“c—²ˆêA–{“c„ˆêA씨“ÄŽjDƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚ÌHMGB1—U‹N’ÉŠo‰ß•q‚ɑ΂·‚é—}§ì—p‚Ì•ªŽqƒƒJƒjƒYƒ€‚ƃgƒƒ“ƒrƒ“ˆË‘¶«‚̉ðÍD‘æ130‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2016, 11, 19, ‹ž“sDiŒû“ª”­•\j

230.       Tsubota, M., Fukuda, R., Miyazaki, T., Domoto, R., Kamitani, N., Nishida, T., Sekiguchi, F., Ishikura, H., Nishibori, M., Kawabata, A. Targeting HMGB1 and its downstream molecules for treatment of oxaliplatin-induced peripheral neuropathy. The 12th International Conference on Protein Phosphatase. 2016, 10, 27-30, Higashi-Osaka. (Oral)

231.       Tomita, S., Sekiguchi, F., Tsubota, M., Kawabata, A. Molecular mechanisms for the upregulation of Cav3.2 T-type calcium channels in the neuropathic pain. The 12th International Conference on Protein Phosphatase. 2016, 10, 27-30, Higashi-Osaka. (Oral)

232.       Miyazaki, T., Fukuda, R., Tsubota, M., Kawabata, A. Cav3.2 T-type calcium channels as therapeutic targets for the oxaliplatin-induced peripheral neuropathy. The 12th International Conference on Protein Phosphatase. 2016, 10, 27-30, Higashi-Osaka. (Poster)

233.       Fukami, K., Ueda, M., Asano, E., Sekiguchi, F., Yoshida, S., Kawabata, A. Interleukin-6-induced neuroendocrine-like differentiation of human prostate cancer cells: cell signaling and upregulation of Cav3.2 T-type calcium channels. The 12th International Conference on Protein Phosphatase. 2016, 10, 27-30, Higashi-Osaka. (Poster)

234.       Domoto, R., Yamasoba, D., Yamanishi, H., Sekiguchi, F., Tsubota, M., Nishibori, M., Kawabata, A. A role of macrophage-derived HMGB1 in paclitaxel-induced peripheral neuropathy in mice. The 12th International Conference on Protein Phosphatase. 2016, 10, 27-30, Higashi-Osaka. (Poster)

235.       ŽR‰ª÷A“´Œû‘å˜aANguyen, H.D.A–k‘º@xA‰ª“c‘ìÆA‘å–ì@ä¿AŠÖŒû•x”üŽqA¼ì—T”VA‹g“c@”ÉA‘º“c˜a–çA¼“cGHA‘å‹v•Û‚‚âŽqA–L‰ª®Ž÷A씨“ÄŽjD6-Prenylnaringenin‚ðƒŠ[ƒh‰»‡•¨‚Æ‚µ‚½V‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–ò‚Ì’TõF“d‹C¶—Šw“IŒŸ“¢D‘æ66‰ñ “ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïD2016, 10,15, ‚’ÎDiƒ|ƒXƒ^[j

236.       Ž®Œ©Žd—EA•y“cŽDAŠÖŒû•x”üŽqA’Ø“c^”¿AŠÝ‰ªŽj˜YA씨@“ÄŽjDƒ}ƒEƒX‚Ì¿œ_Œo•”•ªŒ‹ãF—U‹N_ŒoáŠQ«áu’É‚É‚Í’mŠo_Œo‚É‚¨‚¯‚éCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì”­Œ»‘‰Á‚ªŠÖ—^‚·‚éF“]ŽÊˆöŽqEgr-1‚¨‚æ‚Ñ’Eƒ†ƒrƒLƒ`ƒ“‰»y‘fUSP5‚Ì–ðŠ„D‘æ66‰ñ “ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïD2016, 10, 15, ‚’ÎDiƒ|ƒXƒ^[j

237.       ’†–ì^ŠóA¼ˆä˜aŽ÷AΈä—DŽqA’Ø“c^”¿A씨“ÄŽjDButyrate—U‹N‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錋’°’ÉŠo‰ß•q‚Ö‚ÌCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ66‰ñ “ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïD2016, 10,15, ‚’ÎDiƒ|ƒXƒ^[j

238.       “´Œû‘å˜aAŽR‰ª@÷A‘å–ì@ä¿AŠÖŒû•x”üŽqANguyen, H.D.A“¡“c—F‘ãA‘º“c˜a–çA¼“cGHA‹g“c@”ÉA‘å‹v•Û‚‚âŽqA–L‰ª®Ž÷A씨“ÄŽjDV‹KTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–ò6-prenylnaringenin‚̃CƒIƒ“ƒ`ƒƒƒlƒ‹‘I‘ð«‚ÉŠÖ‚·‚錟“¢F2S‘̂ƃ‰ƒZƒ~‘Ì‚Ì”äŠrD‘æ66‰ñ “ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïD2016, 10,15, ‚’ÎDiƒ|ƒXƒ^[j

239.       –ì“cŽÑ—F—A‘å–ìä¿AŠÖŒû•x”üŽqA‘º“c˜a–çA¼“cGHANguyen, H.D.A–L‰ª®Ž÷A씨“ÄŽjD_Œo‘O‹ì—lNG108-15×–E‚É‚¨‚¢‚ÄV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–ò6-prenylnaringenin‚̓Jƒ“ƒiƒrƒmƒCƒhCB1Žó—e‘Ì‚ð‰î‚µ‚Ä_Œo“Ë‹NL’·‚ð‘£i‚·‚éD‘æ66‰ñ “ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïD2016, 10,15, ‚’ÎDiƒ|ƒXƒ^[j

240.       Kawabata, A. Impact of zinc or ascorbic acid deficiency on Cav3.2-dependent pain. 2016 International Calcium channel Meeting. 2016, 10, 2-7, Hoi An, Vietnam. (Invited)

241.       Tsubota, M. Involvement of Cav3.2 T-type Ca2+channels in the oxaliplatin-induced neuropathic pain. . 2016 International Calcium channel Meeting. 2016, 10, 2-7, Hoi An, Vietnam. (oral)

242.       Tomita, S. Mechanisms of Cav3.2 upregulation in neuropathic pain models. . 2016 International Calcium channel Meeting. 2016, 10, 2-7, Hoi An, Vietnam. (oral)

243.       Kawabata, A. Roles of TLR4 and RAGE targeted by high mobility group box 1 in inflammatory and chemotherapy-induced peripheral neuropathy. Topical Workshop gToll-Like Receptor Pain Mechanismsh in 16th World Congress on Pain. 2016, 9, 26-30, Yokohama, Japan. (Invited speaker)

244.       Terada, Y., Tsubota, M., Sekiguchi, F., Wada, K., Kuwahara, T., Takada, M., Kawabata, A. Tacrolimus causes relapse of pancreatic pain through TRPV1 activation during the recovery from cerulein-induced pancreatitis in mice. 16th World Congress on Pain. 2016, 9, 26-30, Yokohama, Japan. 

245.       Miyazaki, T., Fukuda, R., Tsubota, M., Kawabata, A. Cav3.2 T-type calcium channels contribute to oxaliplatin-induced neuropathic pain in mice. 16th World Congress on Pain. 2016, 9, 26-30, Yokohama, Japan.

246.       Domoto, R., Yamasoba, D., Yamanishi, H., Sekiguchi, F., Tsubota, M., Nishibori, M., Kawabata, A. Macrophage-derived HMGB1 participates in lipopolysaccharide-induced inflammatory hyperalgesia and paclitaxel-induced neuropathic pain in mice. 16th World Congress on Pain. 2016, 9, 26-30, Yokohama, Japan.

247.       씨“ÄŽjDHMGB1Œ¤‹†‚ÌV“WŠJ@`–ƉuŒn‚Æ_ŒoŒn‚̃NƒƒXƒg[ƒN‚É‚¨‚¯‚é–ðŠ„`D‘æ31‰ñ“ú–{‹~–½ˆã—Êw‰ï‘‰ïEŠwpW‰ï@ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[D2016, 9, 16-17, •Ÿ‰ªDiµ‘Òu‰‰j

248.       씨“ÄŽjDƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚Ì“à‘Ÿ’ÉŽ¡—Âւ̉ž—pD‘æ44‰ñ“ú–{’×ᇊw‰ï@ƒVƒ“ƒ|ƒWƒEƒ€uˆã–ò•i‚ÌÁ‰»Ší•a‚Ö‚Ì“K—pŠg‘å‚É‚¨‚¯‚é—˜_\’z@`@‚±‚ꂼÁ‰»Ší–ò—‚Ì—ÍvD2016, 9, 2-3, ˆ®ìDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

249.       ’Ø“c^”¿A•Ÿ“c—º‘¾˜YA‹{è‹M–çA“°–{从ÑAã’J‰Ä¶A¼“c•ŽiAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDOxaliplatin—U‹N_ŒoáŠQ«áu’É‚Ì”­Œ»ƒƒJƒjƒYƒ€‚̉ðÍFHMGB1‚Æ‚»‚Ì•W“I•ªŽq‚ÌŠÖ—^‚ɂ‚¢‚ÄD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2016A2016, 8, 25-26, å‘äDiŒû“ª”­•\j

250.       •½–{Žu‰——¢AŽRŒûŒOA’Ø“c^”¿A“c’†ˆêAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷’ɂɂ̓}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚É‚æ‚éRAGE‚ð‰î‚·‚éH2SŽY¶y‘f‚Ì”­Œ»—U“±‚ªŠÖ—^‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2016A2016, 8, 25-26, å‘äDiƒ|ƒXƒ^[j

251.       ’Ø“c^”¿A•Ÿ“c—º‘¾˜YA‹{è‹M–çA씨“ÄŽjDOxaliplatin—U‹N_ŒoáŠQ«áu’É‚Ö‚ÌCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2016A2016, 8, 25-26, å‘äDiƒ|ƒXƒ^[j

252.       •½–{Žu‰——¢AŽRŒûŒOA’Ø“c^”¿A“c’†ˆêAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NŠÔŽ¿«äNã÷‰Š—lƒ}ƒEƒX‚É‚¨‚¯‚éäNã÷’É‚ÉŠÖ—^‚·‚éHMGB1/RAGEŒn‚ÆH2S/Cav3.2Œn‚Ì‘ŠŒÝŠÖŒWDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2016A2016A2016, 8, 24, å‘äDiŒû“ª”­•\j

253.       ’Ø“c^”¿A•Ÿ“c—º‘¾˜YA‹{è‹M–çA씨“ÄŽjDOxaliplatin—U‹N_ŒoáŠQ«áu’É‚Ö‚ÌHMGB1‚ÌŠÖ—^F‚»‚Ì—R—ˆ‚Æ•W“I•ªŽq‚ɂ‚¢‚ÄDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2016A2016A2016, 8, 24, å‘äDiŒû“ª”­•\j

254.       Kawabata, A., Irie, Y., Tsubota, M., Sekiguchi, F., Ishikura, H., Nishibori, M. High mobility group box 1 mediates pancreatic pain in mice. Physiology 2016, 2016, 7, 28-31, Dublin. (Poster) 

255.       Sekiguchi, F., Sugimoto, R., Imanishi, M., Ueda, N., Kawabata, A. Macrophage-derived high mobility group box 1 enhances neuritogenesis via NMDA receptors in neuron-like NG108-15 cells. Physiology 2016, 2016, 7, 28-31, Dublin. (Poster)

256.       Domoto, R., Yamasoba, D., Yamanishi, H., Sekiguchi, F., Tsubota, M., Nishibori, M., Kawabata, A. Involvement of macrophage-derived high mobility group box 1 in paclitaxel-induced neuropathic pain in mice. Physiology 2016, 2016, 7, 28-31, Dublin. (Poster)

257.       Hiramoto, S., Tsubota, M., Yamguchi, K., Tanaka, J., Sekiguchi, F., Ishikura, H., Nishibori, M., Kawabata, A. Macrophage-derived high mobility group box 1 mediates H2S-dependent bladder pain in mice with cyclophosphamide-induced cystitis. Physiology 2016, 2016, 7, 28-31, Dublin. (Poster)

258.    Maeda, M., Irie, Y., Tsubota, M., Kubo, L., Sekiguchi, F., Ishikura, H., Nishibori, M., Kawabata, A. High mobility group box 1 mediates substance P-induced bladder pain in mice, a model for bladder pain syndrome. Physiology 2016, 2016, 7, 28-31, Dublin. (Poster)

259.       •y“cŽDCŽ®Œ©Žu—ECŠÖŒû•x”üŽqC’Ø“c^”¿C씨“ÄŽjDƒ‰ƒbƒg‚ ‚é‚¢‚̓}ƒEƒX‚Ì_ŒoáŠQ«áu’É‚ÉŠÖ—^‚·‚éˆêŽŸ’mŠo_Œo‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì”­Œ»—U“±ƒƒJƒjƒYƒ€D‘æ38‰ñ“ú–{áu’ÉŠw‰ïA2016, 6, 24-25, ŽD–yDiŒû“ª”­•\j

260.       “°–{从ÑAŽR‘Z‘å’qAŽR¼LŽ÷AŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚Ílipopolysaccharide—U‹N‰ŠÇ«áu’É‚Æpaclitaxel—U‹N_ŒoáŠQ«áu’É‚ÉŠÖ—^‚·‚éD‘æ38‰ñ“ú–{áu’ÉŠw‰ïA2016, 6, 24-25, ŽD–yDiŒû“ª”­•\j

261.       ’Ø“c^”¿A•Ÿ“c—º‘¾˜YA‹{è‹M–çA¼“c•ŽiAΑqG‹±A¼–x³—mA씨“ÄŽjDOxaliplatin—U‹N_ŒoáŠQ«áu’ɂɂ̓}ƒNƒƒtƒ@[ƒWˆÈŠO‚Ì×–E‚É—R—ˆ‚·‚éHMGB1‚ªŠÖ—^‚·‚éD‘æ129‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2016, 6, 24, L“‡DiŒû“ª”­•\j

262.       “V‰Hˆê‹RA‘å–ìä¿AŠÖŒû•x”üŽqA씨“ÄŽjDƒ}ƒEƒXŒãª_Œoß×–E‚É‚¨‚¢‚Ä—°‰»…‘fƒhƒi[‚¨‚æ‚Ñ–Œ“§‰ß«cyclic AMPƒAƒiƒƒO‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚Ä_Œo“Ë‹NL’·‚ð—U‹N‚·‚éF×–EƒTƒCƒY‚É‚æ‚éŒø‰Ê‚̈Ⴂ‚ɂ‚¢‚ÄD‘æ129‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2016, 6, 24, L“‡DiŒû“ª”­•\j

263.       ¼ˆä˜aŽ÷A’†–ì^ŠóAΈä—DŽqAŽ›“c˜Ð‰ÁA’Ø“c^”¿A씨“ÄŽjDŒ‹’°’É‚Ì”­Ç‚É‚¨‚¯‚éNŠQŽó—eƒjƒ…[ƒƒ“”­Œ»•ªŽqTRPV1APAR2‚¨‚æ‚ÑCav3.2‚Ì–ðŠ„‚É‚Â‚¢‚ÄD‘æ129‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2016, 6, 24, L“‡DiŒû“ª”­•\j

264.       Kawabata, A. T-type calcium channels and neuropathic/visceral pain. Symposium entitled gIon channels and pain: current research trendsh organized by Kawabata, Tanabe and Zamponi, “ú–{–òŠw‰ï‘æ136”N‰ïA2016,3,27-29, ‰¡•lDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j 

265.       ”öè—FA’Ø“c^”¿A씨“ÄŽjDCyclophosphamide—U‹NäNã÷‰ŠEäNã÷’Ƀ}ƒEƒX‚É‚¨‚¯‚é—°‰»…‘f/TŒ^Ca2+ƒ`ƒƒƒlƒ‹Œn‚Ì–ðŠ„-‰º•””A˜H‹@”\áŠQ‚ɑ΂·‚éV‚½‚ÈŽ¡—ÕW“I•ªŽq‚Æ‚µ‚Ẳ”\«D‰@¶ƒVƒ“ƒ|ƒWƒEƒ€uŽŸ¢‘ãŽáŽèŒ¤‹†ŽÒ‚Ì’§íI`“«Ž¾Š³‚ɑ΂·‚éV‚½‚È‘n–òƒXƒgƒŒƒeƒW[`viƒI[ƒKƒiƒCƒU[F•ŸdE”öèj“ú–{–òŠw‰ï‘æ136”N‰ïA2016,3,27-29, ‰¡•lDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

266.       “ü]—I•½A’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjD‹}«äX‰Š‚É”º‚¤äX‘Ÿ’ɂւ̃}ƒNƒƒtƒ@[ƒW—R—ˆHMGB 1‚ÌŠÖ—^FRAGE‚¨‚æ‚ÑCXCR4‚Ì•W“I•ªŽq‚Æ‚µ‚Ä‚Ì–ðŠ„D‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3, 9-11, ‰¡•lDiŒû“ª”­•\F‰pŒêj

267.       •y“cŽDAŽ®Œ©Žd—EAŠÖŒû•x”üŽqA’Ø“c^”¿A”’ˆä—º—mA¼–x³—mA씨“ÄŽjDˆŸ‰”Œ‡–R‚É‚æ‚è—U‹N‚³‚ê‚éƒ}ƒEƒX’ÉŠo‰ß•qFCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Æhigh mobility group box 1‚ÌŠÖ—^D‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3, 9-11, ‰¡•lDiŒû“ª”­•\F‰pŒêj

268.       ‘å–ì@ä¿AŽR‰ª@÷AŠÖŒû•x”üŽqAŽsˆä^‹MA“¡“c—F‘ãAoŒû‹M_A’Ø“c^”¿A¼ì—T”VA‹g“c@”ÉA‘º“c˜a–çA¼“cGHA–L‰ª®Ž÷A‘å‹v•Û‚‚âŽqA씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òsophoraflavanone G‚Æ6-prenylnaringenin‚Ì–ò—ì—p‰ðÍF“d‹C¶—Šw“I«Ž¿‚̈Ⴂ‚ƃ}ƒEƒX‚É‚¨‚¯‚é’ÉŠo‰ß•q—}§ì—pD‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3, 9-11, ‰¡•lDiŒû“ª”­•\j

269.       ‘O“c^—ŽqA“ü]—I•½A’Ø“c^”¿A‹v•Û—¢ŽÑAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDSubstance P—U‹NŠÔŽ¿«äNã÷‰Š^äNã÷’ÉÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚Ì–ðŠ„D‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3, 9-11, ‰¡•lDiŒû“ª”­•\j

270.       ŠÖŒû•x”üŽqA™–{@—ËA¡¼–¢ŒÈA씨“ÄŽjD_Œo‚¨‚æ‚у}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚ÍNMDAŽó—e‘Ì‚ð‰î‚µ‚Ä_Œo‘O‹ì—lNG108-15×–E‚Ì_Œo“Ë‹NL’£‚ð‘£i‚·‚éD‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3, 9-11, ‰¡•lDiƒ|ƒXƒ^[j

271.       ’Ø“c^”¿AŽR‘Z‘å’qA“°–{从ÑAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjD––½‘gD’†‚É‚¨‚¢‚ăŒƒhƒbƒNƒXó‘Ԃ̈قȂéHMGB1‚É‚æ‚è—U‹N‚³‚ê‚é’ÉŠo‰ß•qƒƒJƒjƒYƒ€‚Ì‘ŠˆáD‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3, 9-11, ‰¡•lDiƒ|ƒXƒ^[j

272.       ¼‰ª‡‹IA”öè—FA’Ø“c^”¿A씨“ÄŽjDˆŸ‰”ƒLƒŒ[ƒ^[‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì‹@”\‘‹­‚É‚æ‚ècyclophosphamide—U‹NäNã÷‰Š‚É”º‚¤äNã÷’É‚ð‘‹­‚·‚éD‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3, 9-11, ‰¡•lDiƒ|ƒXƒ^[j

273.       •y“cŽDCŽ®Œ©Žu—ECŠÖŒû•x”üŽqC’Ø“c^”¿C씨“ÄŽjD_ŒoáŠQ«áu’Ƀ‚ƒfƒ‹“®•¨‚ÌŒãª_Œoß‚É‚¨‚¯‚éCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì”­Œ»—U“±ƒƒJƒjƒYƒ€‚̉ðÍD’É‚ÝŒ¤‹†‰ï2015.@2015, 12, 17-18, ‰ªèDiŒû“ª”­•\j

274.                                                                                                                                                                                 “ü]—I•½A’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW—R—ˆhigh mobility group box 1‚̓Zƒ‹ƒŒƒCƒ“—U‹N‹}«äX‰Š‚¨‚æ‚уTƒuƒXƒ^ƒ“ƒXP—U‹NŠÔŽ¿«äNã÷‰Š/äNã÷’ÉÇŒóŒQƒ‚ƒfƒ‹‚É‚¨‚¯‚é“à‘Ÿ’É‚ÉŠÖ—^‚·‚éD’É‚ÝŒ¤‹†‰ï2015.@2015, 12, 17-18, ‰ªèDiŒû“ª”­•\j

275.       “°–{从ÑAŽR‘Z‘å’qAŽR¼LŽ÷AŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW—R—ˆhigh mobility group box 1‚̓}ƒEƒX‚É‚¨‚¯‚élipopolysaccharide—U‹N‰ŠÇ«’ÉŠo‰ß•q‹y‚ÑRŠàÜpaclitaxel—U‹N_ŒoáŠQ«áu’É‚ÉŠÖ—^‚·‚éD‘æ128‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2015, 11, 20, –L’†BiŒû“ª”­•\j

276.       “ü]—I•½A‘O“c^—ŽqA‹v•Û—¹A’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDHigh mobility group box 1‚Ísubstance P—U‹NäNã÷’ÉÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éŠÖ˜A’ÉŠo‰ß•q‚Ì”­Œ»EˆÛŽ‚ÉŠÖ—^‚·‚éD‘æ128‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2015, 11, 20, –L’†BiŒû“ª”­•\j

277.       ”öè—FA¼‰ª‡‹IA’Ø“c^”¿A•y“cŽDAŠÖŒû•x”üŽqA“ì•ŽuA씨“ÄŽjDCyclophosphamide—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚éäNã÷’ɂ͈Ÿ‰”Œ‡–R‚É‚æ‚è‘‹­‚³‚ê‚éFTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ128‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2015, 11, 20, –L’†BiŒû“ª”­•\j

278.       ‘å–ìä¿AŽR‰ª÷AŠÖŒû•x”üŽqAŽsˆä^‹MA“¡“c—F‘ãAoŒû‹M_A’Ø“c^”¿A¼ì_”VA‹g“c”ÉA‘º“c˜a–çA¼“cGHA–L‰ª®Ž÷A‘å‹v•Û‚‚âŽqA씨“ÄŽjDSophoraflavanone G‚Æ‚»‚Ì—Þ‰‘Ì6-prenylnaringenin‚ÌTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQì—p‚Ì“d‹C¶—Šw“I“Á’¥‚ÆŠeŽíáu’Ƀ‚ƒfƒ‹‚Å‚Ì—LŒø«D‘æ128‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2015, 11, 20, –L’†BiŒû“ª”­•\j

279.       Kawabata, A., Tsubota, M., Yamaguchi, K., Hiramoto, S., Sekiguchi, F., Tanaka, J., Ishikura, H., Nishibori, M. Bladder pain accompanying cyclophosphamide-induced mouse cystitis involves HMGB1 release upstream of the cystathionine-gamma-lyase/H2S/Cav3.2 pathway in the bladder tissue. Neuroscience 2015, 2015, 10, 17-21, Chicago. (Poster)

280.       Sekiguchi, F., Amo, I., Ono, S., Kawabata, A. Hydrogen sulfide and intracellular cyclic AMP enhance T-type calcium channel-dependent neurite outgrowth in distinct subpopulations of isolated and dissociated mouse dorsal root ganglion neurons. Neuroscience 2015, 2015, 10, 17-21, Chicago. (Poster)

281.       Irie, Y., Tsubota, M., Sekiguchi, F., Ishikura, H., Nishibori, M., Kawabata, A. Macrophage-derived high mobility group box 1 participates in the development and maintenance of pancreatic pain through the activation of RAGE and CXCR4 in mice with cerulein-induced acute pancreatitis. Neuroscience 2015, 2015, 10, 17-21, Chicago. (Poster)

282.       Ozaki, T., Matsuoka, J., Tsubota, M., Tomita, S., Sekiguchi, F., Minami, T., Kawabata, A. Zinc deficiency aggravates bladder pain accompanying cyclophosphamide-induced cystitis through the enhanced activity of Cav3.2 T-type Ca2+ channels in mice. Neuroscience 2015, 2015, 10, 17-21, Chicago. (Poster)

283.       Miyamoto, T., Funakami, Y., Kawasita, E., Nomura, A., Sugimoto, N., Ichida, S., Kawabata, A. Chronic stress enhances the hyperthermia in response to acute restraint stress. Neuroscience 2015, 2015, 10, 17-21, Chicago. (Poster)

284.       Ono, S., Ichii, M., Yamaoka, S., Sekiguchi, F., Fujita, T., Deguchi, T., Tsubota, M., Nishikawa, H., Yoshida, S., Murata, K., Matsuda, H., Toyooka, N., Ohkubo, T., Kawabata, A. The electrophysiological property and antihyperalgesic activity of sophoraflavanone G and 6prenylnaringenin, novel T-type calcium channel blockers. Neuroscience 2015, 2015, 10, 17-21, Chicago. (Poster)

285.       Tomita, S., Sekiguchi, F., Tsubota, M., Kawabata, A. Molecular mechanisms for the upregulation of Cav3.2 T-type calcium channels in the dorsal root ganglion of rats with spinal nerve injury-induced neuropathy: involvement of Egr-1 and USP5. Neuroscience 2015, 2015, 10, 17-21, Chicago. (Poster)

286.       ã’J‰Ä¶A¼“c•ŽiAŽR¼LŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDVincristine—U‹N_ŒoáŠQ«áu’É‚Ì”­Œ»‚¨‚æ‚шێ‚É‚¨‚¯‚éŠj“àƒ^ƒ“ƒpƒNHMGB1‚Ì–ðŠ„D‘æ65‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ï@2015, 10, 17, •x“c—ÑDiƒ|ƒXƒ^[j

287.       ŽR‰ª÷A‘å–ìä¿AŽsˆä^‹MAŠÖŒû•x”üŽqA“¡“c—F‘ãAoŒû‹M_A’Ø“c^”¿A‹g“c”ÉA‘º“c˜a–çA¼“cGHA‘å‹v•Û‚‚âŽqA씨“ÄŽjD‹êŽQ—R—ˆV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òsophoraflavanone G‚¨‚æ‚Ñ‚»‚Ì—Þ‰‘Ì‚Ì–ò—ì—p‰ðÍD‘æ65‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ï@2015, 10, 17, •x“c—ÑDiƒ|ƒXƒ^[j

288.       Œ´“c¬MAˆÉ“¡—R—¢A‚“ˆˆê•½A‰¤Žq“c²•vA씨“ÄŽjD—°‰»…‘f‚É‚æ‚Á‚ÄŽä‹N‚³‚ꂽŠO—L–Ñ×–E‚ÌTRPV4Žó—e‘Ì‚ð‰î‚µ‚½ƒXƒgƒAì“®«ƒJƒ‹ƒVƒEƒ€—¬“üD‘æ25‰ñ“ú–{Ž¨‰ÈŠw‰ï‘‰ïD2015, 10, 7-10, ’·èDiƒ|ƒXƒ^[j

289.       Kawabata, A, Tsubota, M., Uebo, K., Miki, K., Sekiguchi, F., Fukuda, R., Kondo, Y., Takahashi, K., Masutomi, H., Ishigami, A. Vitamin C deficiency aggravates hydrogen sulfide-induced pain/hyperalgesia and chemotherapy-induced neuropathy in mice: possible involvement of T-type calcium channels. 9th Congress of the European Pain Federation EFIC. 2015, 9, 2-5, Vienna. (Poster)

290.       ’Ø“c^”¿Aã–VŒ’‘¾AŽO–ØD‹PA•Ÿ“c—º‘¾˜YAŠÖŒû•x”üŽqA‹ß“¡‰Ã‚A‚‹´Œo‘¾A‘•x—T•¶AÎ_ºlA씨“ÄŽjDAscorbic acidŒ‡–R‚ÍACav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚·‚é’É‚Ý‚ð‘‹­‚·‚éDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€ 2015. 2015, 8, 29, “Œ‹žDiŒû“ª”­•\j

291.       •y“cŽDAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjD‘æ5˜_ŒoØ’f—U‹N_ŒoáŠQ«áu’Ƀ‰ƒbƒg‚ÌŒãª_Œoß‚É‚¨‚¯‚éCav3.2‚Ì”­Œ»—Ê‘‰Á‹@˜‚̉ðÍF“]ŽÊ‘£iˆöŽqEgr-1‚É‚æ‚é”­Œ»—U“±‚Æ’Eƒ†ƒrƒLƒ`ƒ“‰»y‘fUSP5‚É‚æ‚éƒvƒƒeƒAƒ\[ƒ€•ª‰ð—}§DŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€ 2015. 2015, 8, 29, “Œ‹žDiŒû“ª”­•\j

292.       ‘å–ì@ä¿A“V‰Hˆê‹RAŠÖŒû•x”üŽqA씨“ÄŽjDƒ}ƒEƒXÒ‘Œãª_Œoß×–E‚É‚¨‚¯‚é—°‰»…‘fƒhƒi[Na2S‚ÌTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚½_Œo“Ë‹NL’·‘£iŒø‰ÊF×–E‚Ì‘å‚«‚³‚É‚æ‚éŒø‰Ê‚̈Ⴂ‚ɂ‚¢‚ÄDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€ 2015. 2015, 8, 29, “Œ‹žDiƒ|ƒXƒ^[j

293.       “°–{从ÑAŽR‘Z‘å’qAŽR¼LŽ÷AŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚élipopolysaccharide—U‹N‰ŠÇ«’ÉŠo‰ß•q‚¨‚æ‚ÑRŠàÜpaclitaxel—U‹N_ŒoáŠQ«áu’ɂւ̃}ƒNƒƒtƒ@[ƒW—R—ˆhigh mobility group box 1‚ÌŠÖ—^DŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€ 2015. 2015, 8, 29, “Œ‹žDiƒ|ƒXƒ^[j

294.       Ž®Œ©Žd—EA•y“cŽDAŠÖŒû•x”üŽqA’Ø“c^”¿AŠÝ‰ªŽj˜YA씨“ÄŽjDƒ}ƒEƒX‚Ì¿œ_Œo•”•ªŒ‹ãF—U‹N_ŒoáŠQ«áu’É‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„DŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€ 2015. 2015, 8, 29, “Œ‹žDiƒ|ƒXƒ^[j

295.       씨“ÄŽjD“à‘Ÿ’É‚ÌV‚µ‚¢Ž¡—ÕW“I•ªŽqFTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÆHMGB1D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2015D2015, 8, 27-28, ‘D‹´DiƒVƒ“ƒ|ƒWƒEƒ€EƒXƒs[ƒJ[j

296.       ‘å–ì@ä¿AŽsˆä^‹MAŽR‰ª@÷AŠÖŒû•x”üŽqA“¡“c—F‘ãAoŒû‹M_A’Ø“c^”¿A¼ì—T”VA‹g“c@”ÉA‘º“c˜a–çA¼“cGHA–L‰ª®Ž÷A‘å‹v•Û‚‚âŽqA씨“ÄŽjDV‹KTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–òsophoraflavanone G‚¨‚æ‚Ñ6-prenylnaringenin‚Ì“d‹C¶—Šw“I«Ž¿‚Æ’ÉŠo‰ß•q—}§Œø‰ÊD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2015D2015, 8, 27-28, ‘D‹´Diƒ|ƒXƒ^[j

297.       •y“cŽDAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDƒ‰ƒbƒg‘æ5˜_ŒoØ’f‚É‚æ‚è—U‹N‚³‚ê‚é_ŒoáŠQ«áu’É‚¨‚æ‚ÑÒ‘Œãª_Œoß‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹”­Œ»‘‰Á‚Ö‚Ì“]ŽÊ’²ßˆöŽqEgr-1‚Æ’Eƒ†ƒrƒLƒ`ƒ“‰»y‘fUSP5‚ÌŠÖ—^D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2015D2015, 8, 27-28, ‘D‹´Diƒ|ƒXƒ^[j

298.       씨“ÄŽjDPAR2‚Æ’É‚ÝD“ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ï‘æ49‰ñ‘å‰ïD2015, 7, 24-25, ‘åãDiµ‘ÒFµ¿u‰‰j

299.       ’Ø“c^”¿AΈä—DŽqA’†–ì^ŠóAŠ’J—œŠGA¼–x³—mA씨“ÄŽjDButyrate—U‹N‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錋’°’ÉŠo‰ß•q‚Ö‚ÌTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑHMGB1‚ÌŠÖ—^D‘æ127‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2015, 6, 26, Šò•ŒDiŒû“ª”­•\j

300.       “ü]—I•½A’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDCerulein—U‹Nƒ}ƒEƒX‹}«äX‰Šƒ‚ƒfƒ‹‚É‚¨‚¯‚éäX‘Ÿ’É‚Ì”­Œ»EˆÛŽ‚ɂ̓}ƒNƒƒtƒ@[ƒW—R—ˆhigh mobility group box 1‚É‚æ‚éRAGE‚¨‚æ‚ÑCXCR4‚ÌŠˆ«‰»‚ªŠÖ—^‚·‚éD‘æ127‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2015, 6, 26, Šò•ŒDiŒû“ª”­•\j

301.            Ž›“c˜Ð‰ÁA’Ø“c^”¿AŠÖŒû•x”üŽqA˜a“c‹±ˆêAú㌴Œ’A‚“c[—²A씨“ÄŽjD‹}«äX‰ŠEäX‘Ÿ’É“®•¨ƒ‚ƒfƒ‹‚ð—p‚¢‚½•a‘Ô‰ðÍFTŒ^ Ca2+ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑTRPƒ`ƒƒƒlƒ‹‚Ì–ðŠ„D“ú–{–òŠw‰ï‘æ135”N‰ï@u‘åŠw‰@¶ƒVƒ“ƒ|ƒWƒEƒ€vA2015, 3, 26-28, _ŒËDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

302.            “V‰Hˆê‹RA‘å–ì@ä¿AŠÖŒû•x”üŽqA씨“ÄŽjDƒ}ƒEƒXŒãª_Œoß×–E‚É‚¨‚¢‚Ä—°‰»…‘fƒhƒi[Na2S‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚Ä_Œo“Ë‹NL’·‚ð‘£i‚·‚éF×–E‚Ì‘å‚«‚³‚É‚æ‚éŒø‰Ê‚̈Ⴂ‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï‘æ135”N‰ïD2015, 3, 26-28, _ŒËDiƒ|ƒXƒ^[”­•\j

303.            •Ÿ“c—º‘¾˜YAŽR¼LŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqA¼“c•ŽiAΑqG‹±A¼–x³—mA씨“ÄŽjDHMGB1‚Íoxaliplatin—U‹N_ŒoáŠQ«áu’É‚Ì”­Œ»‚¨‚æ‚шێ‚ÉŠÖ—^‚·‚éD“ú–{–òŠw‰ï‘æ135”N‰ïD2015, 3, 26-28, _ŒËDiƒ|ƒXƒ^[”­•\j

304.            ó–ìŠG仉ÖC[ŠC˜aŽ÷CŠÖŒû•x”üŽqC‘×ì–¢—ˆAŠ}¼—²“ñA‹g“c”ÉA씨“ÄŽjD‚ƒOƒ‹ƒR[ƒXðŒ‰º‚Å”|—{‚µ‚½_Œo“à•ª”å—l•ª‰»ƒqƒg‘O—§‘BŠàLNCaP×–E‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì“œ½Cü‚É‚æ‚é‹@”\‘‹­‚Æ•ª”å‹@”\˜´iD“ú–{–òŠw‰ï‘æ135”N‰ïD2015, 3, 26-28, _ŒËDiƒ|ƒXƒ^[”­•\j

305.            ‘ºãi’†ŽRj‰ë—TA’‹”n²‹IA’Ø“c^”¿AŠÖŒû•x”üŽqA¼ŽRŒ«Ž¡3A–Ø‘ºŒ’4AXŽR‰ëO2A씨“ÄŽjDƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚éƒ|ƒ‰ƒvƒŒƒWƒ“ƒN‚Ì—\–hEŽ¡—ÃŒø‰ÊD“ú–{–òŠw‰ï‘æ135”N‰ïD2015, 3, 26-28, _ŒËDiƒ|ƒXƒ^[”­•\jD

306.            ’Ø“c^”¿A씨“ÄŽjDHMGB1‚ð•W“I‚Æ‚·‚é“à‘Ÿ’ÉŽ¡—ÃD‘æ88‰ñ“ú–{–ò—Šw‰ï”N‰ï@ƒVƒ“ƒ|ƒWƒEƒ€uHMGB1‚ð•W“I‚Æ‚·‚鎡—ÂÌV‹K“WŠJvA‘æ88‰ñ“ú–{–ò—Šw‰ï”N‰ïD2015, 3, 18-20, –¼ŒÃ‰®DiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j

307.            [ŠC˜aŽ÷Aó–ìŠG仉ÖAŠÖŒû•x”üŽqA‘×ì–¢—ˆAŠ}¼—²“ñA‹g“c”ÉA씨“ÄŽjD_Œo“à•ª”å—l•ª‰»‚µ‚½‘O—§‘BŠàLNCaP×–E‚É‚¨‚¢‚Ä‚ƒOƒ‹ƒR[ƒXðŒ‰º‚Å‚ÌCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌN-Œ‹‡Œ^ƒOƒŠƒRƒVƒ‹‰»‚É‚æ‚蕪”å‹@”\‚ª˜´i‚·‚éD‘æ88‰ñ“ú–{–ò—Šw‰ï”N‰ïD2015, 3, 18-20, –¼ŒÃ‰®DiŒû“ª”­•\j

308.            ŽR‘Z‘å’qAŠÖ—R‰Á—¢AŽR¼LŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqA”ª–ØGŽ÷A‰vŽq@‚A¼–x³—mA씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚ÍNF-kBŒn‚ð‰î‚µ‚ĉŠÇ«’ÉŠo‰ß•q‚ÉŠñ—^‚·‚éD‘æ88‰ñ“ú–{–ò—Šw‰ï”N‰ïD2015, 3, 18-20, –¼ŒÃ‰®DiŒû“ª”­•\E‰pŒêj

309.            •y“cŽDAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjD_ŒoáŠQ«áu’Ƀ‰ƒbƒg‚Ì’mŠo_Œo‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹”­Œ»—U“±‚É‚Í“]ŽÊˆöŽqEgr-1‚¨‚æ‚Ñ’Eƒ†ƒrƒLƒ`ƒ“‰»y‘fUSP5‚ªŠÖ—^‚·‚éD‘æ88‰ñ“ú–{–ò—Šw‰ï”N‰ïD2015, 3, 18-20, –¼ŒÃ‰®DiŒû“ª”­•\E‰pŒêj

310.            ’‹”n²‹IA‘ºãi’†ŽRj‰ë—TA’Ø“c^”¿AŠÖŒû•x”üŽqA¼ŽRŒ«Ž¡A–Ø‘ºŒ’AXŽR‰ëOA씨“ÄŽjD@ˆŸ‰”ŠÜ—L»Üƒ|ƒ‰ƒvƒŒƒWƒ“ƒN‚Ìcyclophosphamide—U‹NäNã÷‰ŠEäNã÷’ɂɑ΂·‚é—\–h‚¨‚æ‚ÑŽ¡—ÃŒø‰ÊD‘æ88‰ñ“ú–{–ò—Šw‰ï”N‰ïD2015, 3, 18-20, –¼ŒÃ‰®DiŒû“ª”­•\j

311.            Kawabata, A., Kawaishi, Y., Nishida, T., Yamanishi, H., Kamitani, N., Tsubota, M., Sekiguchi, F., Ishikura, H., Nishibori, M. High mobility group box 1 as a target for prevention and therapeutic treatment of chemotherapy-induced neuropathic pain. Pharmacology 2014. 2014, 12, 16-28, London. (Oral)

312.            Terada, Y., Tsubota, M., Sekiguchi, F., Wada, K., Kuwahara, T., Takada, M., Kawabata, K. Effect of tacrolimus on caerulein-induced pancreatitis-related pain in mice. Pharmacology 2014. 2014, 12, 16-28, London. (Poster)

313.            Ozaki, T., Tsubota, M., Kawabata, A. The NK1 receptor antagonist prevents the cyclophosphamide-induced cystitis-related bladder pain and upregulation of cystathionine-ƒÁ-lyase, an H2S-generating enzyme, in mice. Pharmacology 2014. 2014, 12, 16-28, London. (Poster)

314.            Ohno, S., Kanaoka, D., Ide, H., Sekiguchi, F., Yoshida, S., Fukunaga, K., Kawabata, A. The novel cognitive enhancer ST101 induces neurite outgrowth in NG108-15 cells and hyperalgesia in mice through T-type Ca2+ channels. Pharmacology 2014. 2014, 12, 16-28, London. (Poster)

315.            Irie, Y., Kubo, L., Tsubota, M., Sekiguchi, F., Ishimura, H., Nishibori, M., Kawabata, A. Involvement of high mobility group box 1 in substance P-induced cystitis-related bladder pain in mice. Pharmacology 2014. 2014, 12, 16-28, London. (Poster)

316.            Ž›“c˜Ð‰ÁA¼ˆä˜aŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqA˜a“c‹±ˆêAú㌴@Œ’Aûü“c[—²A씨“ÄŽjDCalcineurin‘jŠQ–òtacrolimus‚Ícapsaicin—U‹NŒ‹’°’É‚¨‚æ‚Ñcerulein—U‹N‹}«äX‰ŠŠÖ˜A’É‚ð‘‹­‚·‚éD‘æ126‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2014, 10, 24, ˜a‰ÌŽRDioralj

317.            •y“cŽDAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjD‘æ5˜_ŒoØ’f_ŒoáŠQ«áu’Ƀ‰ƒbƒg‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹”­Œ»‘‰Á‹@˜‚̉ðÍF“]ŽÊ’²ßˆöŽqEgr-1‚Æ’Eƒ†ƒrƒLƒ`ƒ“‰»y‘fUSP5‚Ì‹““®‚ɂ‚¢‚ÄD‘æ126‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2014, 10, 24, ˜a‰ÌŽRDioralj

318.            ŽR‘Z‘å’qAŠÖ—R‰Á—¢AŽR¼LŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqA”ª–ØGŽ÷A‰vŽq@‚A¼–x³—mA 씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚̉ŠÇ«’ÉŠo‰ß•q‚Ö‚ÌŠÖ—^‚Æ•ªŽqì—pƒƒJƒjƒYƒ€‚̉ðÍD‘æ126‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2014, 10, 24, ˜a‰ÌŽRDioralj

319.            Kawabata, A. Hydrogen sulfide: Importance of T-type calcium channels as the molecular target. International Symposium gGasotransmitters: Physiology and Pathophysiologyh. 2014, 9, 21-23, Kazan, Russia. (Invited lecture)

320.            Ozaki, T., Tsubota, M., Kawabata, A. Mechanims for upregulation of cystathionine-gamma-lyase, a hydrogen sulfide-generating enzyme, in mice with cyclophosphamide-induced cystititis: Involvement of substance P/NK1 pathway and NF-kappaB signals. International Symposium gGasotransmitters: Physiology and Pathophysiologyh. 2014, 9, 21-23, Kazan, Russia. (Poster)

321.            •y“cŽDAŠ¢˜Ð”nAŠÖŒû•x”üŽqAìΗY‘åA’Ø“c^”¿A‹g“c@”ÉA‘å‹v•Û‚‚âŽqA씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òRQ-00311651‚Ì“d‹C¶—Šw“I«Ž¿‚¨‚æ‚Ñ_ŒoáŠQ«áu’ɂɑ΂·‚é—}§Œø‰ÊDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2014. 2014, 8, 30, “Œ‘åãD(Poster)

322.            ™–{—ËAã“cضAŠÖŒû•x”üŽqA씨“ÄŽj. . Histone deacetylase‘jŠQ–ò‚Í“àˆö«high mobility group box 1—V—£‚ð‰î‚µ‚Ä_Œo‘O‹ì×–EŠ”NG108-15×–E‚Ì_Œo“Ë‹NL’·‚ð—U‹N‚·‚éDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2014. 2014, 8, 30, “Œ‘åãD(Poster)

323.            ¼ˆä˜aŽ÷AŽ›“c˜Ð‰ÁA’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDCapsaicin—U‹NŒ‹’°’ɂɑ΂·‚écalcineurin‘jŠQ–òFK506‚Ì‘‹­Œø‰ÊDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2014. 2014, 8, 30, “Œ‘åãD(Poster)

324.            Sekiguchi, F., Kawabata, ADExploration of novel T-type Ca2+ channel inhibitors for treatment of intractable painDƒVƒ“ƒ|ƒWƒEƒ€5uNovel therapeutic strategy for treatment of painvA¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2014. 2014,  8,  28-29, “Œ‘åãD(ƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[)

325.            ’Ø“c^”¿A씨“ÄŽjDƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚ð—p‚¢‚½’É‚Ý‚ÌŽ¡—ÃFHMGB1‹z’…E•ª‰ð‘£iì—p‚ÌŠÖ—^DƒVƒ“ƒ|ƒWƒEƒ€4uŒŒ‰t‹ÃŒÅEü—nŒnŠÖ˜AˆöŽq‚ð•W“I‚Æ‚µ‚½‘n–òŒ¤‹†‚ÌV“WŠJvA¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2014. 2014,  8,  28-29, “Œ‘åãD(ƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[)

326.            Ž›“c˜Ð‰ÁA’Ø“c^”¿AŠÖŒû•x”üŽqA˜a“c‹±ˆêAú㌴@Œ’Aûü“c[—²A씨“ÄŽj.@Calcineurin‘jŠQ–òtacrolimus‚ÍTRPV1‚ð‰î‚µ‚Äcerulein—U‹N‹}«äX‰ŠŠÖ˜A’É‚ð‘‹­‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2014. 2014,  8,  28-29, “Œ‘åãD(Poster)

327.            ’‹”n²‹IA’†ŽR‰ë—TA’Ø“c^”¿AŠÖŒû•x”üŽqA¼ŽRŒ«Ž¡A–Ø‘ºŒ’AXŽR‰ëOA씨“ÄŽj.@ƒ|ƒ‰ƒvƒŒƒWƒ“ƒN‚Ícyclophosphamide—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚鉊ÇÇ󂨂æ‚ÑäNã÷’É‚ð—}§‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2014. 2014,  8,  28-29, “Œ‘åãD(Poster)

328.       ’†ŽR‰ë—TA’†‘º‹ŽuA“Œ@„ŽjA¼ŽRŒ«Ž¡AXŽR‰ëOA–Ø‘º@Œ’A씨“ÄŽjDƒ|ƒ‰ƒvƒŒƒWƒ“ƒN‚ðŽg—p‚µ‚½ŠÜšu‰t‚̈À’è«‚Æ•úŽËü«Œûo”S–Œ‰Š‚ɑ΂·‚é—Õ°•]‰¿. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2014. 2014,  8,  28-29, “Œ‘åãD(Poster)

329.       “c•Ó q, ¼‰º ãÄŽq, ¼–{ ‰ÄŠC, ’·ˆä ‹IÍ, ˆÉ“¡ ‹g›’, ¼ì —T”V, 씨 “ÄŽjDƒiƒm‰»‹Zp‚ð—p‚¢‚½V‹K’ŽË—p»Ü‚ÌŠJ”­‚Æ‚»‚Ì—L—p«•]‰¿@|ƒVƒƒXƒ^ƒ][ƒ‹Ã–¬“à“Š—^‚É‚æ‚é”][ÇŽ¡—Ã|D@¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2014. 2014,  8,  28-29, “Œ‘åãD(Poster)

330.       Kawabata, A., Kawaishi, Y., Nishida, T., Yamanishi, H., Kamitani, N., Tsubota, M., Ishikura, H., Sekiguchi, F., Nishibori, M. Prevention and reversal of chemotherapy-induced neuropathic pain by HMGB1 neutralization in rodents. 9th FENS Forum of European Neuroscience, 2014, 7, 5-9, Milan, Italy. (Poster)

331.       Sekiguchi, F., Fujita, T., Deguchi, T., Ichii, M., Yamaoka, S., Nishikawa, H., Yoshida, S., Murata, K., Matsuda, M., Ohkubo, T., Kawabata, A. Sophoraflavanone G as a novel T-type Ca2+ channel inhibitor: electrophysiological evidence in Cav3.2-expressing HEK293 cells and anti-hyperalgesic activity in mice. 9th FENS Forum of European Neuroscience, 2014, 7, 5-9, Milan, Italy. (Poster)

332.       ŠÖŒû•x”üŽqA씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òsophoraflavanone G‚Ì–ò—Šw“I“Á’¥‚Æ’ÉŠo‰ß•q—}§Œø‰ÊD‘æ36‰ñ“ú–{áu’ÉŠw‰ïD2014, 6, 20-21, ‘åãDiOralj

333.       ‹v•Û—¢ŽÑA’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjD‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚¨‚æ‚ÑRHMGB1’†˜aR‘Ì‚Ílipopolysaccharide‚ ‚é‚¢‚Ísubstance PäNã÷“à’“ü‚É‚æ‚è—U‹N‚³‚ê‚éäNã÷’É‚ð—}§‚·‚éD‘æ125‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2014, 6, 20, ‰ªŽRDiOralj

334.       ŽRŒûŒOA“c’†ˆêA’Ø“c^”¿AŠÖŒû•x”üŽqAŠÖ—R‰Á—¢AΑqG‹±A¼–x³—mA씨“ÄŽjDCyclophosphamide—U‹Nƒ}ƒEƒXäNã÷‰Šƒ‚ƒfƒ‹‚É‚¨‚¯‚éäNã÷’É”­ÇƒƒJƒjƒYƒ€‚̉ðÍFŠj“à’`”’HMGB1‚Æ“àˆö«H2S‚Ì–ðŠ„D‘æ125‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2014, 6, 20, ‰ªŽRDiOralj

335.       ã–VŒ’‘¾AŽO–ØD‹PA’Ø“c^”¿AŠÖŒû•x”üŽqA‹ß“¡‰Ã‚A‚‹´Œo‘¾A‘•x—T•¶AÎ_ºlA씨“ÄŽjDCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‘jŠQ‚·‚éascorbic acid‚ÌŒ‡–R‚Í—°‰»…‘f‚É‚æ‚é‘Ì«’ÉE“à‘Ÿ’É‚¨‚æ‚Ñpaclitaxel—U‹N_ŒoáŠQ«áu’É‚ð‘‹­‚·‚éD‘æ125‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2014, 6, 20, ‰ªŽRDiOralj

336.            ¬–¸Ê‰ÁAŠÖ–{WŒÈAŠÖŒû•x”üŽqA씨“ÄŽjDƒqƒgˆÝŠà—R—ˆAGS×–E‚É‚¨‚¯‚é“àˆö«—°‰»…‘f‚Ì×–E‘B‚Ö‚ÌŠÖ—^‚Æ‚»‚̉º—¬ƒVƒOƒiƒ‹‚̉ðÍD‘æ125‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2014, 6, 20, ‰ªŽRDiPosterj

337.       Fukami, K., Kawabata, A. Roles of hydrogen sulfide and T-type calcium channels in neuroendocrine-differentiated prostate cancer cells at androgen-independent stage. Anti-Aging International Mini-Symposium 2014: Cell Signaling and Therapeutic Targets for Geriatric and Inflammatory Diseases. 2014, 6, 7, Higashi-Osaka. (Oral) 

338.       Kawabata, A. Roles of the hydrogen sulfide-Cav3.2 T-type calcium channel pathway in neuronal and neuroendocrine differentiation. Third International Conference on Hydrogen Sulfide in Biology and Medicine, 2014, 6, 4-6, Kyoto. (Invited lecture).

339.       Sekiguchi, F., Takeda, Y., Kanaoka, D., Yoshida, S., Kawabata, A. Involvement of endogenous hydrogen sulfide and T-type calcium channels in cyclic AMP-induced neuronal differentiation in NG108-15 cells. Third International Conference on Hydrogen Sulfide in Biology and Medicine, 2014, 6, 4-6, Kyoto. (Poster)

340.       Tsubota, M., Uebo, K., Miki, K., Sekiguchi, F., Kondo, Y., Takahashi, K., Masutomi, H., Ishigami, A., Kawabata, A. Ascorbic acid deficiency augments hyperalgesia induced by hydrogen sulfide in mice. Third International Conference on Hydrogen Sulfide in Biology and Medicine, 2014, 6, 4-6, Kyoto. (Poster)

341.    ’Ø“c^”¿A씨“ÄŽjDŒ‹’°‚Ìáu’É‚¨‚æ‚щŠÇ‚É‚¨‚¯‚éƒKƒXóî•ñ“`’B•¨Ž¿—°‰»…‘f‚Ì–ðŠ„D“ú–{–òŠw‰ï‘æ134”N‰ï@ƒVƒ“ƒ|ƒWƒEƒ€uŽáŽè–ò—ŠwŽÒ‚ªŠJ‘ñ‚·‚é“«Ž¾Š³‚ÌŽ•ž‚ð–ÚŽw‚µ‚½ŽŸ¢‘ã‘n–òEˆç–òŒ¤‹†v2014, 3, 27-30, ŒF–{iƒVƒ“ƒ|ƒWƒEƒ€j

342.    Kawabata, A. Roles of Cav3.2 T-type Ca2+ channels in prostate cancer cells: impact on an androgen-independent stage. Symposium gNovel aspects of voltage-gated@Ca2+ channels: emerging trends for drug developmenth organized by Kawabata, A. and Mochida, S., ‘æ87‰ñ“ú–{–ò—Šw‰ï”N‰ï@2014”N3ŒŽ19-21“úAå‘äiƒVƒ“ƒ|ƒWƒEƒ€F‰pŒêj

343.    ¼“c•ŽiAìΗY‘åAŽR¼LŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒrƒ“ƒNƒŠƒXƒ`ƒ“—U‹N_ŒoáŠQ«áu’Ƀ‰ƒbƒg‚É‚¨‚¯‚éRHMGB1’†˜aR‘̂ƈâ“`Žq‘gŠ·‚¦ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚Ì—\–hEŽ¡—ÃŒø‰ÊD‘æ87‰ñ“ú–{–ò—Šw‰ï”N‰ï@2014”N3ŒŽ19-21“úAå‘äioralj

344.    ŠÖŒû•x”üŽq, “¡“c—F‘ã, oŒû‹M_, Žsˆä^‹M, ¼ì—T”V, ‹g“c@”É, ‘º“c˜a–ç, ¼“cGH,‘å‹v•Û‚‚âŽq, 씨“ÄŽjD‹êŽQ—R—ˆsophoraflavanone G‚¨‚æ‚Ñ‚»‚Ì—Þ‰‘Ì‚ÌTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQŠˆ«‚Æ’ÉŠo‰ß•q—}§Œø‰ÊD‘æ87‰ñ“ú–{–ò—Šw‰ï”N‰ï@2014”N3ŒŽ19-21“úAå‘äiposterj

345.    Ž›“c˜Ð‰Á, ’Ø“c^”¿, ŠÖŒû•x”üŽq, ˜a“c‹±ˆê, ú㌴@Œ’, ûü“c[—², 씨“ÄŽjDƒJƒ‹ƒVƒjƒ…[ƒŠƒ“‘jŠQ–òƒ^ƒNƒƒŠƒ€ƒX‚̓JƒvƒTƒCƒVƒ“—U‹NŒ‹’°’É‚ð‘‹­‚·‚éD‘æ87‰ñ“ú–{–ò—Šw‰ï”N‰ï@2014”N3ŒŽ19-21“úAå‘äiposterj

346.    ‘å–ì@ä¿A‹à‰ª‘åŽ÷AˆäŽè—mŽ÷AŠÖŒû•x”üŽqA‹g“c@”ÉA•Ÿ‰i_ŽiA씨“ÄŽjDV‹K”F’m‹@”\‰ü‘P–òST101‚É‚æ‚è—U‹N‚³‚ê‚éNG108-15×–E‚É‚¨‚¯‚é_Œo“Ë‹NL’·‘£iì—p‚ƃ}ƒEƒX‚É‚¨‚¯‚é’ÉŠo‰ß•q‚Ö‚ÌTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ87‰ñ“ú–{–ò—Šw‰ï”N‰ï@2014”N3ŒŽ19-21“úAå‘äiposterj

347.    ìΗY‘åAŽR¼LŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqA¼“c•ŽiAΑqG‹±A¼–x³—mA씨“ÄŽji”­•\ŽÒjD’†˜aR‘̂ƈâ“`Žq‘gŠ·‚¦ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚É‚æ‚éHMGB1•sŠˆ‰»‚̓‰ƒbƒg‚¨‚æ‚у}ƒEƒX‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U‹N_ŒoáŠQ«áu’É‚ð—}§‚·‚éD‘æ87‰ñ“ú–{–ò—Šw‰ï”N‰ï@2014”N3ŒŽ19-21“úAå‘äiposterj

348.       Kawabata, A., Tanaka, J., Yamaguchi, K., Ishikura, H., Tsubota, M. Involvement of high mobility group box 1 in cyclophosphamide-induced cystitis-related bladder pain in mice. Pharmacology 2013, 2013, 12, 17-19, London.

349.       Kawabata, A., Miyamoto, Y., Sekiguchi, F., Kanaoka, D., Yoshida, S., Ohkubo, T. Facilitation of T-type calcium currents by endogenous and exogenous hydrogen sulfide in Cav3.2-expressing HEK293 cells. Neuroscience 2013, 2013, 11, 9-13, San Diego, USA. (poster)

350.       Sekiguchi, F., Kawara, Y., Kanaoka, D., Kawaishi, Y., Tsubota, M., Kawakami, E., Ozaki, T., Yoshida, S., Okubo, T., Kawabata, A. RQ-00311651, a novel T-type Ca2+ channel blocker: electrophysiological characterization and anti-hyperalgesic/anti-allodynic activity in somatic and visceral pain models. Neuroscience 2013, 2013, 11, 9-13, San Diego, USA. (poster)

351.       Terada, Y., Fujimura, M., Nishimukra, S., Tsubota, M., Kawabata, A. Roles of TRPA1 channels in addition to Cav3.2 or TRPV1 as the downstream signal of hydrogen sulfide or proteinase-activated receptor-2 in the development of pancreatic pain. Neuroscience 2013, 2013, 11, 9-13, San Diego, USA. (poster)

352.       Tanaka, J., Ishikura, H., Yamaguchi, K., Tsubota, M., Sekiguchi, F., Seki, Y., Kawabata, A. Recombinant human soluble thrombomodulin abolishes bladder pain accompanying cyclophosphamide-induced cystitis in mice. Neuroscience 2013, 2013, 11, 9-13, San Diego, USA. (poster)

353.    ŠÖŒû•x”üŽq, ‹{–{—z‰î, ‹à‰ª‘åŽ÷, ˆäŽè—mŽ÷, ‹g“c@”É, ‘å‹v•Û‚‚âŽqC씨“ÄŽjDCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹”­Œ»HEK293×–E‚É‚¨‚¢‚Ä“àˆö«‚¨‚æ‚ÑŠOˆö«—°‰»…‘f‚̓`ƒƒƒlƒ‹‹@”\‚ð‘‹­‚·‚éD‘æ124‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2013”N11ŒŽ1“úA‹ž“s. (oral)

354.       ’|’†GA’†‘º‘DA’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚Äprostaglandin E2‚É‚æ‚è—U‹N‚³‚ê‚éTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚·‚é‹@ŠB“I’ÉŠo‰ß•q‚Ì“Á’¥FEP2/PKAŒo˜H‚É‚¨‚¯‚é‘«êƒ^ƒ“ƒpƒNAKAP150‚Ìd—v«‚ÆEP1/PKCŒo˜H‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ124‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2013”N11ŒŽ1“úA‹ž“s. (poster)

355.       Ž›“c˜Ð‰ÁA“¡‘ºä—RŽqA¼‘ºK—eA’Ø“c^”¿A씨“ÄŽj. TRPA1‚ÍPAR2‚̉º—¬ƒVƒOƒiƒ‹•ªŽq‚Æ‚µ‚ÄTRPV1‚Æ‚Æ‚à‚ÉäX‰ŠŠÖ˜A’ÉŠo‰ß•q‚Ì”­ÇEˆÛŽ‚ÉŠñ—^‚·‚é. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj

356.       Ž›“c˜Ð‰ÁA“¡‘ºä—RŽqA¼‘ºK—eA’Ø“c^”¿A씨“ÄŽj. äX‘Ÿ’É”­Œ»‚É‚¨‚¯‚éH2S‰º—¬ƒVƒOƒiƒ‹•ªŽq‚Æ‚µ‚Ä‚ÌCav3.2‚¨‚æ‚ÑTRPA1‚Ì–ðŠ„FŒ’펞‚Æ‹}«äX‰Š”­ÇŽž‚̈Ⴂ. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj

357.       ã–VŒ’‘¾AŽO–ØD‹PA’Ø“c^”¿AŠÖŒû•x”üŽqA‹ß“¡‰Ã‚A‚‹´Œo‘¾A‘•x—T•¶AÎ_ºlA씨“ÄŽj. ƒ}ƒEƒX‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚·‚é—°‰»…‘f‚Ì’É‚Ý‘£iŒø‰Ê‚̓AƒXƒRƒ‹ƒrƒ“Ž_Œ‡–R‚É‚æ‚è‘‘å‚·‚éF SMP30/GNLƒmƒbƒNƒAƒEƒgƒ}ƒEƒX‚ð—p‚¢‚½ŒŸ“¢. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj

358.       ‹v•Û—¢ŽÑA’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽj. LipopolysaccharideäNã÷“à’“ü‚É‚æ‚è—U‹N‚³‚ê‚éƒ}ƒEƒXäNã÷‰ŠEäNã÷’ɂɑ΂·‚é‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚ÌŒø‰ÊF“Š—^—Ê‚É‚æ‚éˆá‚¢. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj

359.       ’|“c—DŠóA‹à‰ª‘åŽ÷AŠÖŒû•x”üŽqA‹g“c”ÉA씨“ÄŽj. NG108-15×–E‚É‚¨‚¯‚édibutyryl cyclic AMP—U‹N_Œo•ª‰»‚Ö‚Ì“àˆö«—°‰»…‘f‚ÆCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj

360.       ŠÖ—R‰Á—¢A“c’†ˆêAŽRŒûŒOAΑqG‹±A’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽj. ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚ÍHMGB1ƒVƒOƒiƒ‹‚ð—}§‚·‚邱‚ƂʼnŠÇ«áu’É‚ð—}§‚·‚é. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj

361.       ŽRŒûŒOA“c’†ˆêAŠÖ—R‰Á—¢AΑqG‹±A’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽj. ƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚éƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚ÌäNã÷’É—}§Œø‰ÊFHMGB1‹z’…E•sŠˆ‰»ì—p‚ÌŠÖ—^. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj

362.       ‘å–ì@ä¿A‹à‰ª‘åŽ÷AˆäŽè—mŽ÷AŠÖŒû•x”üŽqA‹g“c@”ÉA•Ÿ‰i_ŽiA씨“ÄŽj. V‹K”F’m‹@”\‰ü‘P–òST101‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚ÄNG108-15×–E‚É‚¨‚¯‚é_Œo“Ë‹NL’·‚ƃ}ƒEƒX‚É‚¨‚¯‚é’ÉŠo‰ß•q‚ð—U‹N‚·‚é. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj

363.       씨“ÄŽjA’Ø“c^”¿AŠÖŒû•x”üŽqDˆâ“`Žq‘gŠ·‚¦ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚̉ŠÇ«áu’É‚¨‚æ‚ÑŠà‰»Šw—Ö@—U‹N_ŒoáŠQ«áu’ɂɑ΂·‚é—\–hEŽ¡—ÃŒø‰ÊFHMGB1‹z’…E•sŠˆ‰»ì—p‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ35‰ñ“ú–{áu’ÉŠw‰ï@2013”N7ŒŽ12-13“úA‚³‚¢‚½‚Üioralj

364.       ŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òRQ-00311651‚Ì“d‹C¶—Šw“I“Á’¥‚Æ‘Ì«’ÉE“à‘Ÿ’Ƀ‚ƒfƒ‹‚É‚¨‚¯‚é’Á’ÉŒø—ÍD‘æ35‰ñ“ú–{áu’ÉŠw‰ï@2013”N7ŒŽ12-13“úA‚³‚¢‚½‚Üioralj

365.       ìΗY‘åAŽR¼LŽ÷A’Ø“c^”¿A¼–x³—mAΑqG‹±A씨“ÄŽjDˆâ“`Žq‘gŠ·‚¦ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚ÍHMGB1ƒVƒOƒiƒ‹‚ð—}§‚·‚邱‚ƂŃpƒNƒŠƒ^ƒLƒZƒ‹—U‹N_ŒoáŠQ«áu’Ƀ‚ƒfƒ‹‚É‚¨‚¢‚Ä—\–h‚¨‚æ‚ÑŽ¡—ÃŒø‰Ê‚ðŽ¦‚·D‘æ123‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2013”N7ŒŽ12“úA–¼ŒÃ‰®ioralj

366.       ‘×ì–¢—ˆA[ŠC˜aŽ÷AŠ}¼—²“ñAŠÖŒû•x”üŽqA‹g“c@”ÉA씨“ÄŽjDƒqƒg‘O—§‘BŠà—R—ˆLNCaP×–E‚É‚¨‚¯‚écyclic AMP—U‹N_Œo“à•ª”å—l•ª‰»‚É”º‚¤H2S/Cav3.2Œn‚Ì‹@”\‘‹­‚Æ‚»‚Ì•ªŽqƒƒJƒjƒYƒ€D‘æ123‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2013”N7ŒŽ12“úA–¼ŒÃ‰®ioralj

367.       “¡“c—F‘ãAŠÖŒû•x”üŽqAoŒû‹M_A‹g“c@”ÉA‘º“c˜a–çA¼“cGHA‘å‹v•Û‚‚âŽqA씨“ÄŽjD‹êŽQ—R—ˆTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ•¨Ž¿‚ÌŒŸõFƒqƒgCav3.2”­Œ»HEK293×–E‚É‚¨‚¯‚é“d‹C¶—Šw“IŒŸ“¢‚ƃ}ƒEƒX‚É‚¨‚¯‚é—°‰»…‘f—U‹N’ÉŠo‰ß•q‚ɑ΂·‚é—}§Œø‰Ê‚Ì•]‰¿D‘æ123‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2013”N7ŒŽ12“úA–¼ŒÃ‰®ioralj

368.       ”öè—FA’Ø“c^”¿A¼‰Y‰À“ߌbA씨“ÄŽjDƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷‰ŠEäNã÷’ɂɑ΂·‚éNK1Žó—e‘ÌhR–ò‚¨‚æ‚Ñcurcumin‚ÌŒø‰ÊF—°‰»…‘f / TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹Œn‚Ìã—¬ƒVƒOƒiƒ‹‚̉ðÍD‘æ123‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2013”N7ŒŽ12“úA–¼ŒÃ‰®ioralj

369.       Kawabata, A. Modulation of Cav3.2 T-type calcium channels by endogenous mediators: impact on pain signals and others. 3rd International Calcium Channel Conference, 2013, 3, 24-29, Krabi, Thailand. (Symposium Speaker)

370.       ’Ø“c^”¿A씨“ÄŽjD—°‰»…‘f‚̶—‹@”\‚Æ•a‘Ô‚Ö‚ÌŠÖ—^F“Á‚É“à‘Ÿ’É‚¨‚æ‚Ñ“à‘Ÿ‰ŠÇ‚É‚¨‚¯‚é–ðŠ„D‘æ90‰ñ“ú–{¶—Šw‰ï‘å‰ï ƒVƒ“ƒ|ƒWƒEƒ€u‹C‘Ì•ªŽq‚̃Zƒ“ƒVƒ“ƒO‚ƶ—‹@”\vA•½¬24”N3ŒŽ27-29“úA“Œ‹žDiƒVƒ“ƒ|ƒWƒXƒgj

371.       Š¢@˜Ð”n, ŠÖŒû•x”üŽq , ‹à‰ª‘åŽ÷, ìΗY‘å, ’Ø“c^”¿, ‹g“c@”É, ‘å‹v•Û‚‚âŽq, ŽRàV”ü, ‰äŽÓ“¿ˆêA‘å锎s, ˆäã@‹`, 씨“ÄŽjDV‹KTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–òRQ-00311651F–Œ“d—¬‚¨‚æ‚уJƒ‹ƒVƒEƒ€—¬“ü‚ɑ΂·‚é—}§Œø‰Ê‚Æ’Á’ÉŒø—ÍD‘æ86‰ñ“ú–{–ò—Šw‰ï”N‰ï 2013”N3ŒŽ21-23“úA•Ÿ‰ªD(poster)

372.       ìãŠG—A’Ø“c^”¿A”öè—FAŠÖŒû•x”üŽqAˆäã‹`A‰œ‘º‹MŽqA씨“ÄŽjDV‹KTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–òRQ-00311651‚ÌŠeŽí“à‘Ÿ’ɂɑ΂·‚鎡—ÃŒø‰ÊD‘æ86‰ñ“ú–{–ò—Šw‰ï”N‰ï 2013”N3ŒŽ21-23“úA•Ÿ‰ªD(poster)

373.       ŠÖ—R‰Á—¢A“c’†ˆêAŽRŒûŒOAΑqG‹±A’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDˆâ“`Žq‘gŠ·‚¦ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚̓‰ƒbƒg‚É‚¨‚¢‚ÄHMGB1ˆË‘¶‰ŠÇ«áu’É‚ð—}§‚·‚éD‘æ86‰ñ“ú–{–ò—Šw‰ï”N‰ï 2013”N3ŒŽ21-23“úA•Ÿ‰ªD(poster)

374.       ŽRŒûŒOA“c’†ˆêAŠÖ—R‰Á—¢AΑqG‹±A’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDˆâ“`Žq‘gŠ·‚¦ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚̓VƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚éäNã÷’É‚ð—}§‚·‚éD‘æ86‰ñ“ú–{–ò—Šw‰ï”N‰ï 2013”N3ŒŽ21-23“úA•Ÿ‰ªD(poster)

375.       ŠÖŒû•x”üŽq, Š¢@˜Ð”n, ‹à‰ª‘åŽ÷, ìΗY‘å, ’Ø“c^”¿, ‹g“c@”É, ‘å‹v•Û‚‚âŽq, ŽRàV”ü, ‰äŽÓ“¿ˆê, ‘å锎s, ˆäã@‹`, 씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òRQ-00311651‚̃`ƒƒƒlƒ‹‘jŠQŒø‰Ê‚Ì“Á’¥‚¨‚æ‚Ñ‘Ì«’ÉŠo‰ß•q‚ɑ΂·‚é—}§Œø‰ÊD‘æ122‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2012”N11ŒŽ16“úA–L’†Dioralj

376.       ’Ø“c^”¿AìãŠG—A”öè—FAŠÖŒû•x”üŽqAˆäã@‹`A‰œ‘º‹MŽqA씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òRQ-00311651‚ÍŠeŽí“à‘Ÿ’É‚ð—}§‚·‚éD‘æ122‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2012”N11ŒŽ16“úA–L’†Dioralj

377.       “c’†ˆêAŽRŒû ŒOAŠÖ—R‰Á—¢AΑqG‹±A’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDˆâ“`Žq‘g‚ÝŠ·‚¦‰Â—n«ƒqƒgEƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚̃}ƒEƒXŠÔŽ¿«äNã÷‰Šƒ‚ƒfƒ‹‚É‚¨‚¯‚éäNã÷’É—}§Œø‰ÊD‘æ122‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2012”N11ŒŽ16“úA–L’†Dioralj

378.       ‹à‰ª‘åŽ÷AŽR’†—Ú”üAŠÖŒû•x”üŽqA‹g“c ”ÉA씨“ÄŽjDNG108-15×–E‚ƃ‰ƒbƒgŒãª_Œoß×–E‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‹@”\‚Ìcyclic AMPˆË‘¶«‘‹­ƒƒJƒjƒYƒ€‚̉ðÍD‘æ122‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2012”N11ŒŽ16“úA–L’†Dioralj

379.       ‘O“c‹MŽjAŽRãp—º‰îAŽO’JŒ’Ž¡A“c’†—F—¢AŠÖŒû•x”üŽqA씨“ÄŽjD’mŠo_Œo×–E‚É‚¨‚¯‚écyclic AMP—U‹N_Œo“Ë‹NL’·‚ɑ΂·‚éTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑK+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ122‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2012”N11ŒŽ16“úA–L’†Dioralj

380.       Kawabata, A., Nishikawa, H., Matsuda, S., Fukatsu, A., Kurokawa, Y., Tsubota-Matsunami, M., Tokuyama, S. Blocking T-type calcium channels protects against the brain injury induced by middle cerebral artery occlusion and reperfusion in mice. Neuroscience 2012, 2012, 10, 13-27, New Orleans, USA. (poster)

381.       Tanaka, J., Seki, Y., Yamaguchi, K., Ishikura, H., Tsubota, M., Sekiguchi, F., Kawabata, A. Recombinant soluble human thrombomodulin abolishes inflammatory hyperalgesia in rats. Neuroscience 2012, 2012, 10, 13-27, New Orleans, USA. (poster)

382.       Maeda, T., Mitani, K., Yamagata, R., Sekiguchi, F., Kawabata, A. Molecular mechanisms for the neurite outgrowth caused by prostaglandin E2 in mouse dorsal root ganglion cells. Neuroscience 2012, 2012, 10, 13-27, New Orleans, USA. (poster)

383.       Kanaoka, D., Takeda, Y., Sekiguchi, F., Yoshida, S., Kawabata, A. Roles of endogenous hydrogen sulfide in the cyclic AMP-induced neuronal differentiation in NG108-15 cells. Neuroscience 2012, 2012, 10, 13-27, New Orleans, USA. (poster)

384.       Kawabata, A. Roles of Cav3.2 and TRPA1 channels targeted by hydrogen sulfide in processing of visceral pain signals in the colon, pancreas and bladder. 7th International Symposium on Cell/Tissue Injury and Cyotoprotection/Organoprotection, 2012, 9, 9-11, Honolulu, Hawaii, USA. (overview)

385.       Sekiguchi, F., Sekimoto, T., Ogura, A., Kawabata, A. Roles of endogenous hydrogen sulfide in proliferation of gastric cancer cells. 7th International Symposium on Cell/Tissue Injury and Cyotoprotection/Organoprotection, 2012, 9, 9-11, Honolulu, Hawaii, USA. (oral)

386.       Sekiguchi, F., Matsumoto, Y., Maeda, Y., Tsubota-Matsunami, M., Nishikawa, H., Kawabata, A. Biological activities of Helicobacter pylori extracts in various cells: no evidence for involvement of proteinase-activated receptors? 7th International Symposium on Cell/Tissue Injury and Cyotoprotection/Organoprotection, 2012, 9, 9-11, Honolulu, Hawaii, USA. (poster)

387.       ŽRãp—º‰îC‘O“c‹MŽjCŽO’JŒ’Ž¡CŠÖŒû•x”üŽqC씨“ÄŽjDƒ}ƒEƒXÒ‘Œãª_Œoß”|—{×–E‚̃vƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2/cyclic AMPŒn‚ð‰î‚·‚é_Œo“Ë‹NL’·‚É‚¨‚¯‚éTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑK+ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2012A2012, 8, 30-31, _ŒËD(poster)

388.       [’ÈǓÞA¼ì—T”VA¼“cŽÑ’mA•‰Í—SŽqA’Ø“c^”¿A“¿ŽR®ŒáA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚é’†‘å”]“®–¬•ÂÇ/ÄŸó—¬—U‹N_ŒoáŠQ‚ɑ΂·‚éTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–ò‚Ì•ÛŒìŒø‰ÊF‹•ŒŒ‘O‚¨‚æ‚Ñğ󗬑O‘¤”]Žº“à“Š—^‚É‚æ‚éŒø‰Ê‚Ì”äŠrD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2012A2012, 8, 30-31, _ŒËD(poster)

389.       씨“ÄŽjD’É‚Ý‚Ìî•ñ“`’B§Œä‚É‚¨‚¯‚é—°‰»…‘fATŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑPAR2‚Ì–ðŠ„DƒVƒ“ƒ|ƒWƒEƒ€u’ɂݧŒä‚ÉŠÖ‚í‚镪Žq‚Æ_Œo‰ñ˜Hv‘æ34‰ñ“ú–{áu’ÉŠw‰ïA2012, 7, 20-21, ŒF–{DiƒVƒ“ƒ|ƒWƒXƒgj@

390.       Kawabata, A. T-type Ca2+ channels and visceral pain: a novel therapeutic target for treatment of colonic, pancreatic and bladder pain. A Satellite Symposium of IUPHAR-GI Section, International Ulcer Week 2012, 2012, 7, 12, Tokyo. (Overview).

391.       Kanaoka, D., Sekiguchi, F., Nakagawa, M., Aoki Y., Nishimoto Y., Yoshida, S., Tsubota-Matsunami, M, Kawabata, A. Prostaglandin E2-induced sensitization of T-type Ca2+ channels: a mechanism for mechanical hyperalgesia. A Satellite Symposium of IUPHAR-GI Section, International Ulcer Week 2012, 2012, 7, 12, Tokyo. (oral).

392.       Fukami, K., Kasamatsu, R., Yasukawa, M., Yoshida, S., Sekiguchi, F., Kawabata, A. Endogenous H2S formed by cystathionine-ƒÁ-lyase promotes secretory functions via the activation of Cav3.2 T-type Ca2+ channels in neuroendocrine-differentiated prostate cancer cells. A Satellite Symposium of IUPHAR-GI Section, International Ulcer Week 2012, 2012, 7, 12, Tokyo. (oral).

393.       “c’†ˆêAŠÖ—R‰Á—¢AŽRŒûŒOAΑqG‹±A’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDˆâ“`Žq‘g‚ÝŠ·‚¦‰Â—n«ƒqƒgEƒgƒƒ“ƒ{ƒ‚ƒfƒ…ƒŠƒ“‚̃‰ƒbƒg‚É‚¨‚¯‚鉊ǫáu’É—}§Œø‰ÊD‘æ121‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2012, 6, 29, “¿“‡Dioralj

394.       ‹à‰ª@‘åŽ÷A’|“c@—DŠóAŠÖŒû@•x”üŽqA‹g“c@”ÉA씨@“ÄŽjDNG108-15×–E‚Ìcyclic AMP‚ð‰î‚µ‚½_Œo•ª‰»‚Ö‚Ì“àˆö«—°‰»…‘f‚Ì–ðŠ„D‘æ121‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2012, 6, 29, “¿“‡Dioralj

395.       Ž›“c˜Ð‰ÁA“¡‘ºä—RŽqA•Ê•{K—eA’Ø“c^”¿A씨“ÄŽjDTRPA1ƒ`ƒƒƒlƒ‹‚Í—°‰»…‘f‚¨‚æ‚ÑPAR2‚̉º—¬ƒVƒOƒiƒ‹•ªŽq‚Æ‚µ‚ÄäX‘Ÿ’É‚Ìî•ñ“`’B‚ÉŠñ—^‚·‚éD‘æ121‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2012, 6, 29, “¿“‡Dioralj

396.       ’†‘º‘DA’Ø“c^”¿A씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚éprostaglandin E2—U‹N‹@ŠB“I’ÉŠo‰ß•q‚Ì”­Œ»‚É‚ÍCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹Šˆ«‰»‚ªŠÖ—^‚·‚é@`ƒvƒƒeƒCƒ“ƒLƒi[ƒ[A‚¨‚æ‚ÑC‚Ì–ðŠ„`D‘æ121‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2012, 6, 29, “¿“‡Dioralj

397.       Kawabata, A, Matsunami, M. Hydrogen sulfide and bladder pain. First European Conference on the Biology of Hydrogen Sulfide, 2012, 6, 15-18, Smolenice, Slovakia. (overview)

398.       ‘å싱¹A¼”g^”¿A씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚Äsubstance PäNã÷“à“Š—^‚Í—°‰»…‘f‡¬y‘f‚Ì”­Œ»—U“±‚ÆCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠˆ«‰»‚ð‰î‚µ‚ÄäNã÷’É^ŠÖ˜A’ÉŠo‰ß•q‚ð—U‹N‚·‚éD“ú–{–òŠw‰ï‘æ132”N‰ïA2012, 3, 28-31, ŽD–yDioralj

399.       ’‡¼hŠóA‘å‹v•ÛŽõ­A¼”g^”¿AŽÄŽR—TŽ¡A씨“ÄŽjD‘æ‚T˜_ŒoØ’f—U‹N_ŒoáŠQ«áu’ɂɑ΂·‚é—¼e”}«ƒAƒXƒRƒ‹ƒrƒ“Ž_—U“±‘Ìdisodium isostearyl 2-O-l-ascorbyl phosphateiDI-VCPj‚Ì‹ÇŠ“K—p‚É‚æ‚鎡—ÃŒø‰ÊD“ú–{–òŠw‰ï‘æ132”N‰ïA2012, 3, 28-31, ŽD–yDioralj

400.       ŠÖ–{WŒÈAŠÖŒû•x”üŽqA씨“ÄŽjDˆÝŠà×–E‚É‚¨‚¯‚é“àˆö«—°‰»…‘f‚Ì×–E‘B‘£iì—p‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï‘æ132”N‰ïA2012, 3, 28-31, ŽD–yDiposterj

401.       Š}¼—²“ñA[ŠC˜aŽ÷A‘×ì–¢—ˆAŠÖŒû•x”üŽqA‹g“c@”ÉA씨“ÄŽjD_Œo“à•ª”å—l•ª‰»‚µ‚½‘O—§‘BŠà—R—ˆLNCaP×–E‚É‚¨‚¯‚é“àˆö«—°‰»…‘f^TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹Œn‚ÌŠˆ«˜´i‚Æ•ª”å‹@”\‘‹­‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï‘æ132”N‰ïA2012, 3, 28-31, ŽD–yDiposterj

402.       ŽR’†—Ú”üA‘O“c—D–AŠÖŒû•x”üŽqA씨“ÄŽjDƒ}ƒEƒXœ‰è×–E—lMC3T3-E1×–E‚É‚¨‚¯‚éproteinase-activated receptor-1‚ð‰î‚µ‚½prostaglandin E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹‚ÌŒŸ“¢D“ú–{–òŠw‰ï‘æ132”N‰ïA2012, 3, 28-31, ŽD–yDiposterj

403.       씨“ÄŽjDCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ð•W“I‚Æ‚µ‚½Šà‰»Šw—Ö@—U‹N_ŒoáŠQ«áu’É‚ÌŽ¡—Ãí—ªDƒVƒ“ƒ|ƒWƒEƒ€uŠà‰»Šw—Ö@‚É”º‚¤_ŒoáŠQ«áu’É\Å‹ß‚ÌŒ¤‹†“®ŒüviƒI[ƒKƒiƒCƒU[F씨“ÄŽjA‘åΗ¹ŽOj‘æ85‰ñ“ú–{–ò—Šw‰ï”N‰ïA2012, 3, 14-16, ‹ž“sDiƒVƒ“ƒ|ƒWƒXƒgj

404.       ŠÖŒû•x”üŽqAŠÖ–{WŒÈA씨“ÄŽjDˆÝŠà×–E‚É‚¨‚¢‚Ä“àˆö«‚ÉŽY¶‚³‚ê‚é—°‰»…‘f‚ÍŠà×–E‘B‚ÉŠÖ—^‚·‚éD‘æ85‰ñ“ú–{–ò—Šw‰ï”N‰ïA2012, 3, 14-16, ‹ž“sDioralj

405.       ‘å‹v•ÛŽõ­A’‡¼hŠóA¼”g^”¿AŽÄŽR—TŽ¡A씨“ÄŽjD‘æ5˜_ŒoØ’f_ŒoáŠQ«áu’Ƀ‚ƒfƒ‹‚É‚¨‚¯‚éV‹K—¼e”}«ƒAƒXƒRƒ‹ƒrƒ“Ž_—U“±‘Ìdisodium isostearyl 2-O-L-ascorbyl phosphate“îp‚Ì’Á’ÉŒø‰ÊD‘æ85‰ñ“ú–{–ò—Šw‰ï”N‰ïA2012, 3, 14-16, ‹ž“sDioralj

406.       ¼”g^”¿A‘å싱¹A‘å‹v•ÛŽõ­AŠÖŒû•x”üŽqA씨“ÄŽjDƒTƒuƒXƒ^ƒ“ƒXP—U‹N’x”­«äNã÷’Ƀ}ƒEƒXƒ‚ƒfƒ‹‚ð—p‚¢‚½ŠÔŽ¿«äNã÷‰Š‚Ì•ªŽq•a‘Ô‰ðÍF“àˆö«—°‰»…‘f‚ÆCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„‚É‚Â‚¢‚ÄD‘æ85‰ñ“ú–{–ò—Šw‰ï”N‰ïA2012, 3, 14-16, ‹ž“sDiposterj

407.       ¼ì—T”VA¼“cŽÑ’mA[’ÈǓÞA•‰Í—SŽqA¼”g^”¿A“¿ŽR®ŒáA씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQÜ‚Ì‹•ŒŒ«”]áŠQŽ¡—Âւ̉ž—pD‘æ85‰ñ“ú–{–ò—Šw‰ï”N‰ïA2012, 3, 14-16, ‹ž“sDiposterj

408.       ‘O“c‹MŽjAŽO’JŒ’Ž¡AŽRãp—º‰îAŠÖŒû•x”üŽqA씨“ÄŽjDƒ}ƒEƒXŒãª_Œoß×–E‚É‚¨‚¯‚éprostaglandin E2/cyclic AMPŒn‚ð‰î‚µ‚½_Œo“Ë‹NL’·‚Ì•ªŽqƒƒJƒjƒYƒ€‚̉ðÍD‘æ85‰ñ“ú–{–ò—Šw‰ï”N‰ïA2012, 3, 14-16, ‹ž“sDiposterj

409.       Kawabata, A., Matsunami, M., Miki, T., Nishiura, K., Hayashi, Y., Okawa, Y., Sekiguchi, F. Impact of Cav3.2 T-type calcium channels targeted by hydrogen sulfide on bladder nociception. Neuroscience 2011, 2011, 11, 12-16, Washington, DC. (poster)

410.       Okubo, K., Matsumura, M., Kawaishi, Y., Matsunami, M., Kawabata, A. Involvement of Cav3.2 T-type calcium channels and TRPA1 channels in mechanical hyperalgesia induced by hydrogen sulfide in mice. Neuroscience 2011, 2011, 11, 12-16, Washington, DC. (poster)

411.       Sekiguchi, F., Kanaoka, D., Nakagawa, M., Aoki, Y., Nishimoto, Y., Yoshida, S., Matsunami, M., Kawabata, A. AKAP-dependent modulation of phosphorylation levels of Cav3.2 T-type calcium channels by protein kinase A and calcineurin: implications for mechanical pain sensitivity. Neuroscience 2011, 2011, 11, 12-16, Washington, DC. (poster)

412.       Kanaoka, D., Sekiguchi, F., Nakagawa, M., Aoki, Y., Nishimoto, Y., Yoshida, S., Matsunami, M., Kawabata, A. Sensitization of T-type calcium channels by prostaglandin E2 via the EP4 receptor/cyclic AMP/protein kinase A pathway: a possible mechanism for mechanical hyperalgesia. Neuroscience 2011, 2011, 11, 12-16, Washington, DC. (poster)

413.       Maeda, T., Mitani, K., Yamagata, R., Sekiguchi, F., Kawabata, A. Molecular mechanisms for the morphine-sensitive neurite outgrowth caused by prostaglandin E2 in sensory neuron-like ND7/23 cells. Neuroscience 2011, 2011, 11, 12-16, Washington, DC. (poster)

414.       ¼”g^”¿A‘å싱¹A씨“ÄŽjDƒTƒuƒXƒ^ƒ“ƒX‚o‚ÌäNã÷“à“Š—^‚É‚æ‚è—U‹N‚³‚ê‚éäNã÷ŠÖ˜A’ÉŠo‰ß•q‚É‚Í—°‰»…‘f‡¬y‘f‚Ì”­Œ»—U“±‚ÆCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ªŠÖ—^‚·‚éD‘æ120‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2011, 11, 11, ‹ž“sD

415.       Kawabata, A. Roles of the hydrogen sulfixde/T-type calcium channel system in somatic and visceral pain processing. 6th International Symposium on cell/tissue injury and cytoprotection/organoprotection – Focus on GI tract. 2011, 10, 12-14, St. Petersburg, Russia (invited lecture).

416.       씨“ÄŽjD—°‰»…‘f‚Æ“à‘Ÿ’ÉD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2011uÁ‰»ŠÇŽ¾Š³‚Ì•a‘Ô¶—‚ÆŽ¡—Öò‚ÌŠJ”­vA2011, 9, 1-2,“Œ‹žDiƒVƒ“ƒ|ƒWƒXƒgj

417.       씨“ÄŽjDProteinase-activated receptor (PAR)‚̶—“IE•a‘Ô¶—Šw“I–ðŠ„D‘æ16‰ñ“ú–{•a‘ÔƒvƒƒeƒA[ƒ[Šw‰ïŠwpW‰ï@ƒ[ƒNƒVƒ‡ƒbƒvA2011, 8, 27, –L’†Diµ‘Òj

418.       ŠÖŒû•x”üŽqA¼”g^”¿A씨“ÄŽjDPGE2—U‹N‹@ŠB“I’ÉŠo‰ß•q‚É‚ÍEP4Žó—e‘Ì^PKAŒn‚É‚æ‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌAKAPˆË‘¶«ƒŠƒ“Ž_‰»‚ªŠñ—^‚·‚éD‘æ33‰ñ“ú–{áu’ÉŠw‰ïA2011, 7, 22-23, ¼ŽRD

419.       ‘å‹v•ÛŽõ­A¼”g^”¿A씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚é—°‰»…‘f—U‹N’ÉŠo‰ß•q‚É‚ÍCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÆTRPA1ƒ`ƒƒƒlƒ‹‚Ì—¼•û‚ªŠÖ—^‚·‚éD‘æ33‰ñ“ú–{áu’ÉŠw‰ïA2011, 7, 22-23, ¼ŽRD

420.       ¼”g^”¿A씨“ÄŽjDŒ‹’°“à‚̈Ÿ‰”‚Í—°‰»…‘f^TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚½Œ‹’°’É”­Œ»‚ð§Œä‚·‚éD‘æ33‰ñ“ú–{áu’ÉŠw‰ïA2011, 7, 22-23, ¼ŽRD

421.       ¼“cŽÑ’mA¼ì—T”VA[’ÈǓÞA•‰Í—SŽqA¼”g^”¿A“¿ŽR®ŒáA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚é’†‘å”]“®–¬•ÂÇ^ÄŠÒ—¬—U‹N_ŒoáŠQ‚Ö‚ÌTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ119‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2011, 7, 8, –¼ŒÃ‰®D

422.       ‘O“c‹MŽjAŽO’JŒ’Ž¡AŽRãp—º‰îAŠÖŒû•x”üŽqA씨“ÄŽjD’mŠo_ŒoŒn×–E‚É‚¨‚¯‚éprostaglandin E2/cyclic AMPŒn‚ð‰î‚µ‚½morphineŠ´Žó«_Œo“Ë‹NL’·D‘æ119‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2011, 7, 8, –¼ŒÃ‰®D

423.       ¼–{—S‘¾A–ؗD‰ÀA¼”g^”¿A씨“ÄŽjDƒTƒCƒNƒŠƒbƒNAMPˆË‘¶«TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹Š´Žó«‘‘å‚É‚æ‚è—U‹N‚³‚ê‚é’ÉŠo‰ß•q‚ÉŠÖ—^‚·‚é’mŠo_ŒoüˆÛ‚Ì“¯’èFˆÙ”g’·ƒTƒCƒ“”gŽhŒƒ‚ɑ΂·‚锽‰ž‚ðŽw•W‚Æ‚µ‚½ŒŸ“¢D‘æ119‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2011, 7, 8, –¼ŒÃ‰®D

424.       ¼”g@^”¿A‘åì@‹±¹A씨@“ÄŽjDƒTƒuƒXƒ^ƒ“ƒXPäNã÷“à’“ü‚É‚æ‚è—U‹N‚³‚ê‚éƒ}ƒEƒXäNã÷‰Š‚¨‚æ‚ÑŠÖ˜A’ÉŠo‰ß•q‚Ö‚Ì“àˆö«—°‰»…‘f‚ÆTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ84‰ñ“ú–{–ò—Šw‰ï”N‰ïA2011, 3, 22-24, ‰¡•lD

425.       [ŠC˜aŽ÷AŠ}¼—²“ñA‹g“c@”ÉAŠÖŒû•x”üŽqA씨“ÄŽjD_Œo“à•ª”啪‰»‚µ‚½‘O—§‘BŠà×–E‚É‚¨‚¢‚Ä“àˆö«H2S‚ÍCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠˆ«‰»‚ð‰î‚µ‚Ä•ª”å‹@”\‚ð‘‹­‚·‚éD‘æ84‰ñ“ú–{–ò—Šw‰ï”N‰ïA2011, 3, 22-24, ‰¡•lD

426.       ‘å‹v•ÛŽõ­A¼‘º@—ÎA¼”g^”¿A씨“ÄŽjD—°‰»…‘f‚É‚æ‚éƒ}ƒEƒX‚Ì‹@ŠB“I’ÉŠo‘‹­‚É‚¨‚¯‚éTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑTRPA1ƒ`ƒƒƒlƒ‹‚̈قȂé–ðŠ„D‘æ84‰ñ“ú–{–ò—Šw‰ï”N‰ïA2011, 3, 22-24, ‰¡•lD

427.       ‘O“c—D–AŽR’†—Ú”üAŠÖŒû•x”üŽqA¼ì—T”VA씨“ÄŽjDƒ}ƒEƒXœ‰è‘O‹ì×–E‚É‚¨‚¯‚éproteinase-activated receptor-1—U‹NƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹‚ɂ‚¢‚ÄD‘æ84‰ñ“ú–{–ò—Šw‰ï”N‰ïA2011, 3, 22-24, ‰¡•lD

428.       ¼‰Y‰À“ߌbA¼”g^”¿AŽO–Ø’—TA씨“ÄŽjDCyclophosphamide—U‹NäNã÷‰Š‚É”º‚¤äNã÷’É‚Ì•ÛŽ‚É‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÍŠÖ—^‚·‚邪TRPA1ƒ`ƒƒƒlƒ‹‚ÍŠÖ—^‚µ‚È‚¢D‘æ84‰ñ“ú–{–ò—Šw‰ï”N‰ïA2011, 3, 22-24, ‰¡•lD

429.       ØŽm‘ŽqA¼”g^”¿A‰œˆä‹M‘åA씨“ÄŽjDTNBS—U‹NŒ‹’°‰Šƒ‰ƒbƒg‚É‚¨‚¯‚é—°‰»…‘f‚Ì”S–Œ•ÛŒìƒƒJƒjƒYƒ€F’mŠo_Œo‚¨‚æ‚ÑTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ84‰ñ“ú–{–ò—Šw‰ï”N‰ïA2011, 3, 22-24, ‰¡•lD

430.       ¼”g^”¿AØŽm‘ŽqA‰œˆä‹M‘åA씨“ÄŽjDŽÀŒ±“IŒ‹’°‰Šƒ‰ƒbƒg‚É‚¨‚¢‚Ä—°‰»…‘f‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚Ä’mŠo_Œo‚ð‹»•±‚³‚¹‚邱‚Æ‚É‚æ‚è•ÛŒìì—p‚ðŽ¦‚·D‘æ118‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2010, 11, 19, ‘åãD

431.       ¼‰Y‰À“ߌbA¼”g^”¿AŽO–Ø’—TA씨“ÄŽjD—°‰»…‘f‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹Šˆ«‰»‚ð‰î‚µ‚ÄäNã÷‰Š‚¨‚æ‚ÑäNã÷’É‚ð—U‹N‚·‚éD‘æ118‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2010, 11, 19, ‘åãD

432.       ‘O“c—D–AŽR’†—Ú”üAŠÖŒû•x”üŽqA¼ì—T”VA씨“ÄŽjDƒ}ƒEƒXœ‰è×–E‘O‹ì×–E‚É‚¨‚¯‚éƒgƒƒ“ƒrƒ“Žó—e‘ÌPAR1Šˆ«‰»‚É‚æ‚éƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹D‘æ118‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2010, 11, 19, ‘åãD

433.       [ŠC˜aŽ÷AŠ}¼—²“ñA‹g“c@”ÉAŠÖŒû•x”üŽqA씨“ÄŽjDƒAƒ“ƒhƒƒQƒ“Š´Žó«‘O—§‘BŠà×–E‚Ì_Œo“à•ª”å—l×–E‚Ö‚Ì•ª‰»‚É”º‚¤—°‰»…‘fŽY¶y‘f‚¨‚æ‚ÑTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì”­Œ»—U“±F•ª”å‹@”\’²ß‚É‚¨‚¯‚é–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2010‹ž“sA2010, 9, 9-1, ‹ž“sD

434.       ‘O“c‹MŽjCŽO’JŒ’Ž¡CŠÖŒû•x”üŽqC씨“ÄŽjDƒ}ƒEƒXÒ‘Œãª_Œoß”|—{×–E‚É‚¨‚¯‚éprostaglandin E2—U”­_Œo“Ë‹NL’·ƒƒJƒjƒYƒ€‚̉ðÍD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2010‹ž“sA2010, 9, 9-1, ‹ž“sD

435.       ‹à‰ª‘åŽ÷CŠÖŒû•x”üŽqC’†ì•‘ŽqC–ؗD‰ÀC¼–{—S‘¾C‹g“c@”ÉC¼”g^”¿C씨“ÄŽjDProstaglandin E2/cyclic AMP/protein kinase AŒn‚ð‰î‚µ‚½TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì‹@”\‘‹­|“d‹C¶—Šw“I‚¨‚æ‚Ñs“®–ò—Šw“IŽè–@‚ð—p‚¢‚½ŒŸ“¢D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2010‹ž“sA2010, 9, 9-1, ‹ž“sD

436.       Kawabata, A., Okubo, K., Takahashi, T., Matsunami, M., Shibayama, H. Therapeutic application of a skin-permeable ascorbic derivative as an ointment to treatment of paclitaxel-induced neuropathic hyperalgesia in rats. 13th World Congress of Pain (IASP2010), 2010, 8, 29 – 9, 2, Montreal, Canada.

437.       Matsunami, M., Kirishi, S., Okui, T., Kawabata, A. Luminal zinc chelators induce colonic pain through activation of T-type calcium channels: A mechanism for hydrogen sulfide-induced visceral pain? 13th World Congress of Pain (IASP2010), 2010, 8, 29 – 9, 2, Montreal, Canada.

438.       Nishiura, K., Matsunami, M., Miki, T., Kawabata, A. T-type calcium channels targeted by hydrogen sulfide are involved in cystitis-related bladder pain and neurogenic inflammation in mice. 13th World Congress of Pain (IASP2010), 2010, 8, 29 – 9, 2, Montreal, Canada.

439.       Kawabata, A., Aoki, Y., Sekiguchi, F., Nakagawa, M., Kanaoka, D., Yoshida, S. Peripheral hyperalgesia via the cyclic AMP/protein kinase A pathway involves activation of T-type calcium channels in rats. 16th World Congress on Basic and Clinical Pharmacology (WorldPharma2010), 2010, 7, 17-23, Copenhagen, Denmark.@

440.       Sekiguchi, F., Maeda, Y., Matsumoto, Y., Matsunami, M., Nishikawa, H., Kawabata, A. Analysis of various biological responses induced by Helicobacter pylori extract: independent of proteinase-activated receptors? 16th World Congress on Basic and Clinical Pharmacology (WorldPharma2010), 2010, 7, 17-23, Copenhagen, Denmark.

441.       Okubo, K., Takahashi, T., Matsunami, M., Shibayama, H., Kawabata, A. Topical application of disodium isostearyl 2-O-l-ascorbyl phosphate, a skin-permeable amphiphilic ascorbic derivative, attenuates chemotherapy-induced neuropathic hyperalgesia in rats. 16th World Congress on Basic and Clinical Pharmacology (WorldPharma2010), 2010, 7, 17-23, Copenhagen, Denmark.

442.       Maeda, Y., Yamanaka, R., Sekiguchi, F., Kawabata, A. Analysis of cellular signaling for epidermal growth factor-mediated suppression of androgen-induced expression of prostate-specific antigen gene in human prostate cancer LNCaP cells. 16th World Congress on Basic and Clinical Pharmacology (WorldPharma2010), 2010, 7, 17-23, Copenhagen, Denmark.

443.       Fukami, K., Kasamatsu, R., Yoshida, S., Sekiguchi, F., Kawabata, A. Hydrogen sulfide promotes function of T-type calcium channels and secretion of prostatic acid phosphatase in neuroendocrine-like prostate cancer cells from the androgen-sensitive LNCaP cell line. 16th World Congress on Basic and Clinical Pharmacology (WorldPharma2010), 2010, 7, 17-23, Copenhagen, Denmark.

444.       ’†ì•‘ŽqA–ؗD‰ÀA‹à‰ª‘åŽ÷AŠÖŒû•x”üŽqA‹g“c@”ÉA¼”g^”¿A씨“ÄŽjDProstaglandin E2‚É‚æ‚è—U‹N‚³‚ê‚é‹@ŠB“I’ÉŠo‰ß•q‚Ö‚ÌTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ117‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2010, 7, 8, “¿“‡D

445.       ‘å‹v•ÛŽõ­A¼‘º@—ÎA¼”g^”¿A씨“ÄŽjD—°‰»…‘f‚É‚æ‚è—U‹N‚³‚ê‚éƒ}ƒEƒX‚Ì‹@ŠB“I’ÉŠo‰ß•q‚ƃAƒƒfƒBƒjƒAFTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑTRPA1ƒ`ƒƒƒlƒ‹‚̈قȂé–ðŠ„D‘æ117‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2010, 7, 8, “¿“‡D

446.       ‘å‹v•ÛŽõ­A‚‹´’mŽqA[ŠC˜aŽ÷A¼”g^”¿AŽÄŽR—TŽ¡A씨“ÄŽjD”畆“§‰ß«V‹KƒAƒXƒRƒ‹ƒrƒ“Ž_ƒvƒƒhƒ‰ƒbƒOdisodium isostearyl 2-O-l-ascorbyl phosphate“îp‚Ì_ŒoáŠQ«áu’ÉŽ¡—Âւ̉ž—pD‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3, 16-18, ‘åãD

447.       ‘å‹v•ÛŽõ­A‚‹´’mŽqA[ŠC˜aŽ÷A¼”g^”¿AŽÄŽR—TŽ¡A씨“ÄŽj. ƒAƒXƒRƒ‹ƒrƒ“Ž_‚¨‚æ‚ÑV‹K—¼e”}«ƒAƒXƒRƒ‹ƒrƒ“Ž_—U“±‘Ì‚Ì—°‰»…‘f—U‹N’ÉŠo‰ß•q‚¨‚æ‚уpƒNƒŠƒ^ƒLƒZƒ‹—U‹N_ŒoáŠQ«áu’ɂɑ΂·‚éŒø‰ÊD‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3, 16-18, ‘åãD

448.       ¼‘ºK—eAΑqG‹±A¼”g^”¿AŽÂè@Œ‹AŠÖŒû•x”üŽqA¬£Œõ‰hAŠì‘½‘º‘וãA–¾Î—²‹gA¼‘ºŒª“ñA씨“ÄŽj. äX‘Ÿ’É”­Œ»‚É‚¨‚¯‚éƒvƒƒeƒA[ƒ[APAR2‚¨‚æ‚ÑTRPV1‚Ì–ðŠ„D‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3, 16-18, ‘åãD

449.       ŽO–Ø’—TA¼”g^”¿A‰ª“cŒ[ŠóA¼‰®G˜aA씨“ÄŽj. EP1ƒAƒ“ƒ^ƒSƒjƒXƒgONO-8130‚Ícyclophosphamide—U‹Nƒ}ƒEƒXäNã÷‰Š‚É”º‚¤’É‚Ý‚ð‹­—Í‚É—}§‚·‚éD‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3, 16-18, ‘åãD

450.       ¼‰Y‰À“ߌbA¼”g^”¿AŽO–Ø’—TA씨“ÄŽj. Cyclophosphamide—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¢‚ÄH2S‚Ì•W“I•ªŽqTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Í_Œoˆö«‰ŠÇ‚ÆäNã÷’É‚ÉŠÖ—^‚·‚é. ‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3, 16-18, ‘åãD

451.       ŽO’JŒ’Ž¡A“c’†—F—¢AŠÖŒû•x”üŽqA‹g“c@”ÉA씨“ÄŽjDƒ‰ƒbƒgŒãª_Œoß—R—ˆND7/23×–E‚É‚¨‚¢‚Äcyclic AMP‚É‚æ‚è—U”­‚³‚ê‚é_Œo“Ë‹NL’·‚¨‚æ‚уCƒIƒ“ƒ`ƒƒƒlƒ‹‹@”\‘‹­‚Ì“Á’¥. ‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3, 16-18, ‘åãD

452.       –ؗD‰ÀA’†ì•‘ŽqAŠÖŒû•x”üŽqA씨“ÄŽj. ƒTƒCƒNƒŠƒbƒNAMP‚É‚æ‚è—U‹N‚³‚ê‚é’ÉŠo‰ß•q‚Ö‚ÌTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^. ‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3, 16-18, ‘åãD

453.       ŠÖŒû•x”üŽq, ‘O“c—D–, ¼–{—TŠì, ¼”g^”¿, ¼ì—T”V, 씨“ÄŽj. Helicobacter pylori’Šo‰t‚É‚æ‚è—U‹N‚³‚ê‚éŽíX‚Ì×–E”½‰žFProteinase-activated receptorŠÖ—^‚Ì—L–³‚ɂ‚¢‚ÄD‘æ116‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2009, 11, 13, ‘å’ÃD

454.       ‘å‹v•ÛŽõ­A¼”g^”¿A‚‹´’mŽqA씨“ÄŽjDŠà‰»Šw—Ö@‚É”º‚¤_ŒoáŠQ«áu’É‚Í—°‰»…‘f‡¬y‘f‘jŠQ–ò‚¨‚æ‚ÑTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–ò‚É‚æ‚è—}§‚³‚ê‚éD‘æ116‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2009, 11, 13, ‘å’ÃD

455.       ŽO’JŒ’Ž¡A“c’†—F—¢AŠÖŒû•x”üŽqA‹g“c@”ÉA씨“ÄŽjDÒ‘Œãª_Œoß—R—ˆND7/23×–E‚É‚¨‚¯‚écyclic AMP—U”­_Œo“Ë‹NL’·‚¨‚æ‚Ñ“dˆÊˆË‘¶«ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì‹@”\“I‘‹­D‘æ116‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2009, 11, 13, ‘å’ÃD

456.       ¼”g^”¿AŽO–Ø’—TA¼‰Y‰À“ߌbA—Ñ—TŽqA씨“ÄŽjD“àˆö«ƒKƒXƒƒbƒZƒ“ƒWƒƒ[H2S‚Ì“à‘Ÿ’Éî•ñ“`’B‚É‚¨‚¯‚é–ðŠ„FäNã÷’É‚Ö‚ÌŠÖ—^D‘æ59‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘å‰ïA2009, 10, 14, “Œ‘åãD

457.       ŽO–Ø’—TA¼”g^”¿A씨“ÄŽjDCyclophosphamide—U‹Nƒ}ƒEƒXäNã÷‰Š^äNã÷’Ƀ‚ƒfƒ‹‚É‚¨‚¯‚éƒvƒƒXƒ^ƒOƒ‰ƒ“ƒfƒBƒ“EP1Žó—e‘̃Aƒ“ƒ^ƒSƒjƒXƒg‚Ìì—pD‘æ59‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘å‰ïA2009, 10, 14, “Œ‘åãD

458.       Kawabata, A., Takahashi, T., Okubo, K., Matsunami, M., Kojima, S., Nishikawa, H., Takemura, M. Buprenorphine strongly attenuates the neuropathic pain induced by spinal nerve injury or chemotherapy in laboratory animals. 13th Congress of the European Federation of Neurological Societies (EFNS 2009), 2009, 9, 12-15, Florence, Italy.

459.       Matsunami, M., Miki, T., Hayashi, Y., Kawabata, A. Hydrogen sulfide is a key mediator for bladder pain during cyclophosphamide-induced cystitis in mice. 13th Congress of the European Federation of Neurological Societies (EFNS 2009), 2009, 9, 12-15, Florence, Italy.

460.       Nishimura, S., Fukushima, O., Matsunami, M., Ishikura, H., Kawabata, A. Activation of ERK in the spinal dorsal horn neurons by distinct pro-nociceptive stimuli in the pancreas: roles of hydrogen sulfide and proteinase-activated receptor-2. 13th Congress of the European Federation of Neurological Societies (EFNS 2009), 2009, 9, 12-15, Florence, Italy.

461.       Okubo, K., Matsunami, M., Takahashi, T., Kawabata, A. Roles of hydrogen sulfide and T-type calcium channels in chemotherapy-evoked neuropathic hyperalgesia in rats. 13th Congress of the European Federation of Neurological Societies (EFNS 2009), 2009, 9, 12-15, Florence, Italy.

462.       Mitani, K., Tanaka, Y., Sekiguchi, F., Yoshida, S., Kawabata, A. Neurite outgrowth and functional up-regulation of voltage-dependent calcium channels caused by cyclic AMP in sensory neuron-like cells. 13th Congress of the European Federation of Neurological Societies (EFNS 2009), 2009, 9, 12-15, Florence, Italy.

463.       Aoki, Y., Maeda, Y., Matsunami, M., Kawabata, A. Peripheral hydrogen sulfide induces hypersensitivity to C-fiber-preferential sine-wave stimulation and concomitant potentiation of ERK phosphorylation in the spinal dorsal horn neurons. 13th Congress of the European Federation of Neurological Societies (EFNS 2009), 2009, 9, 12-15, Florence, Italy.

464.       Fukami, K., Tarui, T., Nagasawa, K., Yoshida, S., Sekiguchi, F., Kawabata, A. Involvement of downstream Src activation of Cav3.2 T-type calcium channels in hydrogen sulfide-induced neuronal differentiation in NG108-15 cells. 13th Congress of the European Federation of Neurological Societies (EFNS 2009), 2009, 9, 12-15, Florence, Italy.

465.       Miki, T., Matsunami, M., Hayashi, Y., Akaogi, K., Kamanaka, Y., Kawabata, A. Prostaglandin EP1 receptors participate in the development of bladder pain in mice with cyclophosphamide-induced cystitis. 13th Congress of the European Federation of Neurological Societies (EFNS 2009), 2009, 9, 12-15, Florence, Italy.

466.       Kawabata, A., Takahashi, T., Okubo, K., Matsunami, M. Involvement of endogenous hydrogen sulfide and T-type calcium channels in neuropathic pain induced by spinal nerve injury or chemotherapy. Pain in Europe VI (6th Congress of the European Federation of IASP Chapters), 2009, 9, 9-12, Lisbon, Portugal.

467.       Matsunami, M., Miki, T., Hayashi, Y., Akaogi, K., Kamanaka, Y., Kawabata, A. The prostaglandin E2 receptor subtype EP1 mediates bladder pain/hyperalgesia accompanying the cyclophosphamide-induced cystitis in mice. Pain in Europe VI (6th Congress of the European Federation of IASP Chapters), 2009, 9, 9-12, Lisbon, Portugal.

468.       Kawabata, A., Takahashi, T., Matsunami, M., Kojima, S., Okubo, K., Takemura, M., Nishikawa, H. Potent anti-hyperalgesic effect of buprenorphine in two distinct neuropathic pain models induced by spinal nerve injury and by paclitaxel. XXXVI International Congress of Physiological Sciences, 2009, 7, 27 – 8, 1, Kyoto.

469.       Sekiguchi, F., Maeda, Y., Ohi, A., Takaoka, K., Nishikawa, H., Kawabata, A. The time lag of PGE2 release and COX-2 up-regulation triggered by PAR1 is due to deficiency of arachidonic acid in gastric epithelial cells. XXXVI International Congress of Physiological Sciences, 2009, 7, 27 – 8, 1, Kyoto.

470.       Okubo, K., Matsunami, M., Takahashi, T., Kawabata, A. Involvement of hydrogen sulfide and T-type calcium channels in the maintenance of hyperalgesia in rats with chemotherapy-induced neuropathy. XXXVI International Congress of Physiological Sciences, 2009, 7, 27 – 8, 1, Kyoto.

471.       Maeda, Y., Sekiguchi, F., matsumoto, Y., Nishikawa, H., Kawabata, A. Effect of Helicobacter pylori extracts on prostaglandin E2 production in human lung alveolar epithelial A549 cells. XXXVI International Congress of Physiological Sciences, 2009, 7, 27 – 8, 1, Kyoto.

472.       ŠÖŒû•x”üŽqA‹v•Û‘ŽqA•‰Í—SŽqA‰ª–{—R‰À—œA“y]ˆÊ’mŽqA씨“ÄŽjD‚°‚ÁŽ•—Þ‚Ì‹C“¹‚¨‚æ‚ÑÁ‰»ŠÇ•½ŠŠ‹Ø‚Ì‹Ù’£«‚É‚¨‚æ‚Ú‚·—°‰»…‘f‚̉e‹¿D‘æ51‰ñ@“ú–{•½ŠŠ‹ØŠw‰ï‘‰ïA2009, 7, 21-23, –¼ŒÃ‰®D

473.       ¼”g^”¿A씨“ÄŽjD“àˆö«—°‰»…‘f‚ÍäNã÷‰Š‚É”º‚¤’É‚Ý‚Ì”­Œ»‚ÉŠÖ—^‚·‚éD‘æ31‰ñ“ú–{áu’ÉŠw‰ïA2009, 7, 17-18, –¼ŒÃ‰®D

474.       Kawabata, A. Roles of hydrogen sulfide in processing of inflammatory pain. In a symposium, gHydrogen sulfide in inflammationh, The First International Conference of Hydrogen Sulfide in Biology and Medicine, 2009, 6, 26-28, Shanghai, China. (Invited Speaker)

475.       Kawabata, A. Hydrogen sulfide and pain. In a symposium, gGases as Neuromodulators in Sensing : From Nitric Oxide to Hydrogen sulfideh, Experimental Biology 2009, 2009, 4, 18-22, New Orleans, USA. (Organizer and Invited Speaker)@

476.       Sekiguchi, F., Tanaka, Y., Hong, H., Kawabata, A. IL-8 release triggered by proteinase-activated receptor-2 stimulation involves both MEK/ERK and PI3 kinase/Akt pathways in gastrointestinal epithelial cells. Experimental Biology 2009, 2009, 4, 18-22, New Orleans, USA.

477.       Fukami, K., Sekiguchi, F., Takaoka, K., Miyake, K., Yamamoto, T., Tanaka, S., Ohno, K., Ishikura, H., Naruse, M., Kawabata, A. Relationship between expression of PARs and infection with H. pylori in the stomach of gastric cancer patients. Experimental Biology 2009, 2009, 4, 18-22, New Orleans, USA.

478.       Maeda, Y., Sekiguchi, F., Ohi, A., Takaoka, K., Nishikawa, H., Kawabata, A. The delayed release of PGE2 mediated by PAR1 involves slowly developing production of arachidonic acid in rat gastric mucosal epithelical cells. Experimental Biology 2009, 2009, 4, 18-22, New Orleans, USA.

479.       ŠÖŒû•x”üŽqA[ŠC˜aŽ÷A‚‰ª•Û—AŽO‘ìAŽR–{—²ŽkA“c’†ÑŒáA‘å–ìkˆêAΑqG‹±A¬£Œõ‰hA씨“ÄŽjDˆÝŠàŠ³ŽÒ‚æ‚è“Eo‚µ‚½ˆÝ‘gD‚̃wƒŠƒRƒoƒNƒ^[EƒsƒƒŠ—R—ˆƒEƒŒƒA[ƒ[’`”’—Ê‚ÆPAR1‚ ‚é‚¢‚ÍPAR2”­Œ»—Ê‚Ì‘ŠŠÖ«‚ɂ‚¢‚ÄD‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3, 16-18, ‰¡•lD

480.       ¼”g^”¿AŽO–Ø’—TA씨“ÄŽjD“àˆö«ƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚̃VƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷‰Š‚¨‚æ‚ÑäNã÷’É‚Ö‚ÌŠÖ—^D‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3, 16-18, ‰¡•lD

481.       ‘å‹v•ÛŽõ­A¼”g^”¿A‰¶’n‹I”ü]A씨“ÄŽjDƒAƒXƒRƒ‹ƒrƒ“Ž_‚Í—°‰»…‘f—U‹N’ÉŠo‰ß•q‚¨‚æ‚уpƒNƒŠƒ^ƒLƒZƒ‹—U‹N_Œoˆö«áu’É‚ð—}§‚·‚éD‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3, 16-18, ‰¡•lD

482.       •‰Í—SŽqA‹v•Û‘ŽqAŽRè—ÇŽqAŠÖŒû•x”üŽqA‰ª–{—R‰À—œA‘O“c—D–A‹v•Ä—˜–¾A•Ÿ“ˆL”VAÔ’rº‹IA씨“ÄŽjD—°‰»…‘f‚É‚æ‚è—U‹N‚³‚ê‚é‘å”]”玿_Œo×–EŽ€‚̃ƒJƒjƒYƒ€‚̉ðÍF“Á‚ÉMEK/ERKŒn‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3, 16-18, ‰¡•lD

483.       ‚‹´’mŽqAŽO’JŒ’Ž¡A’|‘ºŒ³GAŠÖŒû•x”üŽqA씨“ÄŽjD“àˆö«—°‰»…‘f‚Ì•W“I•ªŽqCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Í_Œoˆö«áu’É‚Ì•ÛŽ‚É‚¨‚¢‚Äd—v‚È–ðŠ„‚ðŽ¦‚·D‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3, 16-18, ‰¡•lD

484.       ‚‹´’mŽqA¼ì—T”VA’|‘ºŒ³GA씨“ÄŽjD_Œoˆö«áu’Ƀ‚ƒfƒ‹ƒ‰ƒbƒg‚É‚¨‚¯‚éƒuƒvƒŒƒmƒ‹ƒtƒBƒ“‚Ì‹­—Í‚È’Á’ÉŒø‰ÊD‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3, 16-18, ‰¡•lD

485.       ’Mˆä ‹BA[ŠC˜aŽ÷A’·àVŒi‘¾A‹g“c ”ÉAŠÖŒû•x”üŽqA씨“ÄŽjD—°‰»…‘f‚ÍCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠˆ«‰»‚É‘±‚­SrcŒ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[‚ÌŠˆ«‰»‚ð‰î‚µ‚ÄNG108-15×–E‚Ì_Œo•ª‰»‚ð—U“±‚·‚éD‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3, 16-18, ‰¡•lD

486.       –ؗD‰ÀA‘O“c—C”üA¼”g^”¿A씨“ÄŽjD––½‘gD‚Ì—°‰»…‘f‚Í‚büˆÛ‚ð‰î‚·‚éáu’É”½‰ž‚ÆÒ‘ŒãŠpƒjƒ…[ƒƒ“‚É‚¨‚¯‚éERKƒŠƒ“Ž_‰»‚ð‘‘傳‚¹‚éD‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3, 16-18, ‰¡•lD

487.       •‰Í—SŽqA‹v•Û‘ŽqAŽRè—ÇŽqAŠÖŒû•x”üŽqA‰ª–{—R‰À—œA‘O“c—D–A‹v•Ä—˜–¾A•Ÿ“ˆL”VAÔ’rº‹IA씨“ÄŽjDƒ}ƒEƒX‘ÙŽ™‘å”]”玿_Œo×–E‚É‚¨‚¯‚é“àˆö«ƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚Ì_Œo×–E“Å«‚ÍMEK-ERKŒn‚ÌŠˆ«‰»‚Ɉˑ¶‚·‚éD‘æ114‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2008, 11, 14, _ŒËD

488.       ’Mˆä ‹BA[ŠC˜aŽ÷A’·àVŒi‘¾A‹g“c ”ÉAŠÖŒû•x”üŽqA씨“ÄŽjD—°‰»…‘f‚É‚æ‚éNG108-15×–E‚Ì_Œo•ª‰»‚ÍTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹Šˆ«‰»‚É‘±‚­SrcŒ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[Šˆ«‰»‚Ɉˑ¶‚·‚éD‘æ114‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2008, 11, 14, _ŒËD

489.       –ؗD‰ÀA‘O“c—C”üA¼”g^”¿A씨“ÄŽjD––½‘gD’†‚Ì—°‰»…‘f‚É‚æ‚è—U‹N‚³‚ê‚é’mŠo_ŒoCüˆÛŠ´Žó«‘‘åFˆÙ”g’·ƒTƒCƒ“”gŽhŒƒ‚ɑ΂·‚锽‰ž«•Ï‰»‚ðŽw•W‚Æ‚µ‚½ŒŸ“¢D‘æ114‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2008, 11, 14, _ŒËD

490.       Kawabata, A., Maeda, Y., Aoki, Y., Tarui, T., Mitani, K., Sekiguchi, F., Okubo, K., Yoshida, S., Nishikawa, H. Hydrogen sulfide is pro-nociceptive in the spinal cord as well as peripheral tissues. 6th FENS Forum of European Neuroscience, 2008, 7, 12-16, Geneva, Switzerland.

491.       Sekiguchi, F., Kurokawa, Y., Okamoto, Y., Kubo, S., Yamasaki, Y., Maeda, Y., Kume, T., Fukushima, N., Akaike, A., Kawabata, A. Cell damage induced by hydrogen sulfide in cortical neurons from mouse embryos. 6th FENS Forum of European Neuroscience, 2008, 7, 12-16, Geneva, Switzerland.

492.       Matsunami, M., Fukushima, O., Takemura, M., Kawabata, A. Mechanisms underlying visceral pain induced by colonic luminal hydrogen sulfide in mice. 6th FENS Forum of European Neuroscience, 2008, 7, 12-16, Geneva, Switzerland.

493.       Nishimura, S., Fukushima, O., Ishikura, H., Takahashi, T., Matsunami, M., Tsujiuchi, T., Sekiguchi, F., Naruse, M., Kamanaka, Y., Kawabata, A. Involvement of endogenous hydrogen sulfide in acute pancreatitis-related pain. 6th FENS Forum of European Neuroscience, 2008, 7, 12-16, Geneva, Switzerland.

494.       Tarui, T., Nagasawa, K., Yoshida, S., Ohi, A., Fukami, K., Matsunami, M., Sekiguchi, F., Ichida, S., Nishikawa, H., Kawabata, A. Hydrogen sulfide induces neuronal differentiation via Cav3.2 T-type calcium channels and Src family tyrosine kinase in NG108-15 cells. 6th FENS Forum of European Neuroscience, 2008, 7, 12-16, Geneva, Switzerland.

495.       Takahashi, T., Maeda, Y., Kawabata, A. Neuropathic pain involves sensitization of Cav3.2 T-type calcium channels by endogenous hydrogen sulfide in sensory nerves. 6th FENS Forum of European Neuroscience, 2008, 7, 12-16, Geneva, Switzerland.

496.       ¼‘ºK—eA•Ÿ“‡@CA¼”g^”¿A씨“ÄŽjDäX‘Ÿ“à‚Ì—°‰»…‘f (H2S) ‚¨‚æ‚Ñproteinase-activated receptor-2 (PAR2) ŽhŒƒ‚É‚æ‚Á‚Ä—U‹N‚³‚ê‚éÒ‘ŒãŠp•\‘wƒjƒ…[ƒƒ“‚ÌERKƒŠƒ“Ž_‰»D‘æ113‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2008, 6, 20, ‰ªŽRD

497.       씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ð‰î‚·‚é—°‰»…‘f‚ÌV‚½‚È‹@”\@\@“Á‚Éáu’Éî•ñ“`’B‚Ö‚ÌŠÖ—^‚ɂ‚¢‚ÄDƒVƒ“ƒ|ƒWƒEƒ€9u—°‰»…‘f‚ƈêŽ_‰»’Y‘fF“Å‚É‚àî•ñ•ªŽq‚É‚à‚È‚éƒKƒXvA‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lDiƒVƒ“ƒ|ƒWƒXƒgj

498.       —тЂƂÝA‹v•Û‘ŽqA¼ì—T”VAŠÖŒû•x”üŽqA씨“ÄŽjDƒEƒTƒMŒŒ¬”‚̋ÃW‚¨‚æ‚уJƒ‹ƒVƒEƒ€“®ˆõ‚É‚¨‚æ‚Ú‚·—°‰»…‘f‚̉e‹¿D‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD

499.       “c’†—S•ãAHao HongAŠÖŒû•x”üŽqA씨“ÄŽjDƒqƒgŒ‹’°Šà‚¨‚æ‚шݑBŠà—R—ˆ×–E‚É‚¨‚¢‚ÄPAR2ŽhŒƒ‚É‚æ‚è—U‹N‚³‚ê‚éƒCƒ“ƒ^[ƒƒCƒLƒ“-8—V—£‚ÉŠÖ—^‚·‚é×–EƒVƒOƒiƒ‹D‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD

500.       ‚‹´’mŽqA‘O“c—C”üA씨“ÄŽjD“àˆö«—°‰»…‘f‚¨‚æ‚ÑTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì_Œoˆö«áu’É‚Ö‚ÌŠÖ—^D‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD

501.       ŠÖŒû•x”üŽqA‘åˆäˆŸˆßA‚‰ª•Û—A¼ì—T”VA씨“ÄŽjDƒ‰ƒbƒgˆÝ”S–Œã”ç×–E‚É‚¨‚¯‚éproteinase-activated receptor-1ŽhŒƒ—U‹N’x”­«ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ÉŠÖ‚í‚é×–E“àî•ñ“`’BŒn‚ÌŒŸ“¢D‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD

502.       ‹v•Û‘ŽqA—тЂƂÝA¼ì—T”VA씨“ÄŽjD“àˆö«ƒKƒXóƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚É‚æ‚郉ƒbƒgŒŒ¬”‹ÃW—}§‚Ì“Á’¥D‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD

503.       Žçs˜a”üA¼Œ´‚©‚¨‚èAŠÖŒû•x”üŽqA¼ì—T”VA씨“ÄŽjDƒqƒg”x–Eã”ç×–E‚É‚¨‚¢‚ÄPAR2Šˆ«‰»‚É‚æ‚è—U‹N‚³‚ê‚éƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶‚ɑ΂·‚éƒNƒ‹ƒNƒ~ƒ“‚ÌŒø‰ÊD‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD

504.       ‚‰ª•Û—AM‹MG‹éAŠÖŒû•x”üŽqA씨“ÄŽjDƒ‰ƒbƒg³íˆÝ”S–Œã”ç×–E‚É‚¨‚¢‚ă`ƒAƒ]ƒŠƒWƒ“ƒfƒBƒIƒ“Œn–ò•¨‚ÍPAR1Šˆ«‰»‚É‚æ‚éƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶‚ðPPARƒÁ”ñˆË‘¶«‚ÉCü‚·‚éD‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD

505.       ‘O“c—C”üA–ؗD‰ÀA‚‹´’mŽqAŠÖŒû•x”üŽqA¼ì—T”VA씨“ÄŽjDÒ‘“à‚¨‚æ‚Ñ––½‘gD’†‚Ì—°‰»…‘f‚É‚æ‚é’ÉŠo‰ß•q”­Œ»‚É‚¨‚¯‚éCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÆNMDAŽó—e‘Ì‚Ì–ðŠ„D‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD

506.       ŠÖŒû•x”üŽqA‘åˆäˆŸˆßA‚‰ª•Û—A¼ì—T”VA씨“ÄŽjDƒ‰ƒbƒgˆÝ”S–Œã”ç×–ERGM1‚É‚¨‚¢‚Äproteinase-activated receptor-1‚ð‰î‚µ‚½prostaglandin E2ŽY¶˜´i‚Ì’x‰„‚̓Aƒ‰ƒLƒhƒ“Ž_‹Ÿ‹‹•s‘«‚É‹Nˆö‚·‚éD‘æ26‰ñCytoprotectionŒ¤‹†‰ïA2008, 3, 14, ‹ž“sD

507.       ¼”g^”¿A’Mˆä@‹BAŽO’JŒ’“ñA’·àVŒi‘¾A‹g“c@”ÉA•Ÿ“‡@CA’|‘ºŒ³GA씨“ÄŽjDŒ‹’°“ào—°‰»…‘f‚É‚æ‚è—U‹N‚³‚ê‚é“à‘Ÿ’É‚Ì”­Œ»ƒƒJƒjƒYƒ€‚̉ðÍD‘æ26‰ñCytoprotectionŒ¤‹†‰ïA2008, 3, 14, ‹ž“sDi§—ãÜŽóÜj

508.       ‘O“c—C”üA–ؗD‰ÀA‚‹´’mŽqAŠÖŒû•x”üŽqA¼ì—T”VA씨“ÄŽjDÒ‘“à‚¨‚æ‚Ñ––½‘gD“à‚Ì—°‰»…‘f‚É‚æ‚é’ÉŠo‰ß•qFCaV3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ112‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2007, 11, 16, –L’†D

509.       ‚‰ª•Û—AM‹MG‹éAŠÖŒû•x”üŽqA씨“ÄŽjDƒ‰ƒbƒg³íˆÝ”S–Œã”çRGM1×–E‚É‚¨‚¯‚éPAR1Šˆ«‰»—U‹NƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶‚ɑ΂·‚éƒ`ƒAƒ]ƒŠƒWƒ“ƒfƒBƒIƒ“Œn–ò•¨‚̉e‹¿D‘æ112‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2007, 11, 16, –L’†D

510.       Žçs˜a”üA¼Œ´‚©‚¨‚èAŠÖŒû•x”üŽqA¼ì—T”VA씨“ÄŽjDƒqƒg”x–E—R—ˆã”ç×–E‚É‚¨‚¯‚éPAR2—U‹NƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ɑ΂·‚éƒNƒ‹ƒNƒ~ƒ“‚Ì—}§Œø‰ÊD‘æ112‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2007, 11, 16, –L’†D

511.       Kawabata, A., Nishimura, S., Fukushima, O., Ishikura, H., Takahashi, T., Matsunami, M., Tsujiuchi, T., Sekiguchi, F., Naruse, M., Kamanaka, Y. Hydrogen sulfide as a nociceptive messenger in rat and mouse pancreata. Neuroscience 2007, 2007, 11, 3-7, Dan Diego, USA.

512.       씨“ÄŽjDH2S‚Æ’É‚ÝDƒVƒ“ƒ|ƒWƒEƒ€u‹C‘̃ƒfƒBƒG[ƒ^[‚Æ‘n–òvA¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2007‹à‘òD2007, 9, 13-14, ‹à‘òDiOrganizerEƒVƒ“ƒ|ƒWƒXƒgj

513.       ŠÖŒû•x”üŽqA‹v•Û‘ŽqA•‰Í—SŽqA—тЂƂÝA¼ì—T”VA‰ª–{—R‰À—œA씨“ÄŽjDH2S‚Æ•½ŠŠ‹Ø‰^“®DƒVƒ“ƒ|ƒWƒEƒ€u‹C‘̃ƒfƒBƒG[ƒ^[‚Æ‘n–òvA¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2007‹à‘òD2007, 9, 13-14, ‹à‘òDiƒVƒ“ƒ|ƒWƒXƒgj

514.       ’Mˆä@‹BA’·àVŒi‘¾A•Ÿ“ˆL”VA–ìèŽü‰pA씨“ÄŽjDƒ‰ƒbƒgŠŒF×–EŽî—R—ˆ×–EPC12‚É‚¨‚¯‚éNGF—U‹N_Œo“Ë‹NL’·‚ɑ΂·‚錌Ÿ÷—R—ˆthrombinŽŽ–ò’†šñŽG¶—Šˆ«•¨Ž¿‚Ì‘£iŒø‰ÊD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2007‹à‘òD2007, 9, 13-14, ‹à‘òD

515.       ‚‹´’mŽqA’Mˆä@‹BAŽO’JŒ’Ž¡A’·àVŒi‘¾A‘O“c—C”üA‹g“c@”ÉA씨“ÄŽjD_Œoˆö«áu’Ƀ‚ƒfƒ‹‚É‚¨‚¯‚é—°‰»…‘f‡¬y‘f‘jŠQ–ò‚Ì’Á’ÉŒø‰ÊD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2007‹à‘òD2007, 9, 13-14, ‹à‘òD

516.       Kawabata, A., Nishimura, S., Fukushima, O., Ishikura, H., Takahashi, T., Matsunami, M., Sekiguchi, F., Naruse, M. A pro-nociceptive role for hydrogen sulfide in the pancreas. The 4th Science and Research Symposium: Gastrointestinal motility and Functional gastrointestinal disorders, Basic to Clinic. 2007, 8, 28, Nagoya.

517.       Matsunami, M., Tarui, T., Mitani, K., Nagasawa, K., Yoshida, S., Fukushima, O., Takemura, M., Kawabata, A. Luminal hydrogen sulfide in mouse colon: a novel mediator for visceral pain. The 4th Science and Research Symposium: Gastrointestinal motility and Functional gastrointestinal disorders, Basic to Clinic. 2007, 8, 28, Nagoya. iExcellence AwardŽóÜ)

518.       Kawabata, A. Gastro-intestinal roles for proteinase-activated receptors. Life Sciences 2007, 2007, 7, 8-12, Glasgow, UK. (Invited lecture).

519.       Matsunami, M., Fukushima, O., Takemura, M., Kawabata, A. A novel nociceptive role for luminal hydrogen sulfide in mouse colon. Life Sciences 2007, 2007, 7, 8-12, Glasgow, UK.

520.       Sekiguchi, F., Kubo, S., Kurokawa, Y., Okamoto, Y., Doe, I., Kawabata, A. Effects of hydrogen sulfide on the tone of gastrointestinal and airway smooth muscle preparations from rodents. Life Sciences 2007, 2007, 7, 8-12, Glasgow, UK.

521.       Moriyuki, K., Matsubara, K., Sekiguchi, F., Nishikawa, H., Kawabata, A. Curcumin intervention of PAR2-triggered prostaglandin E2 (PGE2) release in human lung epithelial cells: what are the target molecules downstream of PAR2?@Young Life Scientistsf Symposium 2007 – Advances in Signalling (a satellite to the Life Sciences 2007). 2007, 7, 8, Glasgow, UK.

522.       Takaoka, K., Shigi, H., Sekiguchi, F., Kawabata, A. Modulation of PAR1-triggered prostaglandin E2 production by thiazolidinediones through peroxisome proliferator-activated receptor-ƒÁ-independent pathways in rat gastric mucosal epithelial cells. Young Life Scientistsf Symposium 2007 – Advances in Signalling (a satellite to the Life Sciences 2007). 2007, 7, 8, Glasgow, UK.

523.       Taniguchi, E., Yonezawa, D., Kimura, T., Ishiki, T., Matsunami, M., Sekiguchi, F., Nishikawa, F., Kawabata, A. Hydrogen sulfide (H2S) as a hypothetical pro-inflammatory signaling molecule in ulcerative colitis (UC): impaired detoxification but not generation of H2S in a mouse UC model. Young Life Scientistsf Symposium 2007 – Advances in Signalling (a satellite to the Life Sciences 2007). 2007, 7, 8, Glasgow, UK.

524.       Maeda, Y., Aoki, Y., Takahashi, T., Kawabata, A. T-Type calcium channel-mediated nociceptive signaling triggered by hydrogen sulfide in rat spinal cord and peripheral tissue. Young Life Scientistsf Symposium 2007 – Advances in Signalling (a satellite to the Life Sciences 2007). 2007, 7, 8, Glasgow, UK.

525.       Kurokawa, Y., Kubo, S., Doe, I., Sekiguchi, F., Kawabata, A. Inhibition of the activity of three recombinant nitric oxide synthase isoforms by hydrogen sulfide. Young Life Scientistsf Symposium 2007 – Advances in Signalling (a satellite to the Life Sciences 2007). 2007, 7, 8, Glasgow, UK.

526.       Matsunami, M., Fukushima, O., Takemura, M., Kawabata, A. Colonic pain induced by luminal hydrogen sulfide: a novel mechanism for visceral nociceptive signaling. Young Life Scientistsf Symposium 2007 – Advances in Signalling (a satellite to the Life Sciences 2007). 2007, 7, 8, Glasgow, UK.

527.       ’JŒû‰lˆêA•Ä‘ò‘åŽ÷AΖØ@„A¼”g^”¿AŠÖŒû•x”üŽqA씨“ÄŽjD‰ŠÇ«’°Ž¾Š³(IBD)ƒ‚ƒfƒ‹‚É‚¨‚¯‚é—°‰»…‘fŽY¶E‰ð“Å‚ÉŠÖ—^‚·‚éy‘f‚Ì‹““®D‘æ80‰ñ“ú–{–ò—Šw‰ï”N‰ï2007, 3, 14-16, –¼ŒÃ‰®D

528.       •Ÿ“‡@CA¼‘ºK—eAΑqG‹±A‚‹´’mŽqA¼”g^”¿AŠÖŒû•x”üŽqA¬£Œõ‰hAŠ™’†Šì‹vA씨“ÄŽjDƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚ÍäX‘Ÿ‚Ì’É‚Ý‚ÉŠÖ—^‚·‚éD‘æ80‰ñ“ú–{–ò—Šw‰ï”N‰ï2007, 3, 14-16, –¼ŒÃ‰®D

529.       ¼”g^”¿A‘å‹v•ÛŽõ­A•Ÿ“‡@CA씨“ÄŽjD—°‰»…‘f‚Í“à‘Ÿ’É”­Œ»‚ÉŠÖ—^‚·‚éV‚½‚ȃƒbƒZƒ“ƒWƒƒ[‚Æ‚µ‚Ä‹@”\‚µ‚Ä‚¢‚éD‘æ80‰ñ“ú–{–ò—Šw‰ï”N‰ï2007, 3, 14-16, –¼ŒÃ‰®D

530.       ’·àVŒi‘¾A’Mˆä@‹BA‹g“c@”ÉAó–ì@”£AŠÖŒû•x”üŽqAŽs“c¬ŽuA¼ì—T”VA씨“ÄŽjD—°‰»…‘f‚ÍNG108-15×–E‚É‚¨‚¢‚ÄTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚̃ŒƒhƒbƒNƒX§Œä‚ð‰î‚µ‚Ä_Œo•ª‰»‚ð—U‹N‚·‚éD‘æ80‰ñ“ú–{–ò—Šw‰ï”N‰ï2007, 3, 14-16, –¼ŒÃ‰®D

531.       ‹v•Û‘ŽqAΑqG‹±A’†Š_’qOA씨“ÄŽjDƒ‰ƒbƒgã’°ŠÔ–Œ“®–¬‚É‚¨‚¯‚éactivated protein C‚Ì“à”çˆË‘¶«’oŠÉì—pD‘æ80‰ñ“ú–{–ò—Šw‰ï”N‰ï2007, 3, 14-16, –¼ŒÃ‰®D

532.       ‹v•Û‘ŽqA•‰Í—SŽqA“y]ˆÊ’mŽqA씨“ÄŽjDƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚̓ŠƒRƒ“ƒrƒiƒ“ƒgNO‡¬y‘f‚ÌŠˆ«‚ð‘jŠQ‚·‚éD‘æ80‰ñ“ú–{–ò—Šw‰ï”N‰ï2007, 3, 14-16, –¼ŒÃ‰®D

533.       씨“ÄŽjDProteinase-activated receptor (PAR)‚Ì•a‘Ô¶—Šw“I–ðŠ„D“ú–{–òŠw‰ï–k—¤Žx•”‘æ115‰ñ—á‰ïA2006, 11, 12, •xŽRi“Á•Êu‰‰jD

534.       ‹v•Û‘ŽqA•‰Í—SŽqA“y]ˆÊ’mŽqA씨“ÄŽjDƒKƒXóî•ñ“`’B•¨Ž¿H2S‚ÌNO‡¬y‘f (NOS) ‚ɑ΂·‚éì—p‚̉ðÍFnNOSAiNOS‚¨‚æ‚ÑeNOSŠˆ«‚Ì—}§‚ɂ‚¢‚ÄD‘æ110‰ñ@“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2006, 11, 10, ‹ž“sD

535.       ¼‘ºK—eA•Ÿ“‡@CAΑqG‹±A‚‹´’mŽqA¼”g^”¿AŠÖŒû•x”üŽqA¬£Œõ‰hAŠ™’†Šì‹v”¨“ÄŽjDƒKƒXƒƒbƒZƒ“ƒWƒƒ[H2S‚ÌäX‰ŠŠÖ˜A’É‚Ö‚ÌŠÖ—^D‘æ110‰ñ@“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2006, 11, 10, ‹ž“sD

536.       ’·àVŒi‘¾A’Mˆä@‹BA‹g“c@”ÉA¼ì—T”VA씨“ÄŽjD“àˆö«ƒKƒXóî•ñ“`’B•¨Ž¿H2S‚ÍTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚ÄNG108-15×–E‚Ì_Œo•ª‰»‚ð—U“±‚·‚éD‘æ110‰ñ@“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2006, 11, 10, ‹ž“sD

537.       ‹v•Û‘ŽqA“y]ˆÊ’mŽqA•‰Í—SŽqA씨“ÄŽjDƒKƒXƒƒbƒZƒ“ƒWƒƒ[H2S‚É‚æ‚éNO‡¬y‘fŠˆ«‚Ì‘jŠQFŒŒŠÇ‰^“®’²ß‚Ö‚ÌŠÖ—^D‘æ56‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïA2006, 10, 28, ‹ž“sD

538.       ¼ì—T”VA‰Í‡Œ’‘ A‘å’J—T–çAˆÀ•”’q”VAr–ØG¹A‰i––’mŽqA씨“ÄŽjDPAR-2ŠÖ˜Aƒyƒvƒ`ƒh‚É‚æ‚éPAR-2ˆË‘¶‚¨‚æ‚Ñ”ñˆË‘¶«—܉t•ª”å:\‘¢Šˆ«‘ŠŠÖ‚Æì—p‹@˜‚̉ðÍD‘æ56‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïA2006, 10, 28, ‹ž“si2005”N“xŽx•”§—ãÜŽóÜu‰‰jD

539.       ŠÖŒû•x”üŽqAÖ“¡Ž‡–ìA‚‰ª•Û—A—тЂƂÝA‰Í”ö’¼”VA’·‘ë^ŽÀA씨“ÄŽjDƒgƒƒ“ƒrƒ“Žó—e‘ÌPAR1Šˆ«‰»‚ð‰î‚µ‚½ƒ‰ƒbƒgˆÝ”S–Œã”ç×–E‚©‚ç‚Ì’x‰„«ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àî•ñ“`’BŒn‚ÌŒŸ“¢D‘æ56‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïA2006, 10, 28, ‹ž“si2004”N“xŽx•”§—ãÜŽóÜu‰‰jD

540.       Kawabata, A., Ishiki, T., Maeda, Y., Nagasawa, K., Takahashi, T., Nishikawa, H. A pro-nociceptive role for hydrogen sulfide in peripheral tissues. Neuroscience 2006, 2006, 10, 14-18, Atlanta. (Oral)

541.       Nagasawa, K., Ishiki, T., Yoshida, S., Maeda, Y., Sekiguchi, F., Wada, T., Ichida, S., Nishikawa, H., Kawabata, A. Hydrogen sulfide sensitizes T-type calcium channels via redox modulation. Neuroscience 2006, 2006, 10, 14-18, Atlanta.

542.       Matsunami, M., Okubo, K., Fukushima, O., Takemura, M., Kawabata, A. Hydrogen sulfide is pro-nociceptive in the colon. Neuroscience 2006, 2006, 10, 14-18, Atlanta.

543.       Sugiyo, S., Sakai, Y., Masawaki, A., Shimoda, T., Utaka, S., Kawabata, M., Moritani, M., Yoshida, A., Matsunami, M., Kawabata, A., Takemura, M. Estrous cycle dependent pain related behavior and c-Fos expression after formalin injection into the upper lip. Neuroscience 2006, 2006, 10, 14-18, Atlanta.

544.       ŠÖŒû•x”üŽqC‚‰ª•Û—CŽçs˜a”üC씨“ÄŽjDProteinase-activated receptorŠˆ«‰»‚É‚æ‚éƒvƒƒXƒ^ƒmƒCƒhŽY¶ƒVƒOƒiƒ‹‚Æ•a‘ÔD‘æ34‰ñ@–ò•¨Šˆ«ƒVƒ“ƒ|ƒWƒEƒ€A2006, 9, 28-29, ‚èiŒQ”njDiƒVƒ“ƒ|ƒWƒEƒ€j

545.       Kawabata, A., Ishiki, T., Nagasawa, K., Yoshida, S., Maeda, Y., Takahashi, T., Sekiguchi, F., Nishikawa, H. Evidence that hydrogen sulfide plays a pro-nociceptive role. The 18th Japan-Korea Joint Seminar of Pharmacology, 2006, 9, 23-24, Fukui. (Oral)

546.       Kawabata, A., Moriyuki, K., Nagataki, M., Nishikawa, H. Proteinase-activated receptor-2-triggered prostaglandin E2 formation involves COX-1-dependent up-regulation of microsomal prostaglandin E synthase-1 in human lung epithelial cells. Half-day Symposium on G Protein-Coupled Receptors (GPCRs) (a satellite symposium of 16th International Symposium on Regulatory Peptides), 2006, 9, 2, Hakone.

547.       Moriyuki, K., Nagataki, M., Nishikawa, H., Kawabata, A. Signal transduction for proteinase-activated receptor-2-triggered interleukin-8 formation in human lung epithelial cells. Half-day Symposium on G Protein-Coupled Receptors (GPCRs) (a satellite symposium of 16th International Symposium on Regulatory Peptides), 2006, 9, 2, Hakone.

548.       Takaoka, K., Sekiguchi, F., Saito, S., Hayashi, H., Nagataki, M., Nishikawa, H., Kawabata, A. Prostaglandin E2 production triggered by proteinase-activated receptor-1 in rat gastric mucosal epithelial cells: Cell signaling and modulation by peroxisome proliferator-activated receptor-ƒÁ ligands. Half-day Symposium on G Protein-Coupled Receptors (GPCRs) (a satellite symposium of 16th International Symposium on Regulatory Peptides), 2006, 9, 2, Hakone.

549.       Kubo, S, Ishikura, H., Nakagaki, T., Kawabata, A. Vasorelaxation caused by activated protein C in rat superior mesenteric artery: Are proteinase-activated receptors involved? Half-day Symposium on G Protein-Coupled Receptors (GPCRs) (a satellite symposium of 16th International Symposium on Regulatory Peptides), 2006, 9, 2, Hakone.

550.       ¼”g^”¿A씨“ÄŽjD“àˆö«ƒKƒXóî•ñ“`’B•¨Ž¿H2S‚Í“à‘Ÿ’É‚ð—U‹N‚·‚éD‘æ28‰ñ“ú–{áu’ÉŠw‰ïA2006, 7, 14-15, _ŒËD

551.       ’·àVŒi‘¾A‹g“c@”ÉAŠÖŒû•x”üŽqA씨“ÄŽjD“àˆö«ƒKƒXóî•ñ“`’B•¨Ž¿H2S‚É‚æ‚é‚sŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠ´Žó«‘‘å‚Æ’ÉŠo‰ß•q‚Ì”­Œ»D‘æ28‰ñ“ú–{áu’ÉŠw‰ïA2006, 7, 14-15, _ŒËD

552.       Kawabata, A. Regulation of exocrine secretion by proteinase-activated receptor-2 in the gastrointestinal tract. The Inernational Mini-Symposium on Gastrointestinal Pharmacology – Tissue Injury, Protection and Healing -, 2006, 7, 10, Kyoto. (Invited lecture)

553.       Takaoka, K., Sekiguchi, F., Saito, S., Shigi, H., Hayashi, H., Nagataki, M., Nishikawa, H., Kawabata, A. COX-2 up-regulation and prostaglandin E2 production triggered by proteinase-activated receptor-1 (PAR1) and their facilitation by peroxisome proliferator-activated receptor-ƒÁ ligands in rat gastric mucosal epithelial cells. The Inernational Mini-Symposium on Gastrointestinal Pharmacology – Tissue Injury, Protection and Healing -, 2006, 7, 10, Kyoto.

554.       ¼”g^”¿A•Ÿ“‡@CA씨“ÄŽjDŒ‹’°“àH2S‚É‚æ‚é“à‘Ÿ’É‚¨‚æ‚Ñ“à‘Ÿ’ÉŠo‰ß•q‚Ì”­Œ»D‘æ109‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2006, 6, 16, ‘q•~D

555.       ’·àVŒi‘¾AΖØ@„A‹g“c@”ÉA‘O“c—C”üAŠÖŒû•x”üŽqA˜a“c“NKAŽs“c¬ŽuA¼ì—T”VA씨“ÄŽjD“àˆö«ƒKƒXóî•ñ“`’B•¨Ž¿H2S‚Í–¢•ª‰»NG108-15×–E‚É‚¨‚¢‚Ä‚sŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠ´Žó«‚ð‘‘傳‚¹‚éD‘æ109‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2006, 6, 16, ‘q•~D

556.       씨“ÄŽjDProteinase-activated receptor (PAR) ‚ÌÁ‰»ŠÇ‹@”\‚Æ•a‘Ô‚Ö‚ÌŠÖ—^DƒVƒ“ƒ|ƒWƒEƒ€uÁ‰»ŠÇ•a‘ÔŒ¤‹†‚̃tƒƒ“ƒeƒBƒAvC‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3, 8-10, ‰¡•lDiƒVƒ“ƒ|ƒWƒEƒ€j

557.       ’·‘ë^ŽÀAŽçs˜a”üAŠÖŒû•x”üŽqA¼ì—T”VAr–ØG¹A씨“ÄŽjDƒqƒg”x–Eã”ç×–E‚É‚¨‚¢‚ÄPAR2Šˆ«‰»‚É‚æ‚è—U‹N‚³‚ê‚éIL-8‚¨‚æ‚Ñprostaglandin E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹‚ɂ‚¢‚ÄD‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3, 8-10, ‰¡•lD

558.       ΖØ@„A‘O“c—C”üAŠÖŒû•x”üŽqA씨“ÄŽjDV‚µ‚¢“àˆö«áu’Éî•ñ“`’B•¨Ž¿‚Æ‚µ‚Ä‚Ì—°‰»…‘f‚Ì–ðŠ„D‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3, 8-10, ‰¡•lD

559.       •Ä‘ò‘åŽ÷A‹{–{ŽÀ—¢A’JŒû‰lˆêA–{é‰ë”üAŠÖŒû•x”üŽqA씨“ÄŽjD“àˆö«ƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚̃‰ƒbƒgˆÝ”S–Œ‚É‚¨‚¯‚é•ÛŒì“I–ðŠ„D‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3, 8-10, ‰¡•lD

560.       ‹v•Û‘ŽqAŠŒ´–]“nA“y]ˆÊ’mŽqAŠÖŒû•x”üŽqA씨“ÄŽjDƒ‰ƒbƒgˆÝŒŒŠÇ‹Ù’£«‚¨‚æ‚Ñ”S–ŒzŠÂ“®‘Ô‚É‚¨‚æ‚Ú‚·ƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚ÌŒø‰ÊD‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3, 8-10, ‰¡•lD

561.       “y]ˆÊ’mŽqA‹v•Û‘ŽqAŠÖŒû•y”üŽqA씨“ÄŽjDV‹K“àˆö«ƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚É‚æ‚éƒ}ƒEƒX‹CŠÇŽx•½ŠŠ‹Ø‚Ì’oŠÉD‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3, 8-10, ‰¡•lD

562.       ¼‘ºK—eAΑqG‹±A¼”g^”¿A’Ò“àr•¶AŠÖŒû•x”üŽqA¬£Œõ‰hA’†’Jšæ’jAŠ™’†Šì‹vA씨“ÄŽjDäX‰ŠŠÖ˜A’Ƀ‚ƒfƒ‹‚É‚¨‚¯‚郃Vƒ‹Ž_ƒJƒ‚ƒXƒ^ƒbƒg‚ÌRNŠQŽó—e“Iì—pD‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3, 8-10, ‰¡•lD

563.       씨“ÄŽjDPAR (proteinase-activated receptor) ‚ð•W“I‚Æ‚µ‚½Á‰»ŠÇŽ¾Š³Ž¡—ÖòŠJ”­‚̉”\«‚ɂ‚¢‚ÄD‘æ2‰ñ“ú–{Á‰»ŠÇŠw‰ïA2006, 2, 11-12, “Œ‹žDiƒ[ƒNƒVƒ‡ƒbƒvˆË—Šu‰‰j

564.       Kawabata, A. Proteinase-activated receptors in the gastrointestinal systems: physiological/phathological roles and cell signaling. Seminar at AstraZeneca, 2006, 1, 30, Gothenberg (Sweden). (Invited lecture)

565.       Kawabata, A., Nagataki, M., Moriyuki, K., Sekiguchi, F., Nishikawa, H. Cell signaling by proteinase-activated receptor-2 for interleukin-8 formation in human lung epithelial cells. Cell Signaling World 2006, 1, 25-28, Luxembourg. (Oral presentation)

566.       Kubo, S., Ishiki, T., Doe, I., Sekiguchi, F., Nishikawa, H., Kawai, K., Kawabata, A. Distinct signaling and actions caused by intracellular ligands (pepducins) for proteinase-activated receptor-1 in multiple cells/tissues. Cell Signaling World 2006, 1, 25-28, Luxembourg.

567.       Kawabata, A. Proteinase-activated receptors in the respiratory systems: physiological/phathological roles and cell signaling. Seminar at Department of Physiology and Pharmacology, University of Strathclyde, 2006, 1, 23, Glasgow. (Invited lecture)

568.       Ζ؄A‘O“c—C”üAŠÖŒû•x”üŽqA씨“ÄŽjD“àˆö«ƒKƒXƒƒbƒZƒ“ƒWƒƒ[H2S‚Í––½‘gD‚É‚¨‚¢‚Ä’É‚Ý‚Ìî•ñ“`’B‚ÉŠÖ—^‚·‚éD‘æ108‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2005, 11, 11, ¼‹{D

569.       •Ä‘ò‘åŽ÷A‹{–{ŽÀ—¢A’JŒû‰lˆêA–{é‰ë”üAŠÖŒû•x”üŽqA씨“ÄŽjDV‹KƒKƒXóƒƒbƒZƒ“ƒWƒƒ[H2S‚̃‰ƒbƒgˆÝ”S–Œ‚É‚¨‚¯‚é•ÛŒìŒø‰ÊD‘æ108‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2005, 11, 11, ¼‹{D

570.       ’·‘ë^ŽÀAŽçs˜a”üAŠÖŒû•x”üŽqA*¼ì—T”VA*r–ØG¹A씨“ÄŽjDƒqƒg”x–Eã”ç×–E‚É‚¨‚¯‚éPAR-2‚ð‰î‚·‚éInterleukin-8ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹‚ɂ‚¢‚ÄD‘æ108‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2005, 11, 11, ¼‹{D

571.       ¼ì—T”VC‰Í‡Œ’‘ C‘å’J—T–çC–kì’m’ÃŽqCˆÀ•”’q”VCr–ØG¹C‰i––’mŽqC씨“ÄŽjDPAR-2ŠÖ˜Aƒyƒvƒ`ƒh‚É‚æ‚éPAR-2ˆË‘¶‚¨‚æ‚Ñ”ñˆË‘¶«—܉t•ª”åF\‘¢Šˆ«‘ŠŠÖ‚Æì—p‹@˜‚̉ðÍD‘æ55‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïD2005, 10, 29, _ŒËD i“ú–{–òŠw‰ï‹ß‹EŽx•”§—ãÜŽóÜj

572.       씨“ÄŽjDProteinase-activated receptor (PAR) ‚Ì‘½—l‚È‹@”\‚Æ•a‘Ô‚Ö‚ÌŠÖ—^D‘æ16‰ñ‹ãBŒŒŠÇŒŒðƒtƒH[ƒ‰ƒ€A2005, 10, 15-16, ‹{èi“Á•Êu‰‰j

573.       Kawabata, A., Sekiguchi, F., Saitoh, S., Nagataki, M., Takaoka, K., Hayashi, H., Kawao, N., Nishikawa, H. Cellular signaling responsible for delayed prostaglandin E2 production caused by proteinase-activated receptor-1 activation in rat mucosal epithelial cells. 13th World Congress of Gastroenterology, 2005, 9, 10-14, Montreal, Canada.

574.       Kubo, S., Doe, I., Sekiguchi, F., Kawabata, A. Dual modulation by hydrogen sulfide, a novel endogenous gasomessenger, of the tension in rat gastric artery. 13th World Congress of Gastroenterology, 2005, 9, 10-14, Montreal, Canada.

575.       Yonezawa, D., Miyamoto, M., Taniguchi, E., Honjo, M., Sekiguchi, F., Kawabata, A. A protective role of H2S, a novel gasomessenger, in rat gastric mucosa. 13th World Congress of Gastroenterology, 2005, 9, 10-14, Montreal, Canada.

576.       Matsunami, M., Kawao, N., Kitano, T., Tsutsumi, M., Ishiki, T., Satoh, R., Sekiguchi, F., Minami, T., Kanke, T., Kawabata, A. Proteinase-activated receptor-2 plays distinct roles in colonic hypersensitivity and pancreatitis-related abdominal allodynia. 13th World Congress of Gastroenterology, 2005, 9, 10-14, Montreal, Canada.

577.       Kawabata, A. Proteinase-activated receptors (PARs): physiology, signaling pathways and gastric mucosal function. Seminar at Faculty of Medicine, University of Calgary, 2005, 9, 9, Calgary, Canada. (Invited lecture)

578.       씨“ÄŽjDPAR-2‚Æ’É‚ÝD–ò—ŠwƒTƒ}[ƒZƒ~ƒi[2005D2005, 9, 1-3, ’·èiµ‘Òu‰‰j

579.       ¼”g^”¿A씨“ÄŽjDŒ‹’°’ÉŠo‰ß•q‚¨‚æ‚ÑäX‰ŠŠÖ˜A• •”ƒAƒƒfƒBƒjƒA‚Ì”­Œ»‚É‚¨‚¯‚éPAR-2‚̈قȂé–ðŠ„D–ò—ŠwƒTƒ}[ƒZƒ~ƒi[2005D2005, 9, 1-3, ’·èD

580.       Kanke, T., Kabeya, M., Kondo, S., Yasuoka, K., Tagashira, J., Ishiwata, H., Saka, M., Doi, T., Hattori, Y., Kawabata, A., Plevin, R. A novel peptide-mimetic PAR-2 antagonist, K-14585: inhibition on PAR-2-mediated signal transduction and vascular responses. British Pharmacological Society Summer Meeting, 2005, 7, 6-8, Cambridge, UK.

581.       Kawabata, A. Proteinase-activated receptors in gastric mucosa: physiological roles and cellular signaling. Molecular Mechanisms of Pathogenesis in Commemoration of 120th Anniversary of Yonsei University College of Medicine, 2005, 6, 16-18, Seoul, Korea (Invited Lecture)

582.       Yonezawa, D., Oono, Y., Hiramatsu, K., Inoi, N., Honjo, M., Hirofuchi, M., Ishiki, T., Sekiguchi, F., Iwaki, M., Kanke, T., Ishiwata, H., Kawabata, A. 2-furoyl-LIGRL-NH2 is a highly potent agonist for proteinase-activated receptor-2 and orally effective gastric mucosal protective agent in mice. Molecular Mechanisms of Pathogenesis in Commemoration of 120th Anniversary of Yonsei University College of Medicine, 2005, 6, 16-18, Seoul, Korea

583.       씨“ÄŽjA¼”g^”¿A‰Í”ö’¼”VA–k–ì’qŽqA’ç@‰ëOAΖØ@„A²“¡—æŽqAŠÖŒû•x”üŽqA“ì@•ŽuA›‰Æ@“ODPAR-2‚É‚æ‚é“à‘Ÿ’ɂ̧ŒäFäX‰ŠŽž‚ÌRNŠQ“IE•ÛŒì“I–ðŠ„‚Æ’x”­«Œ‹’°’ÉŠo‰ß•qŒ`¬‚Ö‚ÌŠÖ—^D‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3, 22-24, ‰¡•lD

584.       ’·‘ë^ŽÀA‰Í”ö’¼”VA’·àVŒi‘¾AKelly CushingAŠÖŒû•x”üŽqAWallace K. MacNaughtonAMorley D. HollenbergA¼ì—T”VAr–ØG¹A씨“ÄŽjDƒqƒg”x–Eã”ç×–E‚É‚¨‚¯‚éPAR-2Šˆ«‰»‚É‚æ‚è—U‹N‚³‚ê‚é×–EƒVƒOƒiƒ‹‚ÆCOX-2‚Ì—U“±D‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3, 22-24, ‰¡•lD

585.       •Ä‘ò‘åŽ÷A‘å–ì—TŽqA’–ˆä’¼Ž÷A–{é‰ë”üALŸº—ÏŽqAŠÖŒû•x”üŽqAŠâé³GA›‰Æ“OAΓn”Ž”VA씨“ÄŽjD‚Šˆ«PAR-2ƒAƒSƒjƒXƒg2-furoyl-LIGRL-amide‚Í‹­—Í‚©‚ÂŒoŒû“Š—^‰Â”\‚ȈݔS–Œ•ÛŒì–ò‚Å‚ ‚éD‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3, 22-24, ‰¡•lD

586.       Î–Ø „A‹v•Û‘ŽqA“y]ˆÊ’mŽqAŠÖŒû•x”üŽqA’·‘ë^ŽÀA¼ì—T”VA“c’† ½A씨“ÄŽjDPAR-1 pepducins i×–E“àƒAƒSƒjƒXƒgAƒAƒ“ƒ^ƒSƒjƒXƒgjFŽíX‚Ì×–EE‘gD‚É‚¨‚¯‚銈«•]‰¿D‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3, 22-24, ‰¡•lD

587.       ŠÖŒû•x”üŽqCÖ“¡Ž‡–ìC’·‘ë^ŽÀC‰Í”ö’¼”VC¼ì—T”VCr–ØG¹C씨“ÄŽjDƒ‰ƒbƒgˆÝ”S–Œã”ç×–E‚É‚¨‚¯‚éƒgƒƒ“ƒrƒ“Žó—e‘ÌPAR-1Šˆ«‰»—U”­ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹“`’B‚ÌŒŸ“¢D‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3, 22-24, ‰¡•lD

588.       ‹v•Û‘ŽqA“y]ˆÊ’mŽqAŠÖŒû•x”üŽqA씨“ÄŽjDV‚µ‚¢“àˆö«ƒKƒXóî•ñ“`’B•¨Ž¿H2S‚É‚æ‚郉ƒbƒg“Eo“®–¬‰^“®§Œä‚Ì“Á’¥D‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3, 22-24, ‰¡•lD

589.       ›‰Æ“OA•Ç’JŒ¹ŽkAˆÀ‰ª‹žŽqA“c“ª–çAΓn”Ž”VAâ‰ëŽqA“y”ì•A•ž•”K’jA씨“ÄŽjARobin PlevinDV‹Kƒyƒvƒ`ƒhƒ~ƒƒeƒBƒbƒNPAR-2ƒAƒ“ƒ^ƒSƒjƒXƒgFƒPƒ‰ƒ`ƒmƒTƒCƒgƒVƒOƒiƒ‹“`’B‚ɑ΂·‚é‘jŠQì—pD‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3, 22-24, ‰¡•lD

590.       ‹ß“¡ÍŽsA‹v•Û‘ŽqA‘ê‘òr–¾A•Ç’JŒ¹ŽkAΓn”Ž”VA¼–{ŽŸ˜YA•ž•”K’jA›‰Æ“OA씨“ÄŽjDV‹Kƒyƒvƒ`ƒhƒ~ƒƒeƒBƒbƒNPAR-2ƒAƒ“ƒ^ƒSƒjƒXƒgK-14585FPAR-2ƒAƒSƒjƒXƒg‚É‚æ‚郉ƒbƒgŒŒŠÇ’oŠÉì—p‚È‚ç‚тɃ‚ƒ‹ƒ‚ƒbƒgŒŒŠÇ“§‰ß«˜´i‚ɑ΂·‚é‘jŠQì—pD‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3, 22-24, ‰¡•lD

591.       ¼ì—T”VC‰Í‡Œ’‘ C“c’†@½C‘å’J—T–çC“c’†CˆêC–kì’m’ÃŽqC¼“c@–«CˆÀ•”’q”VCr–ØG¹A씨“ÄŽjDPAR-2ŠÖ˜A•sŠˆ«Œ^ƒyƒvƒ`ƒhLSIGRL-NH2‚̗܉t•ª”åì—p‚ÉŠÖ‚·‚é\‘¢Šˆ«‘ŠŠÖŒ¤‹†D‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3, 22-24, ‰¡•lD

592.       ‹v•Û‘ŽqA씨“ÄŽjDƒ‰ƒbƒgã’°ŠÔ–Œ“®–¬‚ÌŒŒŠÇ‰^“®§Œä‚É‚¨‚¯‚éG’`”’‹¤–ðŒ^ƒvƒƒeƒA[ƒ[Žó—e‘ÌPAR-1‚¨‚æ‚ÑPAR-2‚Ì–ðŠ„D‘æ34‰ñ“ú–{S–¬ŠÇì“®•¨Ž¿Šw‰ïD2005, 2, 4, ‹ž“sD

593.       ›‰Æ“OAΓn”Ž”VA•Ç’JŒ¹ŽkAâ‰ëŽqAÄ“¡’¼LA•Ä‘ò‘åŽ÷AΖ؄A‹v•Û‘ŽqAŠÖŒû•x”üŽqAŠâé³GA씨“ÄŽjARobin Plevin. V‹K‚Šˆ«PAR-2ƒAƒSƒjƒXƒgA2-furoyl-LIGRL-NH2‚̃AƒSƒjƒXƒgŠˆ«‚ÆŽó—e‘Ìe˜a«D‘æ12‰ñ“ú–{–òŠw‰ïˆã–ò•i‰»Šw•”‰ï”N‰ïD2004, 11, 24-26, ‚‚­‚ÎD

594.       Kawabata, A., Kawao, N., Kitano, T., Matsunami, M., Ishiki, T., Yoshida, S., Satoh, R., Tachibana, M., Sekiguchi, F., Kanke, T. Involvement of luminal trypsin and protease-activated receptor-2 in visceral hypersensitivity to capsaicin. Advances in GI Pharmacology – From acid secretion to mucosal protection, 2004, 11, 20-22, Otsu, Japan. (overview, invited)

595.       Sekiguchi, F., Kawao, N., Nagataki, M., Saito, S., Nishikawa, H., Araki, H. and Kawabata, A. Intracellular signaling for prostaglandin E2 production caused by protease-activated receptor-1 activation in rat gastric mucosal epithelial cells. Advances in GI Pharmacology – From acid secretion to mucosal protection, 2004, 11, 20-22, Otsu, Japan. (oral)

596.       Yonezawa, D., Oono, Y., Hiramatsu, K., Inoi, N., Honjo, M., Hirofuchi, M., Ishiki, T., Sekiguchi, F., Iwaki, M., Kanke, T., Ishiwata, H., Kawabata, A. Salivation and gastric mukcosal cytoprotection caused by 2-furoyl-LIGRL-NH2, the most potent agonist for protease-activated receptor-2, in mice. Advances in GI Pharmacology – From acid secretion to mucosal protection, 2004, 11, 20-22, Otsu, Japan.

597.       ‰Í”ö’¼”VA’r“c‹v—YA‰ª“c´FA‰ª–{’m‰ÂŽqA㓈”ÉA¼”ö—A씨“ÄŽjDƒJƒvƒTƒCƒVƒ“—U‹N“à‘Ÿ’É‚É‚¨‚¯‚éPAR-1‚¨‚æ‚ÑPAR-2‚Ì–ðŠ„D‘æ79‰ñ‹ß‹E¶—Šw’k˜b‰ïA2004, 11, 6, ‹ž“sD

598.       ’·‘ë^ŽÀA‰Í”ö’¼”VA’·àVŒi‘¾AKelly CushingA˜a“c“NKAŠÖŒû•x”üŽqAŽs“c¬ŽuAWallace K. MacNaughtonAMorley D. HollenbergA¼ì—T”VAr–ØG¹A씨“ÄŽjDƒqƒg”x–Eã”ç×–E‚É‚¨‚¯‚éPAR-2Šˆ«‰»‚É‚æ‚éCOX-2‚Ì—U“±‚Æ‚»‚ê‚ÉŠÖ—^‚·‚éƒVƒOƒiƒ‹‚̉ðÍD‘æ106‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2004, 11, 5, ‹ž“sD

599.       ‹v•Û‘ŽqAΖ؄A“y]ˆÊ’mŽqAŠÖŒû•x”üŽqA’·‘ë^”üA¼ì—T”VA“c’†½A씨“ÄŽjD×–E“àPAR-1ƒAƒSƒjƒXƒgƒyƒvƒ`ƒh‚¨‚æ‚уAƒ“ƒ^ƒSƒjƒXƒgƒyƒvƒ`ƒh(pepducins)‚ÌŠeŽí×–EE‘gD‚É‚¨‚¯‚éì—p‚̉ðÍD‘æ106‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2004, 11, 5, ‹ž“sD

600.       씨“ÄŽjAŠÖŒû•x”üŽqDÁ‰»ŠíŽ¾Š³Ž¡—Âɂ¨‚¯‚éV‚µ‚¢‘n–ò•W“I•ªŽq‚Æ‚µ‚Ä‚Ìprotease-activated receptors (PARs)D‘æ32‰ñ–ò•¨Šˆ«ƒVƒ“ƒ|ƒWƒEƒ€A2004, 11, 1-2, ‘åãiOrganizerEƒVƒ“ƒ|ƒWƒXƒgjD

601.       ŠÖŒû•x”üŽqA‰Í”ö’¼”VA’·‘ë^ŽÀAÖ“¡Ž‡–ìA¼ì—T”V*Ar–ØG¹*A씨“ÄŽjDƒgƒƒ“ƒrƒ“Žó—e‘ÌPAR-1Šˆ«‰»‚ð‰î‚µ‚½ƒ‰ƒbƒgˆÝ”S–Œã”ç×–E‚©‚ç‚Ì’x‰„«ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àî•ñ“`’BŒn‚ÌŒŸ“¢D‘æ‚T‚S‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘å‰ïA2004, 10, 23, _ŒËDi“ú–{–òŠw‰ï‹ß‹EŽx•”§—ãÜŽóÜj

602.       Kawabata, A., Kawao, N., Kitano, T., Satoh, R., Sekiguchi, F., Matsunami, M., Tachibana, M., Ishiki, T., Kuroda, R. and Kanke, T. Luminal trypsin causes delayed facilitation of capsaicin-evoked visceral nociception by activating protease-activated receptor-2. Neuroscience 2004, 2004, 10, 23-27, San Diego. (oral)

603.       Kawabata, A., Kawao, N., Nagataki, M., Kubo, S., Chushing, K., Ishiki, T., Nagasawa, K., Sekiguchi, F., Hollenberg, M.D., MacNaughton, W.K. and Nishikawa, H. Protease-activated receptors (PARs) and respiratory functions: cellular signaling and enhancement of prostanoid formation in the epithelium. The 17th Korea-Japan Joint Seminar on Pharmacology, 2004, 9, 30 – 10, 1, Jeonju, Korea (oral)iŠØ‘A‘SBŽsj

604.       Sekiguchi, F., Hasegawa, N., Inoshita, K., Yonezawa, D., Kanke, T., Saito, N. and Kawabata, A. Inhibitory and excitatory modulations of mouse gastrointestinal motility by activation of proteinase-activated receptor (PAR)-1 and PAR-2. The 17th Korea-Japan Joint Seminar on Pharmacology, 2004, 9, 30 – 10, 1, Jeonju, Korea iŠØ‘A‘SBŽsj

605.       Kubo, S., Ishiki, T., Doe, I., Sekiguchi, F., Nagataki, M., Nishikawa, H., Tanaka, M. and Kawabata, A. The intracellular agonist and antagonist (pepducins) for proteinase-activated receptor-1: distinct activity in multiple cells/tissues. The 17th Korea-Japan Joint Seminar on Pharmacology, 2004, 9, 30 – 10, 1, Jeonju, Korea iŠØ‘A‘SBŽsj

606.       씨“ÄŽjA›‰Æ@“OA•Ä‘ò‘åŽ÷AΖØ@„A‹v•Û‘ŽqAŠÖŒû•x”üŽqA‘å–ì—TŽqAâ@‰ëŽqA•Ç’JŒ¹ŽkAŠâé³GDProtease-activated receptor-2‚ÌV‹K‚Šˆ«ƒAƒSƒjƒXƒg2-furoyl-LIGRL-NH2: in vitro‚¨‚æ‚Ñin vivo‚É‚¨‚¯‚銈«•]‰¿D‘æ9‰ñ•a‘Ô‚ÆŽ¡—Âɂ¨‚¯‚éƒvƒƒeƒA[ƒ[‚ƃCƒ“ƒqƒrƒ^[Œ¤‹†‰ïA2004, 7, 30-31, –¼ŒÃ‰®D

607.       ŠÖŒû•x”üŽqA‰Í”ö’¼”VA’·‘ë^ŽÀAÄ“¡Ž‡–ìA¼ì—T”VAr–ØG¹A씨“ÄŽjDProtease-activated receptor-1Šˆ«‰»‚É‚æ‚éˆÝ”S–Œã”ç×–E‚©‚ç‚Ìprostaglandin E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒƒJƒjƒYƒ€‚ÌŒŸ“¢D‘æ9‰ñ•a‘Ô‚ÆŽ¡—Âɂ¨‚¯‚éƒvƒƒeƒA[ƒ[‚ƃCƒ“ƒqƒrƒ^[Œ¤‹†‰ïA2004, 7, 30-31, –¼ŒÃ‰®D

608.       Kawabata, A., Kawao, N., Kitano, T., Satoh, R., Ikeda, H., Sekiguchi, F., Kuroda, R., Kanke, T. Protease-activated receptor-2 activation induces delayed facilitation of capsaicin-evoked visceral pain in mice: involvement of endogenous bradykinin. 11th International Pain Clinic World Society of Pain Clinicians, 2004, 7, 11-16, Tokyo.

609.       ŠÖŒû•x”üŽqA‰Í”ö’¼”VA’·‘ë^ŽÀAÄ“¡Ž‡–ìA¼ì—T”VAr–ØG¹A씨“ÄŽjDƒ‰ƒbƒgˆÝ”S–Œã”ç×–ERGM1‚É‚¨‚¯‚éPAR-1Šˆ«‰»‚ð‰î‚µ‚½PGE2ŽY¶˜´i‚ÆŠÖ˜A‚·‚é×–E“àƒVƒOƒiƒ‹D‘æ105‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2004, 6, 17-18, “¿“‡D

610.       ŠÖŒû•x”üŽqCŽO“c—eŽqC‰Í”ö’¼”VC¼‰®G˜aC‘½‰êç—^”üCŠ™’†Šì‹vC씨“ÄŽjDƒJƒ‰ƒQƒjƒ“—U”­”M’ÉŠo‰ß•q‚ɑ΂·‚é—U“±Œ^NO‡¬y‘fiiNOSj‘jŠQ–òONO-1714‚Ì’Á’ÉŒø‰ÊD“ú–{–òŠw‰ï‘æ124”N‰ïC2004, 3, 29-31, ‘åãD

611.       ‰Í”ö’¼”VA–k–ì’qŽqA²“¡—æŽqA’r“c‹v—YA•“c—Ç‘¾˜YAŠÖŒû•x”üŽqA›‰Æ“OA씨“ÄŽjD“à‘Ÿ’É”­Œ»‚É‚¨‚¯‚éPAR-2‚ƃvƒƒeƒA[ƒ[‚Ì–ðŠ„FPAR-2ƒmƒbƒNƒAƒEƒgƒ}ƒEƒX‚¨‚æ‚уƒVƒ‹Ž_ƒiƒtƒ@ƒ‚ƒXƒ^ƒbƒg‚ð—p‚¢‚½ŒŸ“¢D“ú–{–òŠw‰ï‘æ124”N‰ïC2004, 3, 29-31, ‘åãD

612.       Kawabata, A., Kawao, N., Nagataki, M., Wada, T., Ichida, S., Hollenberg, M.D., Kubo, S., Sekiguchi, F. Signal transduction mechanisms for prostanoid formation caused by protease-activated receptor-2 activation in human lung epithelial cells. XVIIth International Congress on Fibrinolysis and Proteolysis, 2004, 3, 21-25, Melbourne. (Oral presentation)

613.       Sekiguchi, F., Hasegawa, N., Yonezawa, D., Kanke, T., Saito, N. and Kawabata, A. Roles of protease-activated receptor-1 and -2 in modulation of mouse gastrointestinal motility. XVIIth International Congress on Fibrinolysis and Proteolysis, 2004, 3, 21-25, Melbourne.

614.       Kubo, S., Nakaya, Y., Ishiki, T., Sekiguchi, F., Kuroda, R., Nishikawa, H., Kawabata, A. Mechanisms underlying contraction/relaxation caused by activation of protease-activated receptors 1 and 2 in rat superior mesenteric artery. XVIIth International Congress on Fibrinolysis and Proteolysis, 2004, 3, 21-25, Melbourne. (Oral presentation)

615.       씨“ÄŽjDŒÄ‹zŠíŒn‚É‚¨‚¯‚éprotease-activated receptors ‚ð‰î‚·‚éƒVƒOƒiƒ‹“`’BDƒVƒ“ƒ|ƒWƒEƒ€uƒvƒƒeƒA[ƒ[Šˆ«‰»Œ^Žó—e‘Ì‚Ì‹@”\‚Æ•a‘Ô¶—vC‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïC2004, 3, 8-10, ‘åãDiOrganizerEƒVƒ“ƒ|ƒWƒXƒgj

616.       ›‰Æ@“OC‘ê‘òr–¾C•Ç‰®Œ¹ŽkC씨“ÄŽjD‘n–òƒ^[ƒQƒbƒg‚Æ‚µ‚Ä‚ÌProtease-activated receptor-2 (PAR-2). ƒVƒ“ƒ|ƒWƒEƒ€uƒvƒƒeƒA[ƒ[Šˆ«‰»Œ^Žó—e‘Ì‚Ì‹@”\‚Æ•a‘Ô¶—vC‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïC2004, 3, 8-10, ‘åãDiƒVƒ“ƒ|ƒWƒXƒgj

617.       ŠÖŒû•x”üŽqC’·’Jì®”üC•Ä‘ò‘åŽ÷C’–ˆä’¼Ž÷A›‰Æ@“OCÄ“¡’¼LC씨“ÄŽjDPAR-1‚¨‚æ‚ÑPAR-2Šˆ«‰»‚É‚æ‚éƒ}ƒEƒXÁ‰»ŠÇ‰^“®’²ß‹@\D‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïC2004, 3, 8-10, ‘åãD

618.       ‰Í”ö’¼”VAL’†–F”üA•“c—Ç‘¾˜YAŠÖŒû•x”üŽqA씨“ÄŽjDƒrƒXƒzƒXƒzƒl[ƒgŒn–ò܃Gƒ`ƒhƒƒl[ƒg‚ÍATPŠ´Žó«ƒJƒŠƒEƒ€ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚ăAƒWƒ…ƒoƒ“ƒgŠÖ߉Šƒ‰ƒbƒg‚É‚¨‚¯‚éƒAƒƒfƒBƒjƒA‚ð—}§‚·‚éD‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïC2004, 3, 8-10, ‘åãD

619.       ‹v•Û‘ŽqAΖ؄A‰Í”ö’¼”VAŠÖŒû•x”üŽqA•“c—Ç‘¾˜YAÄ“¡’¼OA•ž•”K’jAHollenberg, M.D. A씨“ÄŽjDPAR-2‚¨‚æ‚ÑPAR-1Šˆ«‰»‚É‚æ‚éƒ}ƒEƒX‹C“¹•½ŠŠ‹Ø’oŠÉ”½‰žƒƒJƒjƒYƒ€‚̉ðÍD‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïC2004, 3, 8-10, ‘åãD

620.       ¼ì—T”VA‰Í‡Œ’‘ A“c’†@½A‘å’J—T–çA“c’†CˆêAr–ØG¹A씨“ÄŽjDPAR-2ŠÖ˜Aƒyƒvƒ`ƒh‚É‚æ‚éPAR-2”ñˆË‘¶«—܉t•ª”嘴iì—pD‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïC2004, 3, 8-10, ‘åãD

621.       Kawabata, A. Roles of protease-activated receptors in processing of nociception including visceral pain. AstraZeneca Research Grant Symposium 2003 on GI, 2003, 11, 28, Osaka. (Invited lecture)

622.       ‰Í”ö’¼”VA•“c—Ç‘¾˜YAŠÖŒû•x”üŽqA›‰Æ@“OA씨“ÄŽjDPAR-2Šˆ«‰»ƒvƒƒeƒA[ƒ[‚É‚æ‚éƒJƒvƒTƒCƒVƒ“—U‹N“à‘Ÿ’É‚Ì‘‹­FPAR-2 KOƒ}ƒEƒX‚ð—p‚¢‚½ŒŸ“¢D‘æ25‰ñ“ú–{áu’ÉŠw‰ïC2003, 12, 6, “Œ‹ž

623.       씨“ÄŽjA‰Í”ö’¼”VA•“c—Ç‘¾˜YAŠÖŒû•x”üŽqDƒrƒXƒzƒXƒzƒl[ƒgŒn–ò܃Gƒ`ƒhƒƒl[ƒg‚̃AƒWƒ…ƒoƒ“ƒgŠÖ߉Šƒ‰ƒbƒg‚É‚¨‚¯‚éRƒAƒƒfƒBƒjƒAì—pFATPŠ´Žó«ƒJƒŠƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ25‰ñ“ú–{áu’ÉŠw‰ïC2003, 12, 6, “Œ‹ž

624.       ‰Í”ö’¼”VA’·‘ë^ŽÀA“yˆä@A˜a“c“NKAŠÖŒû•x”üŽqA•“c—Ç‘¾˜YAŽs“c¬ŽuAHollenberg, M.D., 씨“ÄŽjDƒqƒgŒÄ‹zŠíã”ç×–E‚É‚¨‚¯‚éPAR-2‚ð‰î‚·‚éƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹‚ɂ‚¢‚ÄD‘æ104‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïC2003, 11, 7, ‘åã

625.       ‹v•Û‘ŽqAΖØ@„AŠÖŒû•x”üŽqA•“c—Ç‘¾˜YA“üŒð´”ŽAÄ“¡’¼OA•ž•”K’jA씨“ÄŽjDPAR-2Šˆ«‰»‚É‚æ‚éƒ}ƒEƒX“Eo‹C“¹•½ŠŠ‹Ø’oŠÉ”½‰ž‚Ì“Á’¥FPAR-2 KO ƒ}ƒEƒX‚ð—p‚¢‚½ŒŸ“¢D‘æ104‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïC2003, 11, 7, ‘åãD

626.       씨“ÄŽjA›‰Æ@“OA•Ä‘ò‘åŽ÷AΖØ@„A‹v•Û‘ŽqAŠÖŒû•x”üŽqA•“c—Ç‘¾˜YAâ@‰ëŽqA•Ç’JŒ¹ŽkAPlevin, R. ƒtƒƒCƒ‹Šî“±“üPAR-2Šˆ«‰»ƒyƒvƒ`ƒh‚Ìin vitro‚¨‚æ‚Ñin vivo‚É‚¨‚¯‚銈«•]‰¿D‘æ104‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïC2003, 11, 7, ‘åã

627.       ‰Í”ö’¼”VA²“¡—æŽqA–k–ì’qŽqA’r“c‹v—YAŠÖŒû•x”üŽqA씨“ÄŽjDƒgƒŠƒvƒVƒ“‚¨‚æ‚Ñ compound 48/80 ‚̃JƒvƒTƒCƒVƒ“—U”­“à‘Ÿ’É‘‹­Œø‰Ê‚ɑ΂·‚郃Vƒ‹Ž_ƒiƒtƒ@ƒ‚ƒXƒ^ƒbƒg‚Ìì—pD‘æ53‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘å‰ïC2003, 11, 1, –‡•û

628.            Kawabata, A., Nishikawa, H., Kawao, N., Nakaya, Y., Saitoh, H., Hiramatsu, K., Inoi, N., Ohno, Y., Sekiguchi, F., Nishida, M. and Kuroda, R. PAR-1 and PAR-2 modulate gastric mucosal functions. 11th International Conference on Ulcer Research, 15th-20th September, 2003, Dubrovnik – Croatia (Oral presentation)

629.            Kawabata, A. Roles for proteinase-activated receptors in the gastrointestinal tract. The 4th International Symposium on Receptor Mechanisms, Signal Transduction and Drug Effects, 2003, 5, 22-24, Fukui. (Invited lecture)

630.            Kawao, N., Ikeda, H, Kuroda, R., Kamanaka, Y. and Kawabata, A. Facilitation and suppression of capsaicin-evoked visceral pain by protease-activated receptors in mice. The 4th International Symposium on Receptor Mechanisms, Signal Transduction and Drug Effects, 2003, 5, 22-24, Fukui.

631.            Nakaya, Y., Kuroda, R., Nishikawa, H., ›Sekiguchi, F. and Kawabata, A. Endothelium-dependent relaxation of rat gastric arterial rings caused by activation of protease-activated receptor-1 and –2. The 4th International Symposium on Receptor Mechanisms, Signal Transduction and Drug Effects, 2003, 5, 22-24, Fukui.

632.            Nishikawa, H., Tanaka, S., Kawai, K., Tanaka, M., Ohtani, H., Araki, H., Ryotaro Kuroda, R. and Kawabata, A. Protease-activated receptor-2 (PAR-2)-derived peptides trigger tear secretion via a pathway distinct from PAR-2. The 4th International Symposium on Receptor Mechanisms, Signal Transduction and Drug Effects, 2003, 5, 22-24, Fukui.

633.            Kawabata, A., Itoh, H., Kawao, N., Kuroda, K., Iwata, I., Ogawa, A., Nakagawa, M. Parotid protease-activated receptor-2 activation stimulates trigeminal capsaicin-sensitive sensory neurons in rats. The 4th International Symposium on Receptor Mechanisms, Signal Transduction and Drug Effects, 2003, 5, 22-24, Fukui.

634.            ‹v•Û‘ŽqC’†‰®—T”üŽqCŠÖŒû•x”üŽqCΖ؄C•“c—Ç‘¾˜YC“üŒð´”ŽC¼ì—T”VCr–ØG¹C씨“ÄŽjDƒ‰ƒbƒgã’°ŠÔ–Œ“®–¬ƒŠƒ“ƒO•W–{‚É‚¨‚¢‚ÄPAR-1‚¨‚æ‚ÑPAR-2Šˆ«‰»‚É‚æ‚è—U‹N‚³‚ê‚éŽûkE’oŠÉ”½‰ž‚Ì“Á’¥D‘æ103‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïC2003, 5, 22, •Ÿˆä

635.            씨“ÄŽjC’†‰®—T”üŽqC•“c—Ç‘¾˜YDƒ‰ƒbƒg“EoˆÝ“®–¬‚É‚¨‚¯‚éƒvƒƒeƒA[ƒ[Žó—e‘ÌPAR‚ð‰î‚µ‚½’oŠÉ”½‰ž‚Ì“Á’¥D“ú–{–òŠw‰ï‘æ123”N‰ïC2003, 3, 27-29, ’·è

636.            ’†‰®—T”üŽqC•“c—Ç‘¾˜YC씨“ÄŽjDƒvƒƒeƒA[ƒ[Žó—e‘ÌPAR-1‚¨‚æ‚ÑPAR-2Šˆ«‰»‚É‚æ‚郉ƒbƒg“EoˆÝ¬“®–¬Žûk«‚̕ω»‚Æin vivo‚ł̈ݔS–ŒŒŒ—¬‚̕ω»D‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ïC2003, 3, 24-26, •Ÿ‰ª

637.            ‰Í”ö’¼”VC’r“c‹v—YC•“c˜N‘¾˜YC씨“ÄŽjDƒJƒvƒTƒCƒVƒ“—U”­ƒ}ƒEƒX“à‘Ÿ’Ƀ‚ƒfƒ‹‚É‚¨‚¯‚éPAR-1‚ ‚é‚¢‚ÍPAR-2ƒAƒSƒjƒXƒg‚ÌŒø‰ÊD‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ïC2003,3, 24-26, •Ÿ‰ª

638.            ˆÉ“¡GŽ÷C•“c—Ç‘¾˜YCŠâ“cKˆêC씨“ÄŽjDƒ‰ƒbƒgŽ¨‰º‘BŠÇŠJŒû•”‚Ö‹ts«’“ü‚µ‚½PAR-2ƒAƒSƒjƒXƒg‚É‚æ‚è—U”­‚³‚ê‚éŽO³_Œo”ö‘¤ˆŸŠj‚É‚¨‚¯‚éFos”­Œ»D‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ïC2003, 3, 24-26, •Ÿ‰ª

639.            ¼ì—T”VC씨“ÄŽjC•½¼DC¼“c–«C“c’†½C‰Í‡Œ’‘ C“c’†CˆêC‘å’J—T–çC•“c—Ç‘¾˜YCr–ØG¹Dƒ‰ƒbƒg‚̈ݎ_•ª”å‹@\‚É‚¨‚¯‚éG’`”’‹¤–ðŒ^ƒvƒƒeƒA[ƒ[Žó—e‘ÌPAR-1‚Ì–ðŠ„D‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ïC2003, 3, 24-26, •Ÿ‰ª

640.            씨“ÄŽjC’†‰®—T”üŽqCÄ“¡m”üC•½¼DC‰Í”ö’¼”VC‹v•Û‘ŽqC•“c—Ç‘¾˜YC¼ì—T”VC–؉º[OCŠ|”óˆêWCr–ØG¹C—L‰’’¼Ž÷C¼“c–«Dƒgƒƒ“ƒrƒ“Žó—e‘ÌPAR-1Šˆ«‰»‚É‚æ‚éˆÝ‚Ì‹@”\•Ï‰»‚ƈݔS–Œ•ÛŒìD‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ïC2003, 3, 24-26, •Ÿ‰ª

641.            씨“ÄŽjD’É‚Ý‚Ìî•ñ“`’BƒƒJƒjƒYƒ€‚ÉŠÖ‚·‚éÅ‹ß‚ÌŒ¤‹†“®ŒüD‘æ‚Q‰ñKampo EyesƒVƒ“ƒ|ƒWƒEƒ€D2003, 2, 15, ‘åãDiŠî’²u‰‰j

642.            씨“ÄŽjDƒgƒƒ“ƒrƒ“Žó—e‘ÌPAR-1‚͈ݔS–Œ‚É‚¨‚¢‚Ä•ÛŒì“I‚É‹@”\‚·‚éD‘æ13‰ñ“ú–{•a‘Ô¶—Šw‰ï‘å‰ïC2003, 1, 25-26, ç—tD

 

1984-2002”N‚ÌŠw‰ï”­•\Eu‰‰